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Doses selected for the 2-year studies were based on the
16-daystudiesinwhichratsandmiceofeachsexreceived
doses of0-2,000mg/kgperdayand on13-week studies in
which rats and mice ofeach sexreceived doses ranging
from 0 to 1,000 mg/kg per day by gavage in corn oil. No
chemically related gross or histopathologic effects were
observed in the 16-day or 13-week studies, but 1/5 high
dose male rats, 4/5 high dose female rats, and all high
dose male and female mice died during the 16-day stud-
ies. During the 13-week studies, 1/10 high dose female
rats and 3/10 high dose female mice died. The high dose
for the 2-year studies was set at 500 mg/kg per day for
each sex ofrats and mice, based mainly on the deaths in
the 13-week studies.
Throughout the 2-year study, the mean body weights
ofthe high dose male rats averaged 5% lowerthan those
ofthevehicle controls. Duringthe second year, the mean
body weights ofthe female high dose rats averaged 8%
lowerthanthoseofthevehiclecontrols,andthehighdose
femalemiceaveraged5%lower.Thesurvivalofhighdose
male ratswas significantlylowerthan that ofthevehicle
controls after week 96 (final survival: vehicle control,
33/50; low dose, 33/50; high dose, 14/50). The survival of
dosed female rats was poor (30/50; 23/50; 20/50), due in
part to 20 gavage-related accidental deaths of dosed
animals. The survival ofmale mice was also low (16/50;
16/50; 19/50), but there was a significant trend toward
increasedsurvival ofdosedfemalemicerelativetothatof
the vehicle controls (26/50; 35/50; 34/50).
Dosed male rats showed a variety of proliferative
lesions ofthe kidney (tubular cell hyperplasia: 0/50; 1/50;
4/50; tubular cell adenoma: 0/50; 0/50; 2/50; tubular cell
adenocarcinoma: 0/50; 3/50; 1/50; epithelial hyperplasia
ofthe renalpelvis: 0/50; 5/50; 5/50). Dosed male rats also
exhibited increased mineralization ofthe medullary col-
lecting ducts (1/50; 31/50; 20/50), and low dose male rats
showed a more severe nephropathy than is commonly
seen in aging F344/N rats. Carcinomas ofthe preputial
gland were increased in high dose male rats (0/50; 5/50;
5/50). With the exception of a moderate increase in
nephropathy (21/50; 39/50; 32/50), female rats did not
showchemicallyrelated increased incidences ofneoplas-
tic or nonneoplastic lesions.
In high dose male mice, isophorone exposure was
associated with increased incidences of hepatocellular
adenomas and carcinomas (18/48; 18/50; 29/50) and of
mesenchymal tumors of the integumentary system
(fibroma, fibrosarcoma, neurofibrosarcoma, or sarcoma:
6/48; 8/50; 14/50). An increased incidence of lymphomas
or leukemias was noted in low dose male mice (8/48;
18/50; 5/50). Coagulative necrosis (3/48; 10/50; 11/50) and
hepatocytomegaly (23/48; 39/50; 37/50) were observed
more frequently in the livers ofdosed male mice than in
vehicle controls. No compound-related neoplastic or non-
neoplastic lesions associated with isophorone exposure
were seen in female mice.
Isophorone was not mutagenic in strains TA100,
TA1535, TA1537, or TA98 ofSalmonella typhimurium
in the presence or absence ofAroclor 1254-induced male
Sprague-Dawley rat or male Syrian hamster liver S9.
Isophorone wasweaklymutagenic in the mouse L5178Y/
TK+/- assayin the absence ofS9; itwas nottested in the
presence of S9. Isophorone induced sister-chromatid
exchanges intheabsenceofS9inChinesehamsterovary
cells; it did not induce sister-chromatid exchanges in the
presence ofAroclor1254-induced maleratliverS9, andit
didnotinduce chromosomal aberrations in Chineseham-
ster ovary cells in the presence or absence of S9.
An audit of the experimental data was conducted for
the 2-year toxicology and carcinogenesis studies of iso-
phorone. No data discrepancies were found that influ-
enced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was soae evidence of carcinogenicity of iso-
phoroneinmale F344/N rats as shownbythe occurrence
of renal tubular cell adenomas and adenocarcinomas in
animals given 250 or 500 mg/kg per day; carcinomas of
the preputial gland were also observed at increased
incidence in male rats given 500 mg/kg. There was no
evidence of carcinogenicity in female F344/N rats
given 250 or 500 mg/kg per day. Formale B6C3F1 mice,
there was equivocal evidence of carcinogenicity of
isophorone as shown by an increased incidence of
hepatocellular adenomas or carcinomas (combined) and
ofmesenchymal tumors in the integumentary system in
animals given 500 mg/kg per day and by an increase in
malignant lymphomas in animals given 250 mg/kg per
day. There was no evidence ofcarcinogenicity of iso-
phorone in female B6C3F1 mice given 250 or 500 mg/kg
per day.
Synonym: 3,5,5-trimethyl-2-cyclohexen-1-one
Report Date: January 1986
TR-292 Tlrichlorfon (CAS: 52-68-6)
Studyconsideredinadequate; noTechnical Reportwill
be issued.
TR-293 Toxicology and Carcinogenesis
Studies ofHC Blue No. 2 [2,2'-((4-((2-
Hydroxyethyl)amino)-3-nitrophenyl)
imino)bis(ethanol)] (CAS No. 33229-34-4)
in F344/N Rats and B6C3F1 Mice (Feed
Studies)
Toxicology and carcinogenesis studies ofHC Blue No.
2 (approximately 98% pure), a semipermanent hair dye,
were conducted by administering the test chemical in
feedfor103weekstogroupsof50F344/N ratsofeach sex
and for 104 weeks to groups of 50 B6C3F1 mice ofeach
sex. The dietary concentrations used were 0, 5,000, or
10,000 ppm formale rats and male mice and 0, 10,000, or
20,000 ppm for female rats and female mice. These
concentrations were selected onthe basis ofresults fromABSTRACTSFROMLONG-TERMCANCER STUDIES, 1976-1992
single-administration gavage and 14-day and 13-week
feed studies. For the 2-year studies, the average daily
doses were approximately 195 and 390 mg/kg in male
rats, 465 and 1,000 mg/kg in female rats, 1,320 and 2,240
mg/kginmale mice, and2,330 and5,600mg/kginfemale
mice.
Thesurvival ofhigh dosemalerats andmalemicewas
better than that for controls, and the survival of dosed
female rats was comparable to that ofthe controls. The
survival ofhigh dose female mice was reduced (P<0.05)
relativetothatofcontrols (control,35/50; lowdose,27/50;
high dose 19/50); this reduced survival was attributed to
a reproductive tract infection. Final mean bodyweights
relativetothoseofcontrolsweredepressedlessthan10%
in dosed male rats, whereas depressions of13% and 22%
were observed in the low dose and high dose groups of
female rats. Final mean body weights for dosed male
mice were within 5% of control values, but final mean
bodyweights for dosed females were 15% (low dose) and
22% (high dose) lower than that ofcontrols.
A dose-related increase in the incidence of hyper-
ostosis ofthe skullwas detected in rats (male, 5/50,8/50,
25/49; female, 2/50, 19/50, 49/50) and in 1/49 high dose
male and 4/50 high dose female mice. Mixed mesenchy-
mal neoplasms ofthe kidney were detected in 2/50 high
dose female rats; none was observed in any other group
offemale or male rats. This tumor is considered uncom-
mon and has not been found in 1,863 historical control
female F344/N rats. A negative trend in fibroadenomas
of the mammary gland was seen in female rats (20/50,
10/50, 4/50).
A marginal (P=0.05) positive trend occurred in the
incidence of lymphomas in male mice (1/50; 5/48; 8/49);
the incidences in the dosed groups were notsignificantly
greater than that in the controls when survival dif-
ferences were taken into account.
HC Blue No. 2 was mutagenic for strains TA97 and
TA98 but notfor strains TA100 orTA1535 ofSalmonella
typhimurium in the presence or absence of Aroclor
1254-induced male Sprague-Dawley rat or Syrian ham-
ster liver S9. HC Blue No. 2 wasmutagenic in the mouse
lymphoma L5178Y/TK+/- assay in the presence of
Aroclor 1254-induced male F344/N rat liver S9.
An audit of the experimental data was conducted for
these carcinogenic studies on HC Blue No. 2. No data
discrepancies were found that influenced the final inter-
pretations.
Under the conditions of these studies, there was no
evidence ofcarcinogenicity inmale and female F344/N
rats or in male and female B6C3F1 mice receiving HC
Blue No. 2 in the diet atconcentrations of0.5% and 1.0%
for males and 1.0% and 2.0% forfemales for 2 years. HC
Blue No.2 administration caused adose-relatedincrease
in the incidence ofhyperostosis ofthe skull in male and
female rats.
Synonym: 2,2'-((4-((-hydroxyethyl)amino)-3-nitro-
phenyl)imino)bis(ethanol)
Report Date: August 1985
TR-294 Toxicology and Carcinogenesis
Studies ofChlorinated Trisodium
Phosphate (CAS No. 56802-99-4)* in
B6C3F1 Mice (Gavage Studies)
Two-year toxicology and carcinogenesis studies of
chlorinated trisodiumphosphate, aninclusioncomplexof
trisodium phosphate and sodium hypochlorite used in
various cleaning compounds, were conducted by admin-
istering 0, 500, or1,000mg/kg(dosevolume: 10mVkg) of
the chemical inwaterby gavage, 5 days perweek for 103
weeks, to groups of50 male and 50 female B6C3F1 mice.
Groups of mice receiving 250 mg/kg were included in
thesestudiesbutwereremovedafter6monthsbecauseof
alackoftoxicityinthe 500 and 1,000mg/kggroups. Two-
yearstudieswerebegun inmale andfemale F344/N rats
at doses of 0, 500, 1,000, or 2,000 mg/kg of chlorinated
trisodium phosphate in water by gavage (10 ml/kg). The
2,000 mg/kg groups were killed at 15 weeks because of
poor survival, and the other groups were killed at 35
weeks because oftoxicity in the 1,000 mg/kg group. The
doses selected for the 2-year studies were based on the
general lack ofadverse effects seen in the 14-day and 13-
week studies in which rats received 0-1,000 mg/kg and
mice received 0-2,000 mg/kg by gavage in water.
No compound-related histopathologic effects were
observed in the 14-day or the 13-week studies inmice. In
the 2-year studies, survival and mean body weights of
dosed andvehiclecontrolmalemice groupswere compar-
able (survival - vehicle control, 39/50; low dose, 35/50;
high dose, 32/50). Survival ofthe dosed female mice was
lower than that of the vehicle controls (30/50; 16/50;
21/50), although at week 80 survival offemale mice was
42/50, 39/50, and 36/50. The mean body weights of the
high dose female mice were lower than those of the
vehicle control mice, primarily afterweek 32; final body
weightswere11%lowerinthehigh dosegroup compared
with that in the vehicle controls. The lower survival and
mean body weights of the dosed female mice may have
been due to a greater incidence ofuterine/ovarian infec-
tions in these mice rather than to a direct toxic effect of
chlorinated trisodium phosphate. Nine of20vehicle con-
trol,20/34 lowdose, and21/29highdosefemalemice that
died before the end of the studies had such infections.
This reduced survival decreased the sensitivity of the
study of female mice for detecting the presence or
absence ofcarcinogenic effects.
Atno sitewastheincidenceofneoplasmsconsideredto
be related to the administration ofchlorinated trisodium
phosphate. minimal necrosis and fatty changes were
observed inthelivers ofmalemice. Kidneysinmale mice
werecharacterizedbysmall,multifocal areas ofmineral-
ization, primarily in the cortex but not at the cor-
ticomedullary junction or in the tubes of the medulla.
Neither effect was considered compound related. Five
different types of ovarian neoplasms were found in six
dosed female mice; because these lesions were from
tissues of different embryonic origin, they were consid-
ered unrelated to administration of chlorinated tri-
sodium phosphate.
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Chlorinated trisodium phosphate was weakly muta-
genic in strain TA1535 ofSalmonella typhimurium in
the presence of Aroclor 1254-induced male Sprague-
Dawley rat or male Syrian hamster liver S9. This com-
pound was not mutagenic in strains TA97, TA98, or
TA100.
An audit of the experimental data was conducted for
these 2-year studies ofchlorinated trisodium phosphate.
No data discrepancies were found that influenced the
final interpretation ofthese experiments.
Under the conditions of these 2-year gavage studies,
there was no evidence of carcinogenicity for either
male orfemale B6C3F1 micegivenchlorinated trisodium
phosphate by gavage in water for 103 weeks at doses of
500 or 1,000 mg. Survival ofdosed female mice was 78%
and 72%after80weeksand32%and42% atthetermina-
tion ofthe study. The studies inmale and female F344/N
rats were considered to be inadequate studies of car-
cinogenicity because the experiments were terminated
at 35 weeks due to poor survival.
Synonym: sodium hypochlorite phosphate
Report Date: December 1986
*The CAS Number(56082-99-4)indicated onthe coverof
the technical report is in error; the correct CAS number
is indicated above.
TR-295 Toxicology and Carcinogenesis
Studies ofChrysotile Asbestos (CAS No.
12001-29-5) in F344/N Rats (Feed Studies)
Lifetime toxicology and carcinogenesis studies of
short-range (SR) and intermediate-range (IR) fiber
length chrysotile asbestos were conducted in groups of
88-250 male and female F344/N rats. Both forms of
asbestos were administered at a concentration of 1% in
pelleted dietforthe lifetime oftherats, startingwith the
dams of the test animals. Subgroups of 100 male and
female IR chrysotile-exposed rats also received 0.47 mg/
g IR chrysotile asbestos in water by gavage during
lactation (preweaning [PW]). At 9 weeks of age, addi-
tional subgroups (125-175) of control and IR chrysotile-
exposed rats received 7.5 mg/kg (male) or 15 mg/kg
(female) 1,2-dimethylhydrazine dihydrochloride (DMH)
by gavage everyotherweekfor atotaloffivedoses.When
the survival of either the control or test group reached
10%, both groups were killed.
Neither type of fiber affected fertility or litter size.
The offspring from mothers exposed to SR chrysotile
were similar in body weight to the controls at birth but
were slightly smaller (13%) atweaning and remained so
throughout their lifetimes. Feed consumption and sur-
vival were comparable among the SR and IR chrysotile
asbestos groups and controls. TheDMH-exposed groups
showed decreased survival due primarily to the develop-
ment oflethal neoplasms.
The administration ofSR chrysotile for the lifetime of
exposed male and female rats did not cause any overt
toxicity. In addition, no neoplastic or nonneoplastic dis-
ease was associated with SR chrysotile exposure.
Male and female rats exposed to IR chrysotile
asbestos did not show anyadverse clinical signs. Benign
epithelial neoplasms (adenomatous polyps) were
observed in the large intestine ofIR chrysotile asbestos
malerats (9/250,3.6%). Although notstatisticallysignifi-
cant(P=0.08) comparedwith concurrentcontrols (0/85),
the incidence ofthese neoplasms was highly significant
(P= 0.003) when compared with the incidence of epi-
thelial neoplasms (benign and malignant combined) of
thelargeintestineinthepooledmalecontrolgroupsofall
the NTP oral asbestoslifetime studies (3/524, 0.6%).The
biologic importance ofthis findingwas supported bythe
observation oflesions ofsimilarmorphologyin the small
intestine or glandular stomach of four additional IR
chrysotile male rats and by a lowincidence (2/100, 2.0%)
ofadenomatous polyps in the largeintestine ofmale rats
in the IR/PW group.
A significant (P<0.05) increase in keratoacanthomas
of the skin was observed in male IR (19/250, 7.6%) and
IR/PW (8/100, 8.0%) chrysotile-exposed rats compared
with the concurrent controls (1188, 1.1%). The biologic
importance of this observation was discounted because
the incidence in these groups did not greatly exceed the
rate observed in the combined male control groups from
alltheotherNTPoralasbestos studies (19/441,4.3%).An
apparent increase in the incidence ofclitoral gland neo-
plasms in female IR (18/250, 7.2%) and IR/PW (4/100,
4.0%) chrysotile-exposed rats compared with that in the
concurrent controls (1188, 1.1%) was also discounted
because of a lack of statistical significance when com-
pared with the pooled female control groups from the
other NTP oral asbestos studies (211441, 4.8%).
Rats exposed to DMH and DMH plus IR chrysotile
asbestos exhibited neoplasiainthose organsknowntobe
targets for DMH (gastrointestinal tract, Zymbal gland,
liver, and kidney). There was a significant difference
(P<0.05) in the incidence of DMH-induced mixed-cell
tumors of the kidney between the DMH alone (13/125,
10%) and DMH plus IRchrysotile asbestos (34/175,19%)
female groups. An increased incidence ofthyroid follicu-
lar cell tumors was observed in DMH plus IR chrysotile
male rats (28/175,16.0%) compared with the DMH alone
group (9/124, 7.3%). The biologic importance of both
observations is questionable, since neither organ repre-
sents a primary target organ for asbestos and no dif-
ference between DMH and DMH plus IR chrysotile was
observed for the primary target organs (intestine and
mesothelium).
An audit of the experimental data was conducted for
these lifetime carcinogenesis studies of chrysotile
asbestos. No data discrepancies were found that influ-
enced the final interpretations.
Under the conditions of these lifetime studies, short-
range and intermediate-range chrysotile asbestos did
notinduce overttoxicityanddid notaffectsurvivalwhen
ingested at a level of 1% in the diet by male and female
F344/N rats. Therewasno evidence ofcarcinogenicity
in male orfemale rats exposed to SR chrysotile asbestos
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or in female rats exposed to IR chrysotile asbestos.
There was scme evidence of carcinogenicity in male
ratsexposed to IR chrysotile asbestos asindicatedby an
increased incidence of adenomatous polyps in the large
intestine. The cocarcinogenesis studies of 1,2-
dimethylhydrazine dihydrochloride and IR chrysotile
asbestos were considered inconclusive for determining
whether IR chrysotile asbestos had either a tumor-
enhancing or protective effect, although an increased
incidence of neoplasms was observed in the kidneys of
female rats exposed to DMH plus IR chrysotile as com-
pared with those exposed to DMH alone.
Report Date: November 1985
Note: Chrysotile Asbestose was also tested in Syrian
Golden Hamsters administered in feed (See TR-246,
reported 1990).
TR-296 Toxicology and Carcinogenesis
Studies ofTetrakis(hydroxymethyl)
phosphonium sulfate (THPS) (CAS No.
55566-30-8) and Tetrakis(hydroxymethyl)
phosphonium chloride (THPC) (CAS No.
124-64-1) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
Toxicologyandcarcinogenesis studiesoftetrakis (hydro-
xymethyl)phosphonium sulfate (THPS) and tetrakis
(hydroxymethyl)phosphonium chloride (THPC) were con-
ductedbecause ofthewidespread useofthesechemicals as
flameretardantsincottonfabrics. THPS wasavailable as a
72% aqueoussolutionandTHPC as a75% aqueoussolution.
Short-term gavage studies with a range of doses were
conducted first to identify toxic effects and affected sites
and to determine doses for the 2-year studies. The doses
selectedforthe 14-day studies ranged from12.5 to200 mg/
kgTHPSforratsandmice,9.4to150mg/kgTHPCforrats,
and 18.8 to 300 mg/kg THPC for mice. Mortality and
reduction in bodyweight gain occurred at the two highest
doses in the 14-day studies. There was hind limb paralysis
in some rats and mice dosed at the highest concentrations
ofTHPS and THPC.
In the 13-week studies, doses ofTHPS ranged from 5
to60mg/kginratsandfrom2to180mg/kginmice; doses
ofTHPC ranged from 3.75 to 60 mg/kgin rats and from
1.5 to135mg/kginmice. Mortalityandreduction inbody
weight gain occurred at the two higher doses for both
sexes and species. Vascular degeneration ofhepatocytes
orhepatocellular necrosis was a common histopathologic
finding. Hind limb paralysis was noted in rats and mice
receivingthehighestdoseofTHPC, and axonaldegener-
ation, characterized by swollen axon sheaths, missing or
fragmented axons, and someproliferation ofneurolemma
cells, was observed in rats. These lesions were found in
the sciatic nerve, dorsalroots ofthe caudal spinal nerves,
and the tracts of the spinal cord, particularly in the
dorsal column ofthe lumbar cord.
Two-year studies were conducted in F344/N rats by
administering 0, 5, or 10 mg/kg THPS or 0, 3.75, or 7.5
mg/kg THPC in deionized water by gavage to groups of
49 or 50 animals ofeach sex, 5 days per week for 103 or
104weeks. Groups of49 or 50 B6C3F1 micewere admin-
istered0,5, or10mg/kgTHPS (each sex), 0, 7.5, or15mg/
kgTHPC (males), or 0, 15, or30 mg/kgTHPC (females).
Survivalofmaleratswasreducedforthelowdose(after
week 102) and the high dose (afterweek 67) groups given
THPS comparedwith that ofthevehicle controls; survival
at terminal kill was as follows: vehicle control, 28/50; low
dose, 13/50; high dose, 16/50. Survival of the high dose
group offemale rats givenTHPC was lower afterweek 70
than that ofthe vehicle controls (survival at terminal kill:
37/50; 34/50; 21/50). Mean bodyweights ofrats dosed with
THPS or THPC were comparable to those ofthe vehicle
controls. Therewas no differencein survival ormeanbody
weights between the vehicle controls and mice dosed with
eitherTHPSorTHPC.Noneurotoxicityoranyothersigns
ofclinical toxicitywere observed.
A nonneoplastic effect common to 13-week and 2-year
exposure to THPS or THPC was an increase in the
incidenceofhepatocellularlesions,primarilycytoplasmic
vacuolization. The incidences of this lesion in the two-
year studies were dose related for all studies except for
the mice receiving THPS. Other lesions observed
included focal hyperplasia ofthe adrenal medullain high
dose male mice given THPS and follicular cell hyper-
plasiaofthethyroidglandinhighdosefemalemicegiven
THPC. The increased incidences of hematopoietic sys-
tem lesions observed in these studies were not consid-
ered biologically related to chemical exposure because
the increases were marginal, no dose-response relation-
shipwasobserved,andtheincidencesoftheselesions are
highlyvariable in untreated rats and mice.
The incidences of mononuclear cell leukemia in low
dosemaleratsadministeredTHPS orTHPCwere some-
what greater than those in the vehicle controls (THPS:
30/50; 36/50; 20/50; THPC: 19/50; 25/50; 16/50). Lowdose
male mice administered THPS had an increased inci-
dence of malignant lymphomas when compared with
vehicle controls (2/50; 9/50; 0/50). These marginal
increases in the incidences of hematopoietic system
tumorswerenotconsideredrelatedtochemicalexposure,
sincetheyweresignificantonlybythelifetabletests and
were not dose related.
THPC demonstrated no mutagenic activity in Salmo-
nella typhimurium strains TA98, TA100, TA1535, or
TA1537with orwithoutmetabolic activation. BothTHPS
and THPC induced forward mutations in mouse lym-
phomaL5178Ycellswithoutmetabolic activation; neither
was tested in the presence of S9. THPC increased the
frequency ofsister-chromatid exchanges and chromoso-
mal aberrations in Chinese hamster ovary cells in the
presence and absence ofexogenous metabolic activation.
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An audit ofthe experimental datawas conducted forthe
2-year studies of THPS and THPC. No discrepancies
were found that influenced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was no evidence ofcarcinogenicity of THPS in
either sex of F344/N rats or B6C3F1 mice given 5 or 10
mg/kg. There was no evidence of carcinogenicity of
THPC in either sex ofF344/N rats given 3.75 or 7.5 mg/
kg, in male B6C3F1 mice given 7.5 or 15 mg/kg, or in
female B6C3F1 mice given 15 or 30 mg/kg.
Report Date: February 1987
TR-297 Benzyl Chloride (CAS: 100-44-7)
NoTechnical Reportissued; results ofstudyinjournal
article.
WLijinsky, Chronic BioassayofBenzylChloridein F344
Rats and C57BL/6JXBALB Mice. J. Nat'l Cancer Inst
77, No. 4:941-949 (1986).
TR-298 Toxicology and Carcinogenesis
Studies ofDimethyl Morpholinophos-
phoramidate (CAS No. 597-25-1) in F344/N
Rats and B6C3F1 Mice (Gavage Studies)
Dimethyl morpholinophosphoramidate (DMMPA,
greater than 99% pure) was developed for use as a
stimulant forthe physical (but notbiologic) properties of
anticholinesterase agents in chemical defense training.
Because ofthepotentialforhuman exposure, thetoxicity
and carcinogenicity of DMMPA were investigated.
Fourteen-day and 13-week studies were conducted to
determine short-term toxicity, to identify target organs,
and to establish doses for the 2-year toxicology and
carcinogenesis studies.
In the 14-day studies, groups of five male and five
female F344/N rats were administered DMMPA in corn
oil by gavage daily at 0, 313, 1,250, 2,500, or 5,000 mg/kg
body weight for 14 consecutive days. All the rats receiv-
ing DMMPA at 2,500 or 5,000 mg/kg, except one male
receiving5,000mg/kg, diedbefore the end ofthe studies.
Rats receiving DMMPA at doses of1,250 mg/kg or less
survived. The final mean bodyweights ofthe surviving
dosed rats were within ± 8% of those of the vehicle
controls. Compound-related gross lesions were notfound
atnecropsy. Groups offiveB6C3F1 miceofeach sexwere
givenDMMPAbythe sameroute onthe same schedule at
0,250,500,1,000,2,000, or4,000mg/kg.Allthemicegiven
DMMPA at 2,000 or 4,000 mg/kg died before the end of
the studies. Mice administered DMMPAatdoses of1,000
mg/kg or less survived. The final mean body weight of
the male mice given DMMPA at 1,000 mg/kg was 14%
greaterthan that ofthevehicle controls, whereas that of
the other dosed survivors was within 10% ofthat ofthe
vehicle controls. Compound-related gross lesions were
not found at necropsy.
Inthe13-weekstudies, groupsof10maleand10female
F344/N rats and B6C3F1 mice were given DMMPA by
gavage in corn oil at 0, 200, 400, 1,200, or 1,600 mg/kg
bodyweight, 5 daysperweekfor13weeks. All rats given
DMMPAat400mg/kgorlesssurvived,andnomorethan
3/10 diedinanyofthehigherdosegroups.Thefinalmean
body weights of the dosed male rats were 6% to 11%
greater than that ofthe vehicle controls; weights ofthe
dosed female rats were similar to that of the vehicle
controls (-6%to1%).Therewasadose-relatedincreasein
liver weight/body weight ratio.
All the mice given DMMPA at 1,600 mg/kg, except one
female, died before the end of the 13-week studies; mice
receiving DMMPA at 1,200 mg/kg or less survived. The
finalmeanbodyweights ofthe dosedmalemicewere 3.4%
to 6.9% greater than that ofthe vehicle controls. The final
mean body weights of dosed female mice and vehicle
controls were similar. Compound-related gross or histo-
pathologic changes were not observed in rats or mice.
In the 2-year toxicology and carcinogenesis studies,
groups of50 male and 50 female F344/N rats were given
DMMPA in corn oil by gavage at doses of0, 150, 300, or
600 mg/kg body weight, 5 days per week for 103 weeks.
Groupsof50maleB6C3F1 miceweregivenDMMPAat0,
150, 300 mg/kg body weight, and groups of 50 female
B6C3F1 mice were given DMMPA at 0, 300, 600 mg/kg
body weight on the same schedule. Doses of 300 or 600
mg/kg were originally selected for male mice for the
2-year study; because 19/50 high dose male mice died
by week 19, all male mice were killed and doses of 0,
150, and 300 mg/kg were selected for the restart of the
2-yearstudyinmalemice.The survivalofhighdosemale
(22/50) and female (24/50) rats was reduced (P<0.025)
relative to that of the male (37/50) and female (36/50)
vehicle controls. Mean bodyweights were less than 10%
lower in the mid dose and high dose male rats and in the
high dose female rats than in the vehicle controls.
DMMPAadministration did notsignificantlyaffectbody
weight gain or survival ofmale and female mice.
Atthe 600mg/kg dose, increased (P<0.05) incidences
ofmononuclear cell leukemia occurred in both male rats
(vehicle control, 14/50; 150 mg/kg, 21150; 300 mg/kg,
19/50; 600 mg/kg, 25/50) and female rats (9/50; 13/50;
12/49; 18/50). DMMPA-related neoplastic or nonneoplas-
tic lesions were not observed in the dosed mice.
DMMPAwas notmutagenic in strains TA100, TA1535,
TA1537, or TA98 of Salmonella typhimurium in the
presence or absence of Aroclor 1254-induced male
Sprague-Dawley rat or male Syrian hamster liver S9.
DMMPA was mutagenic in the L5178Y/TK+/- mouse
lymphomaassayinthe absence ofS9; itwas nottestedin
the presence ofS9. DMMPAinduced chromosomal aber-
rations and sister-chromatid exchanges in Chinese ham-
ster ovary cells in the absence of S9, but cytogenetic
effectswerenotobservedinthepresenceofAroclor1254-
induced rat liver S9.
An audit of the experimental data for these 2-year
carcinogenesis studies on DMMPA was conducted. No
data discrepancies were found that influenced the final
interpretations.
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Under the conditions of these 2-year gavage studies,
therewassane evidence ofcarcinogenicity formale and
female F344/N rats given dimethyl mor-
pholinophosphoramidate, as indicated by increased inci-
dences of mononuclear cell leukemia. There was no
evidence ofcarcinogenicity formale and femaleB6C3Fj
mice given dimethyl morpholinophosphoramidate at doses
of150 (male), 300, or 600 (female) mg/kg for 2 years.
Synonyms: di4iethyl morpholinophosphonate; phos-
phonic acid, morpholino, dimethyl ester; DMMPA; phos-
phonic acid, 4-morpholinyl-, dimethyl ester
Report Date: January 1986
TR-299 Toxicology and Carcinogenesis
Studies ofC.I. Disperse Blue 1 (A
Commercial Dye Containing
Approximately 50% 1,4,5,8-
Tetraaminoanthraquinone, and 20% Water)
(CAS No. 2475-45-8) in F344/N Rats and
B6C3F1 Mice (Feed Studies)
C.I. Disperse Blue 1, a component ofseveral semiper-
manent hair dyes, was studied as a commercial-grade
product (minus lignosulfonate dispersants) containing
approximately 50% 1,4,5,8-tetraaminoanthraquinone,
30% other compounds structurally related to 1,4,5,8-
tetraaminoanthraquinone, and 20% water. C.I. Disperse
Blue 1 was studied for toxicity and carcinogenicity in
single-administration gavage, 14-day feed, 13-week feed,
and 104-week feed studies. All studies used F344/N rats
and B6C3F1 mice.
Inthe single-administration gavage studies, no deaths
occurred within 14 days at doses up to 3,000 mg/kg C.I.
Disperse Blue 1 in rats or up to 2,000 mg/kg in mice. In
the 14-day studies, rats and mice received dietary con-
centrations ofup to 50,000 ppm. All male rats survived,
and 2/5 female rats in the 50,000-ppm group died. All
mice receiving 25,000 ppm or more died. Three of five
males and2/5femalemiceinthe12,500-ppm groups died.
Inthe13-weekstudies, dietscontainingconcentrations
up to 20,000 ppm C.I. Disperse Blue 1 were fed to rats,
and diets containing concentrations up to 10,000 ppm
were fed to mice. No compound-related deaths of rats
occurred; however, pathologic changes occurred at2,500
ppm and higher and included urinary tract calculi, uri-
nary bladder inflammation, hyperplasia of the urinary
bladder transitional epithelium, and nephrosis,
Compound-related deaths occurredat10,000ppminmice
ofeach sex. Pathologic changes included chronic inflam-
mation and hyperplasia of the urinary bladder transi-
tional epithelium and urinary tract calculi at dietary
concentrations of 2,500 ppm and higher and nephrosis,
myocardial necrosis, and testicular degeneration at
10,000 ppm. The renal lesions at 5,000 ppm were consid-
ered to be potentially life threatening. These composite
findings from the short-term studies were used to iden-
tify target organs and to help select dietary concentra-
tions for the longer term studies.
In the 2-year studies in rats, groups of 50 animals of
each sex were administered C.I. Disperse Blue 1 at
dietary concentrations of 0, 1,250, 2,500, or 5,000 ppm.
These dietary concentrations corresponded to 0, 45, 95,
and 217 mg/kg per day for males and 0, 56, 111, and 240
mg/kgperdayforfemales. Survivalofmalesandfemales
in the 5,000 ppm groups and males in the 2,500-ppm
group was significantly reduced. Final body weights, as
percent of controls, were: male-low dose 100%; mid
dose, 94%; high dose, 85%; female-low dose, 99%; mid
dose, 94%; high dose, 87%.
Compound-related effects of feeding diets containing
C.I. Disperse Blue 1 for 104 weeks to F344/N rats
included urinary bladder neoplasms and calculi at the
incidences noted in the table. Positive statistical associa-
tions existed between the presence ofcalculi and transi-
tional cell neoplasms ofthe urinarybladder in male and
female rats, leiomyomas or leiomyosarcomas (combined)
infemalerats, and squamous cellneoplasmsinmalerats.
The increased incidence of pancreatic islet cell ade-
nomas or carcinomas (combined) in high dose male rats
was significant by survival-adjusted analyses (overall
incidences: control, 1/49; low dose, 2/50; mid dose, 5/50;
high dose, 3/50).
In the 2-year studies in mice, 50 animals of each sex
were administered diets containing C.I. Disperse Blue 1
at 0, 600, 1,200, or 2,500 ppm. These dietary concentra-
tions corresponded to doses of0,112,239, and 540mg/kg
per dayformales and 0,108,235, and 520mg/kgper day
forfemales. Survivalwas comparable among control and
dosed male or female mice. Final body weights, as per-
cent of controls, were as follows: male-low dose, 97%;
mid dose,98%; high dose, 101%; female-lowdose,110%;
mid dose, 104%; high dose, 91%.
The incidences of hepatocellular adenomas or car-
cinomas (combined) were increased for dosed male mice
(9/50; 21/50; 16/50) and for low dose female mice (3/50;
13/49; 3/50; 4/50). Alveolar/bronchiolar adenomas or car-
cinomas (combined) occurred with an increased inci-
dence in high dose male mice (4/50; 9/49; 5/50; 11/50).
Several nonneoplastic effects were detected in the
kidneys ofmid dose and high dose male and high dose
female rats and of all dosed groups ofmale and female
mice. These effects onthekidneyincluded calculi, hydro-
nephrosis, and epithelial hyperplasia in rats and casts
and renal tubular degeneration in mice.
C.I. Disperse Blue 1 was studied for mutagenicity in
Salmcnella typhimurium inthepresence orabsence of
Aroclor 1254-induced male Sprague-Dawley rat or male
Syrian hamster liver S9. C.I. Disperse Blue 1 was muta-
genic in strain TA1535 in the presence of S9 and in
strains TA97 and TA98 inthe presence or absence ofS9;
itwas not mutagenic in strain TA100.
An audit of the experimental data was conducted for
the 2-year toxicology and carcinogenesis studies of C.I.
Disperse Blue 1. No data discrepancies were found that
influenced the final interpretations.
Under the conditions of these feed studies of C.I.
Disperse Blue 1, there was clear evidence of car-
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cinogenicity formale and female F344/N rats as shown
by the increased occurrence of transitional cell
papillomas and carcinomas, of leiomyomas and
leiomyosarcomas, and of squamous cell papillomas and
carcinomas ofthe urinary bladder. Urinary bladder cal-
culiwere observed in the groups ofrats inwhichurinary
bladder neoplasms were increased. Positive associations
existed between the presence ofcalculi and transitional
cell neoplasms in male and female rats, leiomyomas or
leiomyosarcomas (combined) in female rats, and
squamous cell neoplasms in male rats. A marginally
increased occurrence ofpancreatic isletcell adenomas or
carcinomas (combined) was observed in male rats
exposed to C.I. Disperse Blue 1. There was equivocal
evidence ofcarcinogenicity of C.I. Disperse Blue 1 in
male B6C3F1 mice as shown by marginally increased
incidences of hepatocellular adenomas or carcinomas
(combined) in dosed male mice and a marginally
increased occurrence of alveolar/bronchiolar adenomas
or carcinomas (combined) in high dose male mice. There
was no evidence of carcinogenicity of C.I. Disperse
Blue 1 in female B6C3F1 mice.
Synonyms: C.I. 64500; 1,4,5,8-tetraamino-9,10-
anthracenedione; 1,4,5,8-tetraaminoanthraquinone
Report Date: May 1986
TR-300 Toxicology and Carcinogenesis
Studies of3-Chloro-2-methylpropene
(Technical Grade Containing 5%
Dimethylvinyl Chloride) (CAS No. 563-47-3)
in F344/N Rats and B6C3F1 Mice (Gavage
Studies)
Toxicology and carcinogenesis studies of technical-
grade 3-chloro-2-methylpropene (containing 5%
dimethylvinyl chloride), a widely used insecticide and a
chemical intermediate, were performed on F344/N rats
and B6C3F1 mice. In the 13-week studies, 50%-100%
mortality occurred in groups of male and female rats
receiving400mg/kg, male rats receiving 300mg/kg, and
male and femalemice receiving500-1,250 mg/kg. Inflam-
mation and necrosis of the liver were seen in rats and
mice, and necrosis of cortical tubules of the kidney was
seen in mice. Based on these observations, groups of 50
male and 50 female rats were administered 3-chloro-2-
methylpropene in corn oil by gavage at doses of0, 75, or
150 mg/kg body weight, 5 days per week for 103 weeks,
and groups of 50 male and 50 female mice received
3-chloro-2-methylpropene at 0, 100, or 200 mg/kg on the
same schedule.
In the 2-year studies, the mean body weight of high
dosemale ratswas consistently 10%-15% lowerthan that
of the vehicle control group, and late in the study there
was a marginal reduction in survival of high dose male
rats. Mean body weights and survival in low dose male
rats and in both dosed groups of female rats were
comparable tothose oftheirvehicle control groups. Mean
body weights ofhigh dose male mice and ofboth dosed
groups offemale mice were slightly (5%-9%) lower than
those of the vehicle controls, whereas survival in both
male and female mice was not affected by 3-chloro-2-
methylpropene administration.
Dose-relatedincreases intheincidence offorestomach
inflammation were observed in male and female mice
(male: vehicle control, 0/49; low dose, 9/49; high dose,
7/49; female: vehicle control, 2/50; low dose, 3/48; high
dose, 9/44). Increased incidences of forestomach basal
cell hyperplasia were observed in rats and mice of each
sex. 3-Chloro-2-methylpropene induced forestomach
squamous cell papillomas and squamous cell carcinomas
in rats and mice as shown in the table. Invasion or
metastasis of the squamous cell carcinomas to other
organs was observed in two low dose male, three high
dose male, and one high dose female mice.
Renal tubular cell adenocarcinomas (1/49), renal tran-
sitional cell carcinomas (1/49), and transitional cell
papillomas (1/49) oftheurinarybladderwereobservedin
high dose male rats, and renal tubular cell adenomas
(1/50) andrenaltubular cell adenocarcinomas (1/50) were
seen in low dose male rats. These urinary tract neo-
plasms were not observed in vehicle controls.
The incidences ofinflammation ofthe nasal cavity and
ofnephropathy/nephrosis were greater in the two dosed
groupsthaninthevehicle controlgroupsofratsandmice
ofeach sex.
Negative trends or lower incidences of phe-
ochromocytomas of the adrenal gland and C-cell ade-
nomas or carcinomas (combined) of the thyroid gland
were observed in dosed male rats. Negative trends were
observed inthe incidences ofhepatocellularadenomas or
carcinomas (combined) in dosed male mice and of
hemangiomas orhemangiosarcomas (combined)indosed
female mice.
3-Chloro-2-methylpropene was weakly mutagenic in
Salmonella typhimurium strain TA1537 with 10% rat
liverS9; resultsinstrainTA100with10% Syrianhamster
liver S9 or with 10% or 30% rat liver S9 were judged
equivocal. Mutagenicity tests with S. typhimurium
strains TA1535 and TA98 were negative with or without
metabolic activation. 3-Chloro-2-methylpropene was
mutagenic inthemouselymphoma L5178/TK+/-forward
mutation assay without exogenous metabolic activation.
Cytogenetics testswith cultured Chinese hamster ovary
cells were positive for induction ofchromosomal aberra-
tions and sister-chromatid exchanges (SCE's) in the
absence of rat liver S9. With metabolic activation, SCE
levels remained significantly elevated, but the number of
chromosomal aberrations was reduced.
An audit of the experimental data was conducted for
these 2-year carcinogenesis studies on 3-chloro-2-
methylpropene. No data discrepancies were found that
influenced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was clear evidence of carcinogenicity for
3-chloro-2-methylpropene as shown by the increased
incidences of squamous cell neoplasms in the fore-
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stomach ofmale and female F344/N rats and ofmale and
female B6C3F1 mice.
Synonyms: 2-methallyl chloride; methyl allyl chloride;
3-methallyl chloride; -r-chloroisobutylene; isobutenyl
chloride; 3-chloro-2-methyl-1-propene; 2-methyl-2-
propenyl chloride
Report Date: June 1986
TR-301 Toxicology and Carcinogenesis
Studies ofORTHO-Phenylphenol (CAS No.
90-43-7) Alone and with 7,12-
Dimethylbenz(a)anthracene (CAS No.
57-97-6) in Swiss CD-1 Mice (Dermal
Studies)
o-Phenylphenol is used primarily as a germicide and
fungicide for citrus fruits and vegetables and was
selected for carcinogenesis studies because ofthe poten-
tial for human exposure. Four-week studies were con-
ducted in which groups of 10 male and 10 female Swiss
Webster mice were given dermal applications to the
dorsal interscapular region of0, 6,11, 21, 36, or 56 mg of
o-phenylphenol in 0.1 ml of acetone. Doses were admin-
istered 3 days per week for 4 weeks, and animals were
monitored for clinical changes. Reductions in body
weights ofacetone vehicle control were observed, but no
compound-related changes in weight or survival
occurred in male or female mice administered o-phe-
nylphenol. o-Phenylphenol caused dose-related ulcera-
tivelesions atthe siteofapplication. The severityofthese
lesions was judged not to be life threatening.
Carcinogenesis studies were conducted to determine
whether o-phenylphenol was a complete carcinogen for
skin or a promoter in a two-stage initiation/promotion
skin paint model. Groups of 50 Swiss CD-1 mice of each
sexwere used forup to 102weeks. Five dose groupswere
used: an acetone vehicle control group; a positive control
group initiated with 7,12-dimethylbenz(a)anthracene
(DMBA) and promoted with 12-0-tetradecanoyl-
phorbol-13-acetate (TPA); an initiator control group that
received DMBA plus acetone; a group that received
repeated applications of o-phenylphenol. The following
doses were applied dermally to a clipped area on the
dorsal interscapular region 3 days per week:
o-phenylphenol-55.5 mg/0.1 ml acetone; or TPA-0.005
mg/0.1 ml acetone. DMBA was administered as a single
dose at a concentration of 0.05 mg/0.1 ml acetone to the
dorsal interscapular region.
Inthe 2-year studies, meanbodyweights oftheo-phe-
nylphenol, DMBA/o-phenylphenol, and DMBA/TPA
groups were not markedly different from those of mice
that received DMBA/acetone. Similarly, there were no
significant group differences in survival except for a
decrease in survival in the positive control group
(DMBA/TPA).
Skin neoplasms classified as squamous cell papillomas,
squamous cell carcinomas, basal cell tumors, basal cell
carcinomas, keratoacanthomas, or sebaceous adenomas
occurred in mice dosed with DMBA/acetone, DMBA/o-
phenylphenol, orDMBA/TPAalone. However,theincidence
of skin neoplasms in mice dosed with DMBA/acetone
(15/100) was similar to that in mice dosed with DMBA/o-
phenylphenol (17/100). The incidence of skin neoplasms in
male and female mice dosedwith DMBA/TPA(52/100) was
substantially greater than those in mice dosed with either
DMBA/acetone or DMBA/o-phenylphenol. Similarly, the
meantimeofappearanceofskinpapillomasoccurredmuch
earlier in the DMBA/TPA groups than in the DMBA/
acetone or DMBA/o-phenylphenol groups. All groups had
nonneoplastic lesions consisting of inflammation, ulcera-
tion, hyperkeratosis, and acanthosis at the site of applica-
tion. These lesions were present in the acetone vehicle
controlgroupand,toalargerextent,intheo-phenylphenol,
DMBA/o-phenylphenol, and DMBA/TPA groups. No skin
neoplasms were observed in male orfemale mice receiving
o-phenylphenol or in the acetone vehicle control groups.
Moreover, a complete histopathologic review revealed no
otherneoplasms atanyothersite atsignificantlyincreased
incidences in the groups receiving o-phenylphenol com-
paredwith the acetonevehicle controls. Therewere also no
tumor-enhancing (or tumor-inhibiting) effects of o-phe-
nylphenol and DMBA given in combination.
o-Phenylphenol was weakly mutagenic in strains
TA1535 ofSalmonella typhimurium onlyintheabsence
of rat liver S9; it was not mutagenic in strains TA1537,
TA98, or TA100. It was mutagenic in the mouse lym-
phoma L5178/TK+/- assay in the presence or absence of
Aroclor 1254-induced male F344 rat liver S9. o-Phe-
nylphenol did not induce sex-linked recessive lethal
mutations inDrosophila melanogaster. o-Phenylphenol
induced sister-chromatid exchanges in Chinese hamster
ovary (CHO) cells only in the absence of rat liver S9. It
did not induce chromosomal aberrations in CHO cells in
the presence or absence of Aroclor 1254-induced male
Sprague-Dawley rat liver S9.
An audit of the experimental data was conducted for
these 2-year studies ofo-phenylphenol. No data discre-
pancies were found that influenced the final interpreta-
tions.
Under the conditions of these 2-year dermal applica-
tion studies, there was no evidence ofcarcinogenicity
in male or female Swiss CD-1 mice administered o-phe-
nylphenol alone or as apromoterfollowinginitiationwith
DMBA. o-Phenylphenol, however, caused nonneoplastic
lesions, which included ulceration, inflammation, and
hyperkeratosis, at the site of application.
Report Date: March 1986
TR-302 1,2-Epoxyhexadecane (CAS:
7320-37-8)
Study considered inadequate; no Technical Reportwill
be issued.
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TR-303 Toxicology and Carcinogenesis
Studies of4-Vinylcyclohexene (CAS No.
100-40-3) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
Toxicology and carcinogenesis studies of 4-vin-
ylcyclohexene (greater than 98% pure), a dimer of 1,3-
butadiene present in the off-gasses from tire curing,
wereconducted byadministeringthe chemical in corn oil
by gavage 5 days perweek at doses of0, 200, or400 mg/
kgbodyweight to groups of50 F344/N rats and B6C3F1
mice of each sex for 103 weeks. Doses selected for the
2-year studies were based on survival, body weight
gains,andhistopathologiceffectsobservedduringthe14-
day and 13 week studies.
All rats and mostmicein the 14-day studies diedwhen
administered dosesgreaterthanorequalto1,250mg/kg,
although no compound-related gross or histopathologic
effects were observed. Final bodyweights were reduced
in the 13-week studies in male rats receiving doses
greaterthanorequalto400mg/kgof4-vinylcyclohexene,
in female rats receiving 800 mg/kg, and in female mice
receiving 600 mg/kg. Extensive mortality was observed
only in mice dosed at 1,200 mg/kg. Compound-related
histopathologic effects in the 13-week studies included
hyaline droplet degeneration ofthe proximal convoluted
tubules ofthe kidney in dosed male rats, the severity of
whichwas doserelated, and areduction in the number of
primary follicles and mature graafian follicles in the
ovaries of female mice receiving 1,200 mg/kg of 4-vin-
ylcyclohexene. No compound-related gross or histo-
pathologic effects were evident in dosed female rats or
male mice in the 13-week studies.
Manydosedratsdiedearlyinthe2-yearstudies (male:
vehicle control, 17/50; low dose, 37/50; high dose, 45/50;
female: vehicle control, 10/50; low dose, 22/50; high dose,
36/50;P<0.001forallgroups exceptlowdosefemalerats,
forwhichP=0.022). Thepoorsurvival ofdosedmaleand
female rats reduced the sensitivity of the studies for
detecting the possible carcinogenic effects of 4-vin-
ylcyclohexene. Mean body weights of dosed rats were
comparable to those oftheir respective vehicle controls,
except for high dose males late in the study. Survival of
highdosemiceofeach sexwas lower(P<0.001)thanthat
ofthevehicle controls,whereas survival oflowdosemice
ofeach sexwascomparable tothatofthevehiclecontrols.
Mean body weights of high dose mice of each sex were
generally lower than those of the vehicle controls
throughout most ofthe 2-year studies.
Administration of 4-vinylcyclohexene to F344/N rats
by gavage for 2 years was associated with a slightly
increased incidence ofepithelial hyperplasia ofthe fore-
stomach (1150; 3/50; 5/47) and squamous cell papillomas
or carcinomas (combined) ofthe skin in high dose males
(0/50; 1/50; 4/50). Low dose female rats, whose survival
was more similar to that of the vehicle controls, had a
marginally increased incidence of adenomas or
squamous cell carcinomas (combined) of the clitoral
gland (1150; 5/50; 0/49).
In B6C3F1 mice, administration of4-vinylcyclohexene
for two years by gavage was associated with mild, acute
inflammatory lesions and epithelial hyperplasia of the
forestomach, especially in males (0/47; 7/50; 7/46), and
with an increased incidence of a number of other non-
neoplasticlesions, includinglungcongestion inhigh dose
males and females, splenic red pulp atrophyin high dose
males, congestion of the adrenal gland in high dose
females, and cytologic alteration ofthe adrenal cortex in
low dose and high dose females.
The incidences ofuncommon ovarian neoplasms were
markedly increased (P<0.01) in both groups of dosed
female mice (mixed tumor, benign: 0/49; 25/48, 52%;
11147, 23%; granulosa cell tumor or carcinoma [com-
bined]: 1149, 2%; 10/48, 21%; 13/47, 28%). In addition, a
slight increase in the incidence of adrenal gland ade-
nomasinhighdosefemaleswasobserved (0/50;3/49,6%;
4/48, 8%). The extensive mortality seen in the high dose
male mice confounded interpretation of the increased
incidences of malignant lymphomas and alveolar/
bronchiolar adenomas or carcinomas (combined) of the
lung seen in these animals surviving to the end of the
study (malignant lymphomas: 3/37, 8%; 5/39, 13%; 4/7,
57%; alveolar/bronchiolar adenomasorcarcinomas [com-
bined]: 3/37, 8%; 9/39, 23%; 3/7, 43%).
4-Vinylcyclohexene was not mutagenic in Salmanella
typhimurium strains TA100, TA1535, TA1537, or TA98
in the presence or absence ofAroclor 1254-induced male
Sprague-Dawley rat or male Syrian hamster liver S9
when tested according to the preincubational protocol.
However, several of its metabolites, including 4-vin-
ylcyclohexene diepoxide, have been shown to be muta-
genic in Salmonella and/or induce chromosomal damage
in vitro.
An audit of the experimental data was conducted for
these 2-year carcinogenesis studies on 4-vinylcyclohex-
ene. No data discrepancies were found that influenced
the final interpretations.
4-Vinylcyclohexene was administered by gavage in
corn oil to F344/N rats and B6C3F1 mice ofeach sex at
doses of 200 or 400 mg/kg for 103 weeks. Under these
conditions, the 2-year gavage studies of4-vinylcyclohex-
ene in male and female rats and male mice were consid-
ered inadequate studies ofcarcinogenicity because of
extensive and early mortality atthe high dose or atboth
doses and the lack of conclusive evidence of a car-
cinogenic effect. There was clear evidence of car-
cinogenicity of4-vinylcyclohexene for female mice, as
shown by markedly increased incidences of uncommon
ovarian neoplasms at both doses. In addition, the
increased incidence of adrenal gland adenomas in high
dose female mice may have been related to the admin-
istration of4-vinylcyclohexene.
Synonym: 4-ethenylcyclohexene
Report Date: August 1986
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TR-304 Toxicology and Carcinogenesis
Studies ofChlorendic Acid (CAS No.
115-28-6) in F344/N Rats and B6C3F1 Mice
(FeedStudies)
Chlorendic acid is a chemical intermediate used in the
preparation offire-retardant polyester resins and plas-
ticizers. Toxicology and carcinogenesis studies of chlo-
rendic acid (greater than 98% pure) were conducted by
administering the chemical in feed te groups of50 male
and 50 female F344/N rats and B6C3F1 mice at con-
centrations of 0, 620, or 1,250 ppm for 103 weeks. The
estimatedmean dailyconsumption ofchlorendic acidwas
27 and 56 mg/kgbodyweightforlowdose and high dose
maleratsand39and66mg/kgforlowdoseandhighdose
female rats. In mice, the estimated daily consumption
was 89 and 185 mg/kg for low dose and high dose males
and 100 and 207 mg/kg for low dose and high dose
females. These concentrations were selected because
higher levels in the 14-day and 13-week studies caused
decreased mean body weights, more deaths, and
increased incidences of liver lesions (rats: centrilobular
cytomegaly, mitotic alterations, bile duct hyperplasia;
mice: centrilobular cytomegaly, mitotic alterations, coag-
ulative necrosis) relative to control groups.
Survival and feed consumption of dosed male and
femalerats andmiceinthe2-yearstudiesweresimilarto
those ofcontrols. Mean body weights ofhigh dose male
and female rats and mice were lower than those of
controls. Mean body weights of high dose female rats
were 16%-24% lower than those of controls during the
second half ofthe study.
Inthe2-yearchlorendic acidfeedstudies,incidences of
nonneoplastic lesions of the liver in dosed male rats
(cystic degeneration) and dosed female rats (gran-
ulomatous inflammation, pigmentation, and bile duct
hyperplasia)wereincreased.Theincidencesofneoplastic
nodules oftheliverwere significantlyincreased in dosed
malerats (control,2/50; lowdose,21150; highdose,23/50)
and high dose female rats (1V50; 3/39; 11150). The inci-
dence ofhepatocellular carcinomas was alsoincreasedin
high dose female rats (0/50; 3/49; 5/50). In mice, the
incidences of nonneoplastic lesions of the liver were
increased in dosed males (coagulative necrosis) and high
dose females (mitotic alterations). The incidences of
hepatocellular adenomas (5/50; 9/49; 10/50), hepatocellu-
lar carcinomas (9/50; 17/50; 20/50), and hepatocellular
adenomas orcarcinomas (combined) (13/50; 23/49; 27/50)
were increased in dosed male mice. Hepatocellular car-
cinomasmetastasizedtothelungin2/50control,4/49low
dose, and 7/50 high dose male mice. Hepatocellular ade-
nomas or carcinomas (combined) were not significantly
increased in female mice (3/50; 7/49; 7/50).
The incidences of acinar cell hyperplasia (0/49; 4/50;
4/50) and acinar cell adenomas (0/49; 4/50; 6/50) of the
pancreas were increased in dosed male rats relative to
those of controls. Pancreatic acinar cell adenoma is an
uncommon neoplasm inuntreated control F344/N rats in
NTP studies (3/1,667).
In dosed male rats, incidences ofalveolar/bronchiolar
adenomas of the lung (0/50; 3/50; 5/50) were increased.
The incidences ofalveolar/bronchiolar adenomas or car-
cinomas (combined) in dosed female mice were also
increased (1150; 5/50; 6/50). Preputial gland carcinomas
occurred at a greater incidence in low dose male rats
(1150; 8/50; 4/50) than in controls. An adenoma and a
squamous cell papilloma were observed in two low dose
male rats. The incidences ofsarcomas, fibrosarcomas, or
neurofibrosarcomas (combined) of the salivary gland
(1150; 2/49; 4/50) were increased in dosed male rats. The
incidences in the dosed groups were not significantly
different from that in the controls, but these tumors are
uncommon in F344/N rats receiving no treatment
(3/1,689).
Chlorendic acid was not mutagenic in strains TA100,
TA98, TA1535, or TA 1537 ofSalmonella typhimurium
in the presence or absence ofAroclor 1254-induced male
Sprague-DawleyratormaleSyrianhamsterliveractiva-
tion when tested according to the preincubational pro-
tocol. Chlorendic acid was mutagenic in the L5178Y/
TK+/- mouse lymphoma cell forward assay (in the
absence ofactivation) at a dose resulting in toxicity.
An audit of the experimental data was conducted for
the 2-year studies ofchlorendic acid. No data discrepan-
cies were found that influenced the final interpretations.
Under the conditions of these 2-year feed studies,
therewas clearevidence ofcarcinogenicity ofchloren-
dic acid for male F344/N rats as shown by increased
incidences of neoplastic nodules of the liver and acinar
cell adenomas of the pancreas. Increased incidences of
alveolar/bronchiolar adenomas and preputial gland car-
cinomasmayalsohavebeenrelatedtotheadministration
of chlorendic acid. There was clear evidence of car-
cinogenicity of chlorendic acid for female F344/N rats
as shown by increased incidences of neoplastic nodules
and ofcarcinomas oftheliver. Therewasclearevidence
ofcarcinogenicity of chlorendic acid for male B6C3F1
mice as shown byincreased incidences ofhepatocellular
adenomas and of hepatocellular carcinomas. There was
no evidence of carcinogenicity of chlorendic acid for
female B6C3F1 mice given chlorendic acid in the diet at
concentrations of620 or 1,250 ppm for 103 weeks.
Synonym: 1,4,5,6,7,7-hexachloro-5-norbornene-2,3-
dicarboxylic acid
Report Date: April 1987
TR-305 Toxicology and Carcinogenesis
Studies ofChlorinated Paraffins (C23, 43%
Chlorine) (CAS No. 108171-27-3) in F344/N
Rats and B6C3F1 Mice (Gavage Studies)
Toxicology and carcinogenesis studies of chlorinated
paraffins (C23,43% chlorine), anextreme-pressure lubri-
cantandflameretardant, wereconductedbyadminister-
ing the chemical in corn oil by gavage to groups of 50
F344/N rats and 50 B6C3F1 mice ofeach sex, 5 days per
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week for 103 weeks. Additional groups of10 rats per sex
and dosewere examined at6 and at12months. Male rats
received doses of 0, 1,875, or 3,750 mg/kg body weight;
female rats were given 0, 100, 300, or 900 mg/kg. Male
and female mice received 0, 2,500, or5,000mg/kg. Doses
selected for the 2-year studies were based on the results
from13-week studies inwhich rats ofeach sexreceived 0
to3,750mg/kg, andmiceofeachsex,0to7,500mg/kg. No
toxicity ofchlorinated paraffins (C23, 43% chlorine) was
observed in male rats orinmale orfemalemiceinthe 13-
week studies. A dose-related inflammation of the liver
was observedinfemale ratsinthe13-week studies and in
male and female rats in the 13-week studies and in male
and female rats at 6 and 12 months in the 2-year studies.
Chlorinated paraffins (C23, 43% chlorine) administra-
tion did not influence mean bodyweights ofrats during
the 2-year studies, but both male and female low dose
mice gained less weight than did vehicle controls or the
high dose groups. Survival of dosed and vehicle control
groups was similar for each sex and species (male rats:
vehicle control, 30/50; low dose, 32/50; high dose, 27/50;
female rats: 34/50; 30/50; 33/50; 31/50; male mice: 29/50;
36/50; 28/50; femalemice: 21/50;22/50; 20/50). Forfemale
mice, 60%-70% of the early deaths in each group were
attributed to utero-ovarian infection. The lower survival
forfemalemicemayhavedecreasedthesensitivityofthis
study to detect a carcinogenic effect.
Pheochromocytomas of the adrenal gland medulla
occurred with an increased incidence in female rats
exposed to chlorinated paraffins (C23, 43% chlorine)
(vehicle control, 1/50; lowdose, 4/50; mid dose, 6/50; high
dose, 7/50). However, adrenal gland medullary hyper-
plasia was not increased (6/50; 3/50; 1/50; 6/50). Malig-
nant lymphomas were increased in dosed male mice
(6/50; 12/50; 16/50). High dose female mice showed a
marginal increase in the incidence ofhepatocellular car-
cinomas (1/50; 1/49; 6/50) and in the incidence of ade-
nomas or carcinomas (combined) (4/50; 3/49; 10/50).
The primary nonneoplastic lesion associated with
chlorinated paraffins (C23, 43% chlorine) administration
was a diffuse lymphohistiocytic inflammation in the liver
and in the pancreatic and mesenteric lymph nodes of
maleandfemalerats.Spleniccongestionwasasecondary
effect. These lesions occurred earlier and atlower doses
in female rats than in male rats. No significant non-
neoplastic lesions were considered compound related in
mice.
Chlorinated paraffins (C23, 43% chlorine) was not
mutagenic in strains TA100, TA1535, TA97, or TA98 of
Salmonella typhimurium in the presence or absence of
Aroclor 1254-induced male Sprague-Dawley rat or male
Syrian hamster liver S9 when assayed according to the
preincubation protocol.
An audit of the experimental data was conducted for
these 2-year studies of chlorinated paraffins (C23, 43%
chlorine). No data discrepancies were found that influ-
enced the final interpretations.
Under the conditions of these 2-year gavage studies,
therewasno evidence ofcarcinogenicity ofchlorinated
paraffins (C23, 43% chlorine) formale F344/N rats given
1,875 or 3,750 mg/kg per day. There was equivocal
evidence of carcinogenicity of chlorinated paraffins
(C23, 43% chlorine) for female F344/N rats as shown by
an increased incidence of adrenal gland medullary phe-
ochromocytomas. There was clear evidence of car-
cinogenicity of chlorinated paraffins (C23, 43%
chlorine) formale B6C3F1 mice as shownbyan increase
in the incidence of malignant lymphomas. There was
equivocal evidence of carcinogenicity of chlorinated
paraffins (C23, 43% chlorine) forfemale B6C3F1 mice as
shown by a marginal increase in the incidence of
hepatocellular neoplasms.
Report Date: May 1986
*The Chemical Abstract Service Service (CAS) number
that appeared on this technical report at the time of
publication (63449-39-8) reflects the generic CAS num-
ber for chlorinated paraffins. This number has been
replaced in the NTP Chemtrack chemical tracking sys-
tem with the more appropriate number.
TR-306 Toxicology and Carcinogenesis
Studies ofDichloromethane (Methylene
Chloride) (CAS No. 75-09-2) in F344/N Rats
andB6C3F1 Mice (Inhalation Studies)
Dichloromethane is widely used in industrial processes,
food preparation, and agriculture. In industry,
dichloromethane is used as a solvent in paint removers,
degreasing agents, aerosol propellants, and triacetate
solutions; as a blowing agent in flexible urethane foams;
and as a process solvent in the manufacture ofsteroids,
antibiotics, vitamins, and tablet coatings. The use of
dichloromethane as an extraction solvent for spice
oleoresins, hops, and caffeine from coffee has been
approved by the U.S. Food and Drug Administration.
Dichloromethane has been used as an inhalation anes-
thetic and as a fumigant for grain and strawberries.
Toxicology and carcinogenesis studies of
dichloromethane (99% pure) were conducted by inhala-
tion exposure ofgroups of50maleand 50female F344/N
rats and B6C3F1 mice 6 hours per day, 5 days perweek,
for 102 weeks. The exposure concentrations used (0,
1,000, 2,000, or 4,000 ppm for rats and 0, 2,000, or 4,000
ppm for mice) were selected on the basis ofresults from
13-weekinhalation studies inwhich groups of10 rats and
10 mice ofeach sex were exposed to dichloromethane at
concentrations of525-8,400 ppm 6 hours per day, 5 days
perweek.
During the 2-year studies in rats, body weight gains
forexposed males and females were comparable to those
of the chamber controls. The survival of exposed male
rats was comparable to that of the chamber controls;
however, the survival ofall groups ofmales at the termi-
nation of the study was low (control, 16/50; low dose,
16/50; mid dose, 17/50; high dose, 9/50). Mostofthe early
deaths amongmale rats occurred duringthefinalweeks
ofthe study; the survival ofmale ratsthroughweek86 of
172ABSTRACTS FROMLONG-TERM CANCER STUDIES, 1976-1992
the study was 36/50, 39/50, 37/50, and 33/50. This
decreased survival is believed to be related to the high
incidence of leukemia (34/50; 26/50; 32/50; 35/50). Sur-
vival of female rats exposed at 4,000 ppm was reduced
relative to that of the chamber controls (30/50; 22/50;
22/50; 15/50); leukemia occurred frequently in all female
rat groups. Final mean body weights ofhigh dose male
mice and low and high dose female mice were 10%-17%
lower than those of the chamber controls; these reduc-
tions occurred during the last 16weeks ofthe study. The
survival of dosed male mice and high dose female mice
was reduced relative to that of the chamber controls
(male: control, 39/50; low dose, 24/50; high dose, U/50;
female: 25/50; 25/50; 8/50). This reduced survival may
have been due to the chemically induced development of
liver and lung neoplasia in male and female mice.
Increased incidences of benign mammary gland
lesions (adenomas and fibroadenomas) occurred in male
and female rats exposed to dichloromethane (male: 0/50;
0/50; 2/50; 5/50; female: 5/50; 11/50; 13/50; 23/50). The
incidence ofmalignant mammary gland neoplasms was
not increased in female rats (2/50; 2/50; 2/50; 0/50); none
was observed in male rats. In addition, integumentary
system tumors in the area of the mammary chain
occurredwithapositivetrendinmalerats(subcutaneous
tissue fibroma or sarcoma: 1/50; 1/50; 2/50; 5/50); the
combinedincidence ofalltumorsinthemammaryareain
male rats was 1/50, 1/50, 4/50, and 9/50.
Exposure to dichloromethane was associated with
increased incidences of hepatic hemosiderosis,
cytomegaly, cytoplasmic vacuolization, necrosis, gran-
ulomatous inflammation, and bile duct fibrosis in both
male and female rats. There was a positive butmarginal
trend in the incidence of hepatocellular neoplastic nod-
ules or hepatocellular carcinomas (combined) in female
rats (2/50; 1/50; 4/50; 5/50). The incidence of squamous
metaplasia of the nasal cavity was increased in female
rats exposed at 4,000 ppm (1/50; 2/50; 3/50; 9/50) but not
in males (4/50; 5/50; 3/50; 3/50). No nasal cavity tumors
wereobservedin rats. Theincreased incidences ofmono-
nuclear cell leukemia in mid dose and high dose female
rats (17/50; 17/50; 23/50; 23/50) were statistically signifi-
cant by age-adjusted analyses. In male rats, meso-
theliomas (arising primarily from the tunica vaginalis)
occurred at increased incidences (0/50; 2/50; 5/50; 4/50).
Lungtumors occurred atincreasedincidences inmale
and female mice exposed to dichloromethane (alveolar/
bronchiolar adenomas: male -3/50; 19/50; 24/50;
female -2/50; 23/48; 28/48; alveolar/bronchiolar car-
cinomas: male-2/50; 10/50; 28/50; female-I/50; 13/48;
29/48). Cytologic degeneration ofthe liverwas observed
at increased incidences in high dose male and dosed
female mice (male: 0/50; 0/49; 22/49; female: 0/50; 23/48;
21/48). Incidences of hepatocellular adenomas or
hepatocellular carcinomas (combined) were increased in
high dose male and dosed female mice (male: 22/50;
24/49; 33/49; female: 3/50; 16/48; 40/48). There were also
dose-related increases in the numbers of mice bearing
multiple lung or liver neoplasms. Dose-related increases
were observed in the incidences oftesticular atrophy in
male mice and uterine and ovarian atrophy in female
mice; these effects are considered to be secondary
responses to neoplasia.
An audit of the experimental data was conducted for
the 2-year studies of dichloromethane. No data discre-
pancies were found that influenced the final interpreta-
tions.
Under the conditions ofthese inhalation studies, there
was some evidence of carcinogenicity of dichloro-
methane formale F344/N rats as shownbyan increased
incidence of benign neoplasms of the mammary gland.
There was clear evidence of carcinogenicity of
dichloromethane for female F344/N rats as shown by
increased incidences ofbenign neoplasms ofthe mamm-
arygland. Therewas clearevidenceofcarcinogenicity
ofdichloromethane formale andfemaleB6C3F1 mice, as
shown by increased incidences of alveolar/bronchiolar
neoplasms and ofhepatocellular neoplasms.
Synonyms: DCM; methylene chloride
Report Date: January 1986
TR-307 Toxicology and Carcinogenesis
Studies ofEphedrine Sulfate (CAS No.
134-72-5) in F344/N Rats and B6C3F1 Mice
(FeedStudies)
Ephedrine sulfate is a sympathomimetic amine that
affects both the central andperipheral nervous systems.
An effective bronchiodilator and weak vasoconstrictor,
ephedrine sulfate is used extensively in nonprescription
pharmaceutical preparations such as nose drops, cold
tablets, cough syrups, and, in particular, asthma relief
medicines. Ephedrine sulfate was nominated for car-
cinogenesis studies by the National Cancer Institute
becauseofitswidespread andlong-termusefortherelief
of symptoms associated with asthma.
In 14-day repeated-exposure studies, F344/N rats of
each sexreceived dietscontaining0-1,500ppmephedrine
sulfate or drinking water containing 0-1,200 ephedrine
sulfate; B6C3F1 mice received diets or drinking water
containing 0-5,000 ppm ephedrine sulfate. In the feed
studies, the average feed consumption by dosed rats and
micewas comparable to that oftheirrespective controls.
The average water consumption by rats and mice
decreased with increasing concentration of ephedrine
sulfate in the drinking water. Thus, subsequent studies
used the feed route ofadministration.
Dosesforthe2-yearstudieswereselected onthebasis
ofresults from 13-week studies in which F344/N rats of
each sex were given diets containing 0, 125, 250, 500,
1,000, or 2,000 ppm ephedrine sulfate and B6C3F1 mice
ofeach sexwere given diets containing 0, 310, 630,1,250,
2,500, or 5,000 ppm ephedrine sulfate. The major
response that occurred during the 13-week studies was
compound-associated reduction in weight gain. Toxicol-
ogyandcarcinogenesis studies ofephedrine sulfatewere
conducted by administering diets containing 0, 125, or
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250 ppm ephedrine sulfate to groups of 50 F344/N rats
and 50 B6C3F1 mice of each sex for 103 weeks. The
estimated average amount of ephedrine sulfate con-
sumed perdayduring the 2-year studywas 4 mg/kg and
9 mg/kg for low dose and high dose male rats, 5 mg/kg
and 11 mg/kg for female rats, 14 mg/kg and 29 mg/kg
for male mice, and 12 mg/kg and 25 mg/kg for female
mice.
Survival ofchemically exposed female rats during the
2-year study was greater than that ofthe controls (con-
trol, 27/50; lowdose, 39/50; high dose, 39/50); survival of
exposedmaleratsandmaleandfemalemicewascompar-
able to that of controls. Throughout most of the 2-year
studies, mean bodyweights ofrats and mice ofeach sex
receiving diets containing ephedrine sulfate were lower
than those ofcontrols.
Neoplasms that occurred in these studies were not
considered to be related to administration of ephedrine
sulfate. Two high dose female mice had ovarian gran-
ulosa cell tumors, and luteomas were found in one low
dose and onehigh dosefemale mouse. Because ofthelow
incidence, these uncommon, benign tumors could not be
clearly related to ephedrine sulfate administration.
Ephedrine sulfatewas notmutagenicinfourstrains of
Salmonella typhimurium (TA100, TA1535, TA97, or
TA98) with or without Aroclor 1254-induced male
Sprague-Dawley rat or Syrian hamster liver S9 activa-
tion. Ephedrine sulfate did not induce sister-chromatid
exchanges or chromosomal aberrations in cultured Chi-
nese hamster ovary cells.
An audit of the experimental data was conducted for
these2-yearstudiesofephedrine sulfate. Nodatadiscre-
pancies were found that influenced the final interpreta-
tions.
Under the conditions of these studies, there was no
evidence ofcarcinogenicity forF344/N rats orB6C3F1
mice of either sex receiving 125 or 250 ppm ephedrine
sulfate in the diet for 2 years.
Report Date: May 1986
TR-308 Toxicology and Carcinogenesis
Studies ofChlorinated Paraffins (C12, 60%
Chlorine) (CAS No. 108171-26-2*) in F344/N
Rats and B6C3F1 Mice (Gavage Studies)
Toxicology and carcinogenesis assessments of chlori-
nated paraffins (C12, 60% chlorine), a material widely
used as a flame retardant and extreme-pressure lubri-
cant,wereconductedinmaleandfemaleF344/Nratsand
male and female B6C3F1 mice in single-administration,
16-day, 13-week, and 2-year studies. Doses used in the
2-year studieswere 0, 312, or625mg/kgbodyweightper
day administered by gavage in corn oil five times per
week to groups of70 male and female rats and 0, 125, or
250mg/kgadministered to groups of50male and female
mice. Tenmale and 10female ratswere killed after 6 and
12 months ofdosing and examined for toxicity.
No chemically related toxicity was observed in single-
administration studies in which male and female rats
received doses of chlorinated paraffins (C12, 60% chlo-
rine) up to 13,600 mg/kg body weight and male and
female up to 27,200 mg/kg. In 16-day studies, deaths did
occur in groups ofmale and female rats given 7,500 mg/
kg and in groups ofmale and female mice given doses of
1,875 mg/kg or higher. In 13-week studies, no chemically
related deaths occurred among male and female rats
givenup to 5,000mg/kgormice givenup to 2,000mg/kg.
Increased liver weights were noted in dosed rats and
mice of each sex in the short-term studies, and dosed
male rats showed more severe nephropathy than did
vehicle controls. Doses selected for the 2-year studies
werethosethatcausedaminimalincreaseinliverweight
in the short-term studies.
Liverand kidneyweightswereincreased in dosed rats
killed at 6 and 12 months. Morphometric measurements
demonstrated hepatocyte hypertrophy in the livers of
dosed rats. Lesions ofthe kidneytubules and interstitial
inflammation increased with dose in male and female
rats.
During the 2-year studies, body weights ofhigh dose
male rats were 8%-12% lower than those of vehicle
controls afterweek20, andbodyweightsofdosedfemale
micewere about10% lowerthan those ofvehicle controls
during the second year. Survival ofdosed male rats was
lower than that ofvehicle controls after about week 85,
perhaps due to toxicity to the kidney (final survival:
vehicle control, 27/50; low dose, 6/50; high dose, 3/50).
Survival oflow dose female rats was lower than that of
vehicle controls (34/50; 24/50; 29/50). Survival of dosed
male mice was not significantly different from that of
vehicle controls (34/50; 31/50; 31/50). Survival of high
dose female mice was lower than that ofvehicle controls
after about week 75 (final survival: 36/50; 31/50; 25/50).
Chemically related nonneoplastic lesions consisted of
hypertrophy and minimal focal necrosis of the liver in
rats; erosion, inflammation, andulceration oftheglandu-
lar stomach and forestomach a in male rats; and forma-
tion ofmultiple cysts in the kidney tubules ofmale rats.
The incidence of nephropathy was also increased in
dosedfemaleratsandmice.Themaximumtolerateddose
may have been exceeded in male and female rats.
Neoplastic lesions associated with chlorinated paraf-
fins (C12, 60% chlorine) administrationwerefoundinthe
liver of rats and mice of each sex (see table p. 12 of
Technical Report)
Dosed male rats showed increased incidences of
kidney tubular cell hyperplasia (1/50; 9/50; 12/49) and of
tubular cell adenomas (0/50; 7/50; 3/49); two low dose
males had tubular cell adenocarcinomas. The incidences
of mononuclear cell leukemia were increased in dosed
male rats (7/50; 12/50; 14/50) and in low dose female rats
(11/50; 22/50; 16/50). Pancreatic acinar cell tumors
occurred at increased incidences in low dose male rats
(11/50; 22/50; 17/50). Follicular cell adenomas or car-
cinomas (combined) of the thyroid gland were found at
increasedincidences inbothfemalerats (0/50; 6/50; 6/50)
and female mice (8/50; 12/49; 15/49).
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Chlorinated paraffins (C12, 60% chlorine) was not
mutagenic in Salmwnella typhimurium strains TA97,
TA98, TA100, or TA1535 in the presence or absence of
Aroclor1254-induced male Sprague-DawleyormaleSyr-
ian hamsterliver S9whentested according to theprein-
cubational protocol.
An audit ofthe experimental data was conducted for
these 2-year studies on chlorinated paraffins (C12, 60%
chlorine). No data discrepancies were found that influ-
enced the final interpretations.
Under the conditions ofthese 2-year gavage studies,
there was clear evidence ofcarcinogenicity of chlori-
nated paraffins (C12, 60% chlorine) for F344/N rats
based on increased incidences of hepatocellular neo-
plasms (primarilyneoplasticnodules)inmaleandfemale
rats, ofadenomas oradenocarcinomas (combined) ofthe
kidney tubular cells in male rats, and of follicular cell
adenomas orcarcinomas (combined) ofthethyroidgland
in female rats. Mononuclear cell leukemia in dosed male
rats may have been related to administration of chlori-
nated paraffins (C12, 60% chlorine). There was clear
evidence of carcinogenicity of chlorinated paraffins
(C12, 60% chlorine) for B6C3F1 mice as shown by
increased incidences ofhepatocellular adenomas and of
adenomas or carcinomas (combined) in dosed male and
femalemiceandincreasedincidences ofadenomas andof
adenomas or carcinomas (combined) of thyroid gland
follicular cells in dosed female mice.
Report Date: May 1986
*The Chemical Abstract Service Service (CAS) number
that appeared on this technical report at the time of
publication (63449-39-8) reflects the generic CAS num-
ber for chlorinated paraffins. This number has been
replaced in the NTP Chemtrack chemical tracking sys-
tem with the more appropriate number.
TR-309 Toxicology and Carcinogenesis
Studies ofDecabromodiphenyl Oxide (CAS
No.1163-19-5) In F344/N Rats and B6C3F,
Mice(FeedStudies)
Toxicology and carcinogenesis studies of
decabromodiphenyl oxide, a flame retardant for plastics
and othermaterials, were conducted byexposing groups
of50 male and 50 female F344/N rats and B6C3F1 mice
at 0, 25,000, and 50,000 ppm in the diet for 103 weeks.
These concentrations were selected because no toxicity
wasobservedatanydoseinthe14-dayor13-weekstudies
and 50,000 ppm chemical in the diet is considered to be
the highest dose to which rats and mice can be exposed
for extended periods oftime without reducing the nutri-
tional value of the diet. No compound-related gross or
microscopic pathologic effects were observed in the 14-
day or 13-week studies.
Bodyweights ofdosed male and female rats and mice
in the 2-year studies were comparable to those of the
controls. Decreased survival of low dose male rats was
not believed to be compound related. No other effects on
survival were observed in the 2-year studies. Loss of
control male mice (presumably due to fighting) was
significant during the first part ofthe study.
In the 2-year studies, nonneoplastic lesions were
observed atincreasedincidences inrats andmiceofeach
sex. Thrombosis and degeneration oftheliver,fibrosis of
the spleen, and lymphoid hyperplasia were observed in
high dose male rats. Degeneration of the eye was
observed in low dose female rats. Nonneoplastic lesions
observed in dosed mice were granulomas in the liver of
low dose males and hypertrophy in the liver oflow dose
and high dose males. Follicular cell hyperplasia was
observed in thyroid glands ofdosed male mice (control,
2/50; low dose, 10/50; high dose, 19/50).
The incidences ofneoplastic nodules in the liver oflow
and high dose male rats (1/50; 7/50; 15/49) and high dose
female rats (1/50; 3/49; 9/50) were significantly greater
than those in the controls. Mononuclear cell leukemia
occurred in dosed maleratswith apositive trend (30/50;
33/50; 35/50); this marginal increase was not considered
biologically significant. Acinar cell adenomas were
observedinthepancreas offourhighdosemalerats, and
asarcomawas observedinthespleenofonelowdoseand
one high dose male rat. Hepatocellular adenomas or
carcinomas(combined)occurredatmarginallyincreased
incidences in dosed male mice (8/50; 22/50; 18/50). The
incidences of thyroid gland follicular cell adenomas or
carcinomas (combined)wereincreasedindosemalemice
(0/50; 4/50; 3/50).
A study of decabromodiphenyl oxide absorption from
the gastrointestinal tract indicated that absorption was
minimal,possiblylessthan1%, atthedosesadministered
in the 2-year studies. Additional chemical analysis indi-
cated than the decabromodiphenyl oxide used in these
studies contained several less brominated diphenyl
oxides. Therefore, since absorption and toxicity ofminor
impurities are unknown, effects observed in these stud-
ies must be attributed to the approximately 95% pure
preparationusedratherthantopuredecabromodiphenyl
oxide.
Decabromodiphenyl oxide was not mutagenic in
strains TA1535, TA1537, TA98, or TA100 ofSalmcnella
typhimurium in the presence or absence of Aroclor
1254-induced Sprague-Dawley male rat or Syrian ham-
ster liver S9 when tested according to the preincuba-
tional protocol. Decabromodiphenyl oxide was not
mutagenic in the mouse lymphoma L5178Y/TK+/- assay
inthepresence orabsenceofAroclor1254-induced F344/
N male rat liver S9. Decabromodiphenyl oxide did not
induce sister-chromatid exchanges orchromosomal aber-
rations in Chinese hamster ovary cells in vitro in the
presenceorabsenceofS9preparedfromliversofAroclor
1254-induced male Sprague-Dawley rats.
An auditofexperimental datawas conducted forthese
2-year studies on decabromodiphenyl oxide. No data
discrepancies were found that influenced the final inter-
pretations.
Under the conditions of these 2-year feed studies of
decabromodiphenyl oxide, there was some evidence of
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carcinogenicity for male and female F344/N rats as
shown by increased incidences of neoplastic nodules of
the liver in low dose (25,000 ppm) males and high dose
(50,000 ppm) groups of each sex. There was equivocal
evidence ofcarcinogenicity for male B6C3F1 mice as
shown by increased incidences of hepatocellular ade-
nomas or carcinomas (combined) in both dosed groups.
There was no evidence of carcinogenicity for female
B6C3F1 mice receiving 25,000 or 50,000 ppm in the diet.
Severalnonneoplastic lesions wereobserved atincreased
incidences, the most notable being thyroid gland follicu-
lar cell hyperplasia in male mice.
Synonyms: decabromodiphenyl ether; bis(pen-
tabromophenyl)ether; DBDPO
Report Date: May 1986
TR-310 Toxicology and Carcinogenesis
Studies ofMarine Diesel Fuel (NO CAS)
and JP-5 Navy Fuel (CAS No. 8008-20-6) in
B6C3F1 Mice (Dermal Studies)
Toxicology and carcinogenesis studies were conducted
byapplyingmarinedieselfuel orJP-5 navyfueltoclipped
dorsal interscapular skin of male and female B6C3Fj
mice to determine both systemic and dermal effects.
Doses for the 2-year studies were set by conducting 14-
day and 13-week studies. Doses of 2,000-40,000 mg/kg
marinedieselfuel wereapplied neatinthe14-daystudies;
in the 13-week studies, doses of250-4,000 mg/kg marine
diesel fuel in acetone were applied with a dose volume of
0.1 ml. Doses of 5,000-40,000 mg/kg JP-5 navy fuel in
ethanol were applied in the 14-day studies with a dose
volume of 0.5 ml; in the 13-week studies, doses of
500-8,000 mg/kg JP-5 navy fuel in acetone were applied
with a dose volume of 0.2 ml. For the 2-year studies,
doses were selectedwhich did not cause deaths, decrease
bodyweight gain, orproduce excessive dermatitis in the
14-day or 13-week studies. Two-year studies were con-
ducted by administering marine diesel fuel or JP-5 navy
fuel by dermal application to groups of49 or50 male and
50femaleB6C3F1 miceatdoses of0,250, or500mg/kgin
an acetone vehicle with a dose volume of0.1 ml.
Both sexes ofmice dosed with 500 mg/kg marine diesel
fuel (84-week exposure) and female mice dosed with 500
mg/kgJP-5 navyfuel (90-weekexposure) were killed early
because ofexcessive irritation and ulceration at the site of
application and to preventthe spread ofinfection. Survival
rates at those times were 26/50 males and 29/50 females
dosedwithmarine dieselfuel and17/50females dosedwith
JP-5 navyfuel. Survival rates attheend ofthe studies (104
weeks) were reduced (P<0.01) in low dose female mice
receiving marine diesel fuel (40/50 in vehicle controls com-
pared with 12/50 in the low dose group) orwith JP-5 navy
fuel (44/50 in vehicle controls compared with 33/50 in the
low dose group). Body weight gain was decreased below
that of the vehicle controls after week 30 in all groups of
mice receivingmarine diesel fuel and inboth sexes ofmice
receiving the high dose ofJP-5 navy fuel.
There was a marked increase in the incidence of
chronic dermatitisinmicereceivingmarine dieselfuel or
JP-5 navy fuel. Chronic dermatitis was defined as a
composite lesion of epidermal histopathologic changes
generallyconsistingofacanthosis,hyperkeratosis, andin
some instances necrosis and ulceration of the overlying
epidermis. Dermal changes frequentlyincluded fibrosis,
increased amounts ofmelanin, and the presence ofacute
and chronic inflammatorycellinfiltrates. Adose-related,
proportional increase in the severity ofthe lesions was
twofold to threefold greater in the dosed groups than in
thevehiclecontrols.Theaveragedegreeofseverityofthe
lesions wasjudged to be minimal in the vehicle controls,
mild in the low dose groups, and moderate in the high
dosegroupsofmicedosedwithmarinedieselfuel orJP-5
navy fuel. There were similar responses at the site of
inguinal skin to which the chemicals had migrated after
application, but the degree ofseverity ofthe lesions was
judged to be minimal to mild in the vehicle control and
dosed groups ofmice.
Squamous cell papillomas or carcinomas (combined)
occurred with a positive trend (P<0.05) at the site of
application in male mice administered marine diesel fuel
(vehiclecontrol, 0/49; lowdose, 0/49;highdose,3/49). The
total numbers ofmice with squamous cell papillomas or
carcinomas (combined) both for the site of application
and the adjacent inguinal skin were 1150, 2/49, and 3/50
forthevehicle control, lowdose, and high dose groups of
malemice and0/50,1/45, and2/48forfemalemice. There
are no NTP historical data for B6C3F1 mice that
received acetone by dermal application. The NTP histor-
icalincidence ofsquamous cell papillomas or carcinomas
(combined) inuntreatedmale andfemaleB6C3F1 miceis
0.3%-0.4% in over 3,500 observations.
Marine diesel fuel was not mutagenic in Salmonella
typhimurium TA98, TA100, TA1535, or TA1537, and
JP-5 navyfuelwas notmutagenic in strains TA97, TA98,
TA100, or TA1535 in the presence or absence ofAroclor
1254-induced male Sprague-Dawley rat or male Syrian
hamster S9 when tested according to the preincubation
protocol.
Audits of the experimental data were conducted for
these 2-year studies on marine diesel fuel and JP-5 navy
fuel. No data discrepancies were found that influenced
the final interpretations.
Under the conditions of these 2-year dermal studies,
marine dieselfuel atdoses of250 and 500mg/kgresulted
in dose-related increased incidences of squamous cell
neoplasms ofthe skin (primarily carcinomas), providing
equivocal evidence of carcinogenicity for male and
female B6C3F1 mice. The sensitivity for detecting sys-
temic carcinogenicity in female mice dosed with marine
diesel fuel was reduced by poor survival. Under the
conditions ofthese 2-yeardermal studies, JP-5 navyfuel
at doses of 250 and 500 mg/kg provided no evidence of
carcinogenicity for male and female B6C3F1 mice.
Report Date: September 1986
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TR-311 lTxicology and Carcinogenesis
Studies ofTetrachloroethylene
(Perchloroethylene) (CAS No. 127-18-4) in
F344/N Rats and B6C3F1 Mice (Inhalation
Studies)
Tetrachloroethylene is used primarily as a dry clean-
ingagent, an industrial solventforfats, oils, tars, rubber,
ftnd gums, and a metal degreasing agent. Tetra-
chloroethylene had antihelminthic uses, particularly for
hookworms (1.6-8 g/60 kg), and was formerly used in
combination with some grainprotectants and fumigants.
Toxicology and carcinogenesis studies of
tetrachloroethylene (99.9% pure) were conducted by
inhalation exposure of groups of 50 male and 50 female
F344/Nrats andB6C3F1 mice6hours perday,5days per
week, for 103 weeks. The exposure concentrations used
(0, 200, or 400 ppm for rats and 0, 100, or 200 ppm for
mice) were selected on the basis ofresults from 13-week
inhalation studies inwhich groups of10 rats and 10 mice
of each sex were exposed to tetrachloroethylene at
100-1,600 ppm for 6 hours per day, 5 days per week.
During the 13-week studies, 1,600 ppm
tetrachloroethylene was lethal to 20%-70% of the rats
andmice andreducedthefinalbodyweights ofsurvivors.
Inrats, tetrachloroethylene at200-800 ppm caused mini-
maltomildhepaticcongestion. In dosedmaleandfemale
mice, minimal to mild hepatic leukocytic infiltration,
centrilobular necrosis, bile stasis (400-1,600 ppm), and
mitotic alteration (200-1,600 ppm) were produced.
Tetrachloroethylene exposure also caused minimal renal
tubularcellkaryomegalyinmiceatconcentrations aslow
as 200 ppm.
During the 2-year studies, exposure to
tetrachloroethylene did not consistently affect body
weight gains in either rats ormice. Exposure at400 ppm
tetrachloroethylene reduced the survival of male rats
(control, 23/50; low dose, 20/50; high dose, 12/50). This
reduced survival may have been related to an increased
incidence of mononuclear cell leukemia.
Tetrachloroethylene at both exposure concentrations
reduced the survival of male mice (46/50; 25/50; 32/50),
whereas exposure at 200 ppm reduced female mouse
survival (36/50; 31150; 19/50). Early deaths in mice may
have been related to the development of hepatocellular
carcinomas.
Both concentrations oftetrachloroethylene were asso-
ciated with increased incidences of mononuclear cell
leukemiainmalerats (28/50; 37/50; 37/50). Infemalerats,
tetrachloroethylene increased the incidence ofleukemia
(18/50; 30/50; 29/50) and decreased the time to occur-
renceofthedisease. Tetrachloroethylene produced renal
tubular cell karyomegaly in male and female rats, renal
tubular cell hyperplasia in male rats, and renal tubular
cell adenomas or adenocarcinomas (combined) in male
rats (1/49; 3/49; 4/50).
The incidence of the renal tubular cell tumors was
statistically significant; these uncommon tumors have
been consistently found at low incidences in male rats in
other 2-year studies of chlorinated ethanes and eth-
ylenes. One low dose male rat had a kidney lipoma, and
anotherhad anephroblastoma. Fourhigh dosemale and
two high dose female rats had gliomas of the brain,
whereas onecontrolmaleand onecontrolfemalehadthis
tumor.
In male and female mice, tetrachloroethylene caused
dose-relatedincreasesintheincidences ofhepatocellular
neoplasms. In males, tetrachloroethylene at 200 ppm
increased the incidence of hepatocellular adenomas
(11149; 8/49; 18/50) and at both concentrations increased
the incidence of hepatocellular carcinomas (7/49; 25/49;
26/50). In female mice, tetrachloroethylene at both con-
centrations increased the incidences of hepatocellular
carcinomas (1V48; 13/50; 36/50). Tetrachloroethylene also
producedrenaltubularcell karyomegalyinboth sexes of
mice, and one low dose male mouse had a tubular cell
adenocarcinoma.
In these inhalation studies, there were no neoplastic
changes in the respiratory tracts of either species, but
there was an increase in the incidence of squamous
metaplasia in the nasal cavities in dosed male rats (0/50;
5/50; 5/50).
Tetrachloroethylene was notmutagenicinSalmomella
typhimurium strains TA98, TA100, TA1535, or TA1537
in the presence or absence of male Syrian hamster or
male Sprague-Dawley rat liver S9. Tetrachloroethylene
was not mutagenic in L5178Y/TK+/- mouse lymphoma
cells with or without metabolic activation and did not
induce sex-linked recessive lethal mutations in J3ros-
ophila melanogaster. Tetrachloroethylene did not
inducesister-chromatid exchanges orchromosomal aber-
rationsin Chinesehamster ovarycellsinthepresence or
absence ofmetabolic activation.
An audit of the experimental data was conducted for
these 2-year studies on tetrachloroethylene. No data
discrepancies were found that influenced the final inter-
pretations.
Under the conditions ofthese 2-year inhalation stud-
ies, there was clear evidence of carcinogenicity of
tetrachloroethyleneformaleF344/Nratsasshownbyan
increased incidence of mononuclear cell leukemia and
uncommonrenaltubularcellneoplasms.Therewassome
evidence ofcarcinogenicity oftetrachloroethylene for
female F344/N rats as shown byincreased incidences of
mononuclear cell leukemia. There was clear evidence of
carcinogenicity forB6C3F1 miceasshownbyincreased
incidences of both hepatocellular adenomas and car-
cinomas in males and of hepatocellular carcinomas in
females.
Synonyms: carbon bichloride; carbon dichloride; eth-
ylene tetrachloride; per; perc; perchlor; perchlor-
ethylene; perchloroethylene; perk; tetrachlorethylene;
1,1,2,2-tetrachloroethylene
Trade names: Ankilostin; Antisal 1; Dee-Solv; Didakene;
Dow-Per; ENT 1860; Fedel-Un; Nema; Perclene; Per-
cosolv; Perklone; PerSec; Tetlen; Tetracap; Tetraleno;
Tetravec; Tetroguer; Tetropil
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Report Date: August 1986
Note: Tetrachloroethylene was previously tested in
Osborne-Mendel rats and B6C3F1 mice by gavage (See
TR-13, reported 1977).
TR-312 Toxicology and Carcinogenesis
Studies ofn-Butyl Chloride (CAS No.
109-69-3) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
Toxicology and carcinogenesis studies ofn-butyl chlo-
ride (greater than 99.5% pure), a solvent as well as an
alkylating agent, were conducted by exposing groups of
F344/N ratsandB6C3F1 miceton-butylchloridein corn
oilby gavage for14 days, 13weeks, and2 years. Inthe14-
day studies, no compound-related gross pathologic
effects were observed in groups of five male or female
rats or mice administered doses of up to 3,000 mg/kg
body weight. However, deaths occurred in the groups
administered 750, 1,500, or 3,000 mg/kg. Tremors and
convulsions following gavage administration were
observed.
Inthe13-weekstudies, groups of10male and10female
rats were administered upto500mg/kgn-butylchloride,
and similar groups of mice received up to 1,000 mg/kg,
Three of 10 male rats in the 500 mg/kg dose group and
one female mouse in the 120 mg/kg dose group died
before the end of the studies. Mild to moderate extra-
medullary hematopoiesis was observed in 3/10 male rats
receiving 500 mg/kg. Mean body weights of male and
female rats receiving 250 or 500 mg/kg were lower than
those ofthe vehicle controls. Convulsions were observed
in male and female rats receiving 250 mg/kg or higher
and in 2/10 female mice receiving 1,000 mg/kg. Based on
these results, 2-yeartoxicology and carcinogenesis stud-
ies ofn-butyl chloride were conducted by administering
doses of 0, 60, or 120 mg/kg in corn oil by gavage to
groups of50 male and 50 female rats and doses of0, 500,
or 1,000 mg/kg to groups of50 male and 50 female mice.
Inthe2-year studies, survivalrelativetothatofvehicle
controls was significantly lower in high dose male rats
(40/50 vs17/50) andhigh dosefemale rats (35/50 vs11150)
and in male mice receiving 1,000 mg/kg (33/50 vs 10/50).
Due to excessive mortality in the 1,000 mg/kg female
mice, the group was terminated in the 45th week and a
second series of 2-year studies in mice of each sex was
started at concentrations of0 and 250 mg/kg. Male mice
in the 1,000 mg/kg group had 10% lower mean body
weights than the vehicle control group. No adverse
effects on survival orbodyweights in otherdosed groups
of rats and mice were observed. Convulsions were
observed before or after gavage administration on sev-
eral occasions duringtheratstudies. These observations
were noted primarily in the high dose groups (male:
vehicle control, 1/50; low dose, 3/50; high dose, 27/50;
female: vehicle control, 0/50; low dose, 7/50; high dose,
45/50). Hemorrhage of the brain and alveoli were
observed primarily in high dose male and female rats
dyingfromconvulsions. Lymphoiddepletionofthespleen
and splenic hemosiderosis were also observed in these
animals. In mice, convulsions were observed only in the
first studies (in the high dose female mice that were
terminated early and in 6/50 high dose male mice).
Pheochromocytomas ofthe adrenal gland occurred at
marginally increased incidence in low dose female rats
(1150; 6/50; 1V49). Hyperplasia was observed in 3/50vehi-
cle controls, 7/50 low dose females, and 4/49 high dose
females. The incidence of pheochromocytomas was low,
not dose related, and not seen in males, and thus it was
not considered to be compound related. Cytoplasmic
vacuolization ofthe adrenal cortexoccurred atincreased
incidences in males (5/50; 10/50; 20/50) but not in female
rats. Nephropathy of the kidney occurred at increased
incidences in female rats (13/50; 25/50; 20/50) but not in
male rats. Additional nonneoplastic lesions such as con-
gestion, inflammation, or nephrosis were not present to
anydegree in eithervehicle control ordosed female rats.
An increased incidence of alveolar/bronchiolar ade-
nomasorcarcinomas(combined)wasobservedinthe500
mg/kggroupoffemalemice (3/50vs9/50),butlittle effect
was seen in the 250 mg/kg group (6/50 vs 8/50). The
incidences of adenomas or carcinomas (combined) in
dosed female mice were not significantly different from
thatinthepooledvehicle control groupfromthefirstand
second studies (pooled controls, 9/100; 250 mg/kg, 8/50;
500 mg/kg, 9/50). The lack ofhyperplasia in female mice
and the negative trend in male mice suggest that these
marginal effectswere probably notrelated to the admin-
istration ofn-butyl chloride.
An increased incidence ofhepatocellular adenomas or
carcinomas (combined) was observed in the 500 mg/kg
dosegroupoffemalemice(3/50vs8/50)butnotinthe250
mg/kg dose group (9/50 vs 7/50). An increased incidence
ofhemangiosarcomas was observed in male mice in the
first study (1150; 3/50; 4/50) but not in the second study
(4/50 vs 2/50). Neither of these marginal effects was
regarded as compound related.
n-Butyl chloride was not mutagenic in Salmonella
typhimurium strains TA98, TA1535, or TA1537 in the
presence or absence of Aroclor 1254-induced male
Sprague-Dawley rat liver S9 or in the presence ofmale
SyrianhamsterliverS9.n-Butyl chloridewasmutagenic
in the mouse lymphoma L5178Y/TK+/- assay in the
absence ofAroclor-induced male rat liver S9 andwas not
tested in the presence of S9. n-Butyl chloride did not
induce sister-chromatid exchanges orchromosomal aber-
rations in Chinesehamster ovarycells inthe presence or
absence ofAroclor-induced male rat liver S9.
An audit of the experimental data was conducted for
the2-yearstudies ofn-butylchloride. Nodatadiscrepan-
cies were found thatinfluenced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was no evidence of carcinogenicity of n-butyl
chloride for male and female F344/N rats at daily doses
of60 or120mg/kg, formaleB6C3F1 mice atdosesof250,
500, or 1,000 mg/kg, or for female B6C3F1 mice at doses
of 250 or 500 mg/kg. Chemical-induced toxicity in high
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dose rats (primarily females) reduced the sensitivity of
the study for determining carcinogenicity.
Synonyms: 1-chlorobutane; butyl chloride; n-propylcar-
binyl chloride
Report Date: April 1986
TR-313 Toxicology and Carcinogenesis
Studies ofMirex (1,la,2,2,3,3a,4,5,5,5a,5b,6-
Dodecachlorooctahydro-1,3,4-metheno-1
H-cyclobuta[cdlpentalene) (CAS No.
2385-85-5) in F344/N Rats (Feed Studies)
Mirex(95%pure),formerlyusedasystemicinsecticide
and as a fire retardant, was studied for toxicologic and
carcinogenic effects byadministering diets containing0,
0.1, 1.0, 10, 25, or 50 ppm mirex to groups of 52 F344/N
rats of each sex for 104 weeks. Doses selected for the
2-year studies were based primarily on the effects on
body weights and survival of rats in a 26-week study.
Duringthefirst6 months ofthe2-year study, because of
good survival andthe absence ofobservable toxic effects
in female rats, additional groups (termed second study)
of52 F344/N female rats were started at higher dietary
concentrations of0,50, and100ppmmirex.Basedonfeed
consumption data, the estimated average intake per day
was0,0.007,0.075,0.75,1.95, and3.85mgmirex/kgbody
weight for male rats and female rats in the first study,
and 0, 3.9, and 7.7mg/kgforfemale rats inthe additional
study.
Body Weights, Feed Consumption, and Survival in
Two-Year Studies: Mean bodyweights ofmale rats that
received 25 or 50 ppm mirex were 5%-18% lower than
thoseofthecontrols throughoutmostofthestudy; mean
bodyweights offemale rats that received 50 or 100 ppm
mirexwere4%-18%lowerthanthoseofthecontrolsafter
week 40; mean bodyweights ofgroups receiving 0.1, 1.0,
or 10 ppm were similar to those of controls. Feed con-
sumption by dosed male rats was 83%-91% that by
controls, and that by dosed female rats was 86%-99%
thatbycontrols. The top dietaryexposure groups ofrats
receivedthe equivalent of3.85mgmirex/kgbodyweight,
whereasthe100-ppmgroupoffemalerats(secondstudy)
averaged 7.7 mg/kg. At the end ofthe study, survival of
male rats that received 25 or 50 ppm ofmirex was lower
than that of controls, whereas survival of all dosed
groups of female rats was similar to that of controls
(male:control,44/52;0.1ppm,37/52;1ppm,36/52;10ppm,
37/52; 25 ppm, 19/52; 50 ppm, 15/52; female -first study:
38/52; 38/52; 35/52; 41/52; 35/52; female-second study:
control, 44/52; 50 ppm, 44/52; 100 ppm, 39/52).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies:Themostnotablecompound-relatedeffectswere
observed in the liver of male and female rats. Fatty
metamorphosis, cytomegaly, angiectasis (males only),
and necrosis of the liver were observed at increased
incidences in dosed rats. The incidences ofofneoplastic
nodules ofthe liverwere dose related, and in the 10-, 25-,
and 50-ppm groups of males and the 50- and 100-ppm
groups of females (second study), they were markedly
greater than those in controls (52/group-male: control,
3; 0.1ppm, 5; 1ppm, 5; 10ppm, 14; 25ppm, 15; 50ppm, 26;
female (second study): control, 2; 50 ppm, 23; 100 ppm,
30). In the first study in female rats, the incidences of
neoplastic nodules were not significantly different
betweencontrolanddosedgroups(10;5;4; 5; 9; 7).The10
neoplastic nodules ofthe liver seen in the control group
(19%) was significantly greater than the mean incidence
observed historically (57/2,015; 2.8%). The incidences of
hepatocellular carcinomas in control and dosed groups
were relatively low and were not significantly different
between groups.
The incidences of pheochromocytomas of the adrenal
glandoccurredwithapositivetrendinmalerats(8/51;7/52;
13/52; 11/52; 18/51,19/51); the incidences in the 25- and 50-
ppm male rats were greater than that in controls; malig-
nantpheochromocytomas were observed in 2 controls and
in 2 mirex-exposed male rats. The incidence of phe-
ochromocytomas in 50-ppm female rats in the first study
was marginally greater than thatin controls (control, 1/51;
50ppm, 6/52); thisborderline increasewas notobserved in
thesecondfemaleratstudyandthusisnotconsideredtobe
due to the dietary administration ofmirex.
Nephropathy occurred at similar incidences in control
and mirex-exposed groups ofmale and female rats; how-
ever, the severity ofthis nonneoplastic lesionwasjudged
to be slightly greater in the groups given 25, 50, or 100
ppmmirex(male: severevs.moderateincontrols; female:
moderate to severe vs. moderate). Hyperplasia of the
transitionalepithelium ofthekidneypelviswas observed
in dosed male rats (0/51; 2/51; 2/52; 5/52; 14/51; 9/52).
Transitional cell papillomas of the renal pelvis in male
rats occurred with a positive trend (P<0.02) (0/51; 0/51;
0/52; 1/51; 3/52). The highest incidence previously
observed in untreated male F344/N rats in NTP studies
is1/48,andthemeanhistoricalincidenceis5/1,968(0.3%).
In both the first and second studies in female rats, the
incidence of mononuclear cell leukemia showed dosed-
related increases (fiLrst study: 8/52; 8/52; 11/52; 14/52;
18/52; 18/52; second study: 6/52; 9/52; 14/52). When the
data from both studies are combined, the incidences are
significantly increased in the 10-, 25-, 50-, and 100-ppm
groups. The mean historical incidence is 19% (375/2,021).
For the thyroid gland, there was a positive trend for
follicular cell neoplasms in male rats (0/51; 1/50; 0/47;
1/47;0/35;4/49)and anegativetrendforC-cellneoplasms
in male rats (8/51; 6/50; 4/47; 7/47; 3/35; 0/49) and in
female rats in the first study (12/50; 13/50; 7/48; 9/47;
6/48; 2/46). Neither observation is considered to be asso-
ciated with the dietary administration ofmirex.
Genetic Toxicology: Mirex was not mutagenic in the
Salmonella typhimurium-microsome assay when
tested in a preincubation protocol in the presence or
absence of exogenous metabolic activation in strains
TA98, TA100, TA1535, or TA1537. Mirex did not induce
either sister chromatid exchanges or chromosomal aber-
rations in Chinese hamsterovarycellsinthepresence or
absence ofS9.
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Conclusions: Undertheconditions ofthese2-yearfeed
studies ofmirex, thereisclearevidenceofcarcinogenic
activity for male and female F344/N rats, as primarily
indicated bymarked increased incidences ofbenign neo-
plastic nodules of the liver, as well as by increased
incidences of pheochromocytomas of the adrenal gland
and transitional cell papillomas of the kidney in males
andbyincreasedincidences ofmononuclearcellleukemia
in females.
Nonneoplastic effects induced by mirex include
cytomegaly, fatty metamorphosis, angiectasis (males
only), and cellular necrosis in the liver.
Synonyms and Trade Names: 1,la,2,2,3,3a,4,5,5,5a,5b,6-
dodecachlorooctahydro-1,3,4-metheno-lH-cyclobuta
[cd]pentalene; hexachloropentadiene dimer; dodeca-
chloropentacyclodecane; perchloropentacyclodecane;
hexachlorocyclopentadiene dimer; Dechlorane®; Fer-
riamicide®
Report Date: February 1990
TR-314 Toxicology and Carcinogenesis
Studies ofMethyl Methacrylate (CAS No.
80-62-6) in F344/N Rats and B6C3F1 Mice
(InhalationStudies)
Toxicologyandcarcinogenesis studies ofmethylmeth-
acrylate, aliquid chemical intermediate used in theplas-
tics industry in the manufacture ofplexiglass and other
acrylic products, were conducted by exposing groups of
F344/N rats andB6C3F1 micebyinhalation for14weeks
and 2 years.
Inthe14-weekstudies, groupsof10maleand10female
rats and mice were exposed to methyl methacrylate at
concentrations ofup to 5,000 ppm. All male and female
rats and eight male and eight female mice exposed at
5,000 ppm died, one male and nine female rats and four
male and no female mice exposed at 3,000 ppm died, and
one male and three female rats and two male and one
female mouse exposed at 2,000 ppm died; all rats and
mice exposed at 500 or 1,000 ppm survived. Compared
with the controls, the bodyweights ofthe exposed male
and female rats and mice were lower. Compound-related
lesions included inflammation associated with necrosis
andlossofolfactoryepitheliuminthenasalturbinatesin
both male and female rats; malacia and gliosis in female
rats; inflammation of the nasal turbinates and nasal
epitheliummetaplasia in both male andfemale mice; and
renal cortical necrosis, renal cortical tubular degenera-
tion, renalfocalmineralization, andlivernecrosis inmale
mice. Based ontheseresults,2-yearinhalationtoxicology
and carcinogenesis studies were conducted in which
groups of50maleratswereexposedtomethylmethacry-
late at 0, 500, or 1,000 ppm; female rats at 0, 250, or 500
ppm; and male and female mice at 0, 500, or 1,000
ppm.
Inthe2-year studies, thebodyweights ofthe lowdose
and high dose male and female rats were within 10% of
those ofthe controls. Therewas no differencein survival
betweenthedosedmaleandfemaleratsandthecontrols.
Incidences of inflammation of the nasal cavity and
degeneration of the olfactory sensory epithelium were
greater in the dosed male and female rats than in the
controls, with lesions seen in virtually all high dose
animals.
An increased incidence of mononuclear cell leukemia
wasobservedinfemaleratsexposedtomethylmethacry-
late at 500 ppm compared with the controls (control,
11150; 250ppm, 13/50; 500ppm,20/50). Thisincreasewas
not significant by life table tests, the method ofanalysis
most appropriate for this fatal neoplasm.
Themeanbodyweightsofdosedmaleandfemalemice
were5%-8%lowerthanthoseofthecontrolsattheendof
the 2-year studies. However, during most ofthe second
yearofthe studies, bodyweights ofdosedmalemice and
high dosefemalemicewere 10%-18% lowerthanthose of
thecontrols. Survivalrates ofthedosedand controlmice
were similar.
Incidences ofinflammation and epithelial hyperplasia
of the nasal cavity and degeneration of the olfactory
sensoryepitheliumweresignificantlygreaterinalldosed
groups ofmale and female mice compared with those of
the controls. Compound-related neoplastic lesions were
not found in the dosed mice.
Significant dose-related decreases were observed in
the incidences of pituitary gland and preputial gland
tumors in male rats, alveolar/bronchiolar adenomas or
carcinomas (combined) inmalemice, hepatocellular ade-
nomasinbothmaleandfemalemice, andpituitarygland
adenomas or adenocarcinomas (combined) and uterine
adenocarcinomas in female mice.
Methyl methacrylate was not mutagenic in strains
TA100, TA1535, TA97, or TA98 of Salmonella
typhimurium in the presence or absence ofmale rat or
hamster liver S9 when assayed by a preincubational
protocol but gave a positive response in L5178Y/TK+/-
mouselymphomacellsinthepresence orabsenceofmale
rat liver S9. In cultured Chinese hamster ovary cells,
methyl methacrylate produced a reproducible, dose-
related increase in the frequency of sister-chromatid
exchanges, both with and without rat liver S9. A slight,
dose-related increase in chromosomal aberrations was
also induced in cultured Chinese hamster ovary cells in
the absence of S9; in the presence of S9, an increase in
the frequency ofaberrations was seen only at the high-
est, near-lethal dose of5 mg/ml.
An audit of the experimental data was conducted for
the 2-year carcinogenesis studies on methyl methacry-
late. No data discrepancies were found that influenced
the final interpretations.
Under the conditions of these 2-year inhalation stud-
ies, there wasno evidence ofcarcinogenicity ofmethyl
methacrylate for male F344/N rats exposed at 500 or
1,000 ppm, forfemale F344/N rats exposed at250 or 500
ppm, orformaleandfemaleB6C3F1 miceexposed at500
or 1,000 ppm. Inhalation of methyl methacrylate was
associated with inflammation of the nasal cavity and
degeneration ofthe olfactory sensoryepithelium inmale
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and female rats and mice; epithelial hyperplasia of the
nasal cavity was also observed in exposed mice.
Synonyms: acrylic acid, 2-methyl, methyl ester; meth-
acrylic acid, methyl ester; methyl cx-methylacrylate;
methyl methylacrylate; methyl-2-methylpropenoate;
methyl-2-methyl-2-propenoate; 2-methyl-2-propenoic
acid methyl ester; MME
Report Date: October 1986
TR-315 Toxicology and Carcinogenesis
Studies ofOxytetracycline Hydrochloride
(CAS No. 2058-46-0) in F344/N Rats and
B6C3F1 Mice (Feed Studies)
Toxicology and carcinogenesis studies were conducted
on oxytetracycline hydrochloride (greater than 98.8%
pure), a broad-spectrum antibiotic. Groups of F344/N
rats and B6C3F1 mice were fed diets containing oxy-
tetracyclinehydrochloride foraseries of14-day, 13-week,
and 2-year studies. In the 14-day studies, no compound-
related gross pathologic effects were seen in rats ormice
(groups of five animals per sex per species) given up to
100,000 ppm intheirfeed. The final mean bodyweight of
maleratsreceivinginfeedwas27%lowerthanthatofthe
controls. Final mean bodyweights ofmice that received
25,000, 50,000, or 100,000 ppm were lower (male: 11%;
16%; 17%; female: 6%; 5%; 17%) than those of the con-
trols. In the 13-week studies, groups of 10 male and 10
female rats and mice were fed diets containing up to
50,000 ppm in feed, and no chemically related gross or
histopathologic effects were observed in mice of either
sexorinfemalerats. Inmalerats,fattymetamorphosis of
minimal severity was diagnosed in the liver of 5/10
animals at 6,300, 12,500, and 50,000 ppm and in 2/10
animals at 3,100 and 25,000 ppm. None was seen in the
controls. Oxytetracycline levels in bones ofrats and mice
(as determined fluorometrically) at the end of the 13-
week studies increasedwith dose, thehighestlevels (3-10
times background levels) being observed at 50,000 ppm.
The2-yeartoxicologyand carcinogenesis studieswere
conducted byadministering diets containing0,25,000, or
50,000ppmoxytetracyclinehydrochloridetogroupsof50
male and 50 female rats and diets containing 0, 6,300, or
12,500ppmoxytetracyclinehydrochloridetogroupsof50
male and 50 female mice for103weeks. The highest dose
selected forrats was considered tobe themaximumlevel
thatwould not affect the nutritional value ofdosed feed.
The dietary concentrations correspond to the following
approximate doses: rats-0, 1,000, or 2,000 mg/kg body
weight per day; mice-0, 650, or 1,400 mg/kg per day.
Mean bodyweights were approximately 5%-8% lower
than those of controls in high dose male rats during
weeks 4-47, in high dose male mice afterweek 31, and in
high dose female mice after week 26. The mean body
weights of dosed female rats and low dose male and
female mice were comparable to those of controls. The
survival of control male rats was lower than that of the
high dose group (22/50 vs 38/50). No significant dif-
ferences in survival were observed between the
remaining groups ofrats orbetween anygroups ofmice.
Pheochromocytomas of the adrenal gland occurred
withpositive trendsinmalerats (control,10/50; lowdose,
18/50; high dose, 24/50), and the incidence in the high
dose group was greater than that in the controls. Two
additional controlmalesandoneadditionallowdosemale
had malignant pheochromocytomas. The incidence of
adrenal gland medullary hyperplasia was elevated
slightly but not significantly in dosed male rats (7/50;
14/50; 9/50).
Adenomas and adenomas and adenocarcinomas (com-
bined) ofthepituitaryglandinfemalerats occurredwith
positivetrends, and theincidencesinthehighdosegroup
were greater than that in the controls (adenomas: 19/50;
17/50; 30/50; adenomas or adenocarcinomas [combined]:
20/50; 24/50; 32/50). The incidence of pituitary gland
hyperplasia was slightly decreased in dosed female rats
(16/50; 10/50; 11150).
No compound-related increases in nonneoplastic or
neoplastic lesions were observed in male or female mice.
Oxytetracycline hydrochloride was not mutagenic in
Salmonella typhimurium strains TA100, TA1535,
TA1537, or TA98 in the presence or absence of Aroclor
1254-induced male Sprague-Dawley rat or male Syrian
hamster liver S9 when assayed according to the prein-
cubational protocol. Oxytetracycline hydrochloride was
mutagenicinL5178Y/TK+/- mouselymphomacellsinthe
presence but not in the absence ofAroclor 1254-induced
male rat liver S9. In cultured Chinese hamster ovary
cells, oxytetracycline was weakly positive in inducing
sister-chromatid exchanges both with and without
Aroclor 1254-induced male Sprague-Dawley rat liver S9
but did not induce chromosomal aberrations.
An audit of the experimental data was conducted for
these 2-year carcinogenesis studies of oxytetracycline
hydrochloride. No data discrepancies were found that
influenced the final interpretations.
Under the conditions of these 2-year feed studies of
oxytetracycline hydrochloride, there was equivocal evi-
dence ofcarcinogenicity for male F344/N rats, as indi-
cated by increased incidences ofpheochromocytomas of
the adrenal gland. There was equivocal evidence of
carcinogenicity for female F344/N rats fed diets con-
taining oxytetracycline hydrochloride, as indicated by
increased incidences ofadenomas ofthe pituitary gland.
There was no evidence of carcinogenicity for male or
female B6C3F1 mice fed diets containing 6,300 or 12,500
ppm oxytetracycline hydrochloride for 2 years.
Synonyms: 2-naphthacenecarboxamide,4(dimethyla-
mino)-1, 4,4a,5,5a,6,11,12a-octahydro-3,6-10,12,12a-
pentahydroxy-6-methyl-1,11-dioxo-monohydrochloride;
Biosolvmycin; Hydrocyclin; Liquamycin; Otetryn;
Oxlopar; 5-hydroxytetracycline hydrochloride; Ter-
ramycin Hydrochloride; Tetramine; Tetran Hydro-
chloride
Report Date: January 1987
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TR-316 Tbxicology and Carcinogenesis
Studies ofDimethylvinyl Chloride (1-
Chloro-2-Methylpropene) (CAS No.
513-37-1) in F344/N Rats and B6C3F1 Mice
(Gavage Studies)
Dimethylvinyl chloride is a clear colorless liquid,
which, because ofits volatility and flammability at room
temperature, is a significant fire hazard. It has aboiling
point of 68.10 C (1550 F) and a density at 200 C of 0.919
g/ml. Dimethylvinyl chloride is a byproduct in the pro-
duction of3-chloro-2-methylpropene by the chlorination
ofisobutene. Itis notknowntobeproducedinthe United
States for otherthanlaboratory purposes. This chemical
was nominated for toxicologic studies because of its
reported presence in ambient air in the Baltimore area
and was selected fortoxicologic characterizationbecause
of its structural similarity to the known animal and
human carcinogen, vinyl chloride monomer.
Toxicology and carcinogenesis studies of
dimethylvinyl chloride (96%-98%pure), astructural ana-
log of vinyl chloride monomer, a known human car-
cinogen, by administered dimethylvinyl chloride in corn
oilby gavage to groups of50male and 50 female F344/N
rats and B6C3F1 mice at doses of 0, 100, or 200 mg/kg
body weight 5 days per week for 102 or 103 weeks. The
selection ofthese doses was based on results of13-week
studies, which included depression of body weight at
doses of 500 mg/kg or above in rats as well as histo-
pathologic changes intestinal epithelium, bone marrow,
hepatocytes, and the testes at doses of 250 mg/kg and
above; doses in mice were selected on the basis ofhisto-
pathologic changes in lymphopoietic cells, liver, pancrea-
tic islets, ovary, testis, and spleen, with changes being
most prominent at doses of500 mg/kg and above.
In the 2-year studies, body weights of rats and mice
given 100 mg/kg were comparable to those ofthe vehicle
controls except for the lastfewweeks in micewhen body
weights were markedly lower than those for the vehicle
controls. At 200 mg/kg, the mean body weights of rats
and mice were progressively decreased relative to those
of vehicle controls, with the significant departure from
vehicle controls occurring somewhat earlier in males
than in females. Survival ofvehicle control rats and mice
was comparable to historicalvalues; however, survival of
dosed male and female rats was significantly lower than
that of vehicle controls, with the incidence of mortality
being more severe at the high dose than at the low dose.
There were no survivors in the high dose group ofmale
ratsafterweek85 orinthehighdose groupoffemalerats
after week 97. Survival was significantly lower among
dosed male and female mice compared with vehicle con-
trols. In the absence oftoxicological findings that would
explain the early deaths, it is assumed that the high
incidence of tumors and chemical- related toxicity con-
tributedtothedecreasedsurvivalofdosedratsandmice.
In rats, the severity and incidence of nonneoplastic
lesions were minimal; these lesions included necrosis of
the duodenum and epithelial hyperplasia at the sites of
tumor formation-the nasal cavity, esophagus, and fore-
stomach. In mice, the severity of nonneoplastic lesions
was also minimal; the lesions included necrosis of the
liver,bonemarrowgranulocytichyperplasia, andinflam-
mation ofthe nasal cavity (small number, females only.)
Several types ofneoplastic lesions occurred with sig-
nificantly increased incidences in dosed animals as
shown in the following table (see page 11 of Technical
Report). Among rats, these lesions included malignant
epithelial tumors of the nasal cavity and squamous cell
tumors ofthe oral cavity, esophagus, and forestomach in
males and females. The increased number of fibro-
adenomasofthemammaryglandinfemaleratsmayhave
been related to dimethylvinyl chloride administration.
Thelackofacleardose-responserelationshipforcertain
tumorsinratsisconsideredtoberelatedtotheincreased
numberofearlydeathsobservedinthehighdosegroups.
Amongdosed mice, therewere significantlyincreased
incidences of squamous cell carcinomas of the fore-
stomach (both sexes), squamous cell papillomas of the
forestomach (males), and squamous cell carcinomas of
the preputial gland (males). The increased incidence of
papillary adenomas ofthe harderian gland and alveolar/
bronchiolaradenomas or carcinomas in female mice may
have been related to administration of dimethylvinyl
chloride.
Limited metabolism studies of 14C-labeled
dimethylvinyl chloride were conducted in male F344/N
rats and B6C3F1 mice. Single doses of 150 mg/kg were
administered to ratsfor1,2, or4consecutive days.About
25% of the administered doses was exhaled as carbon
dioxide; this amount was independent of the number of
doses administered. Another 25%-35% of the admin-
istered dose was exhaled; 96% ofthis parent was mate-
rial. Approximately 35% and 6% were excreted in the
urine and feces, respectively. The elimination half-life of
radioactivelabelwas3-4daysfortheliverandkidney,the
two organs containing the greatest amounts of the
administered dose. In mice, a much smaller fraction of
the dose was exhaled and a larger proportion was
excreted in urine compared with rats.
Dimethylvinyl chloride was not mutagenic in four
strains of Salmonella typhimurium with or without
metabolic activation, but it was mutagenic in the mouse
lymphoma L5178Y/TK+/- assay in the absence ofmeta-
bolic activation. Sister-chromatid exchanges were
inducedin Chinese hamsterovarycellswith andwithout
metabolic activation, but there was no increase in chro-
mosomal aberrations. When fed to Drosophila,
dimethylvinyl chloride induced significant increases in
thefrequencies ofboth sex-linked recessive lethal muta-
tions and reciprocal translocations.
Studies of the immunotoxicity of dimethylvinyl chlo-
ride were conducted in which female B6C3F1 mice
received daily oral doses of 0, 50, 100, 200, or 400 mg
dimethylvinyl chloride per kilogram body weight.
Compound-related increases in susceptibility to bac-
terial infection and decreases in macrophage cytostasis
were observed at all doses. At the highest dose, the
decreased resistance to bacterial and viral challenge
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could be related to alterations in specific immune func-
tion. However, theincreasedmortalityinrats andmicein
the 2-year studies was not relatable to infectious pro-
cesses.
An audit of the experimental data was conducted for
these 2-year toxicology and carcinogenesis studies on
dimethylvinyl chloride. No data discrepancies were
found that influenced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was clear evidence ofcarcinogenicity of dime-
thylvinyl chloride for both sexes of F344/N rats and
B6C3F1 mice. Thiswas based on increased incidences of
neoplasms ofthenasalcavity, oralcavity,esophagus, and
forestomach of male and female F344/N rats. B6C3Fj
mice showed increased incidences of squamous cell neo-
plasms of the forestomach in males and females and
squamous cell carcinomas of the preputial gland in
males.
Synonym: 1-chloro-2-methylpropene
Report Date: August 1986
TR-317 Toxicology and Carcinogenesis
Studies ofChlorpheniramine Maleate
(CAS No. 113-92-8) in F344/N Rats and
B6C3F1 Mice (Gavage Studies)
Toxicology and carcinogenesis studies of chlor-
pheniramine maleate (99% pure), a widely used anti-
histaminic drugin human andveterinarymedicine, were
conducted by administering this chemical in deionized
waterbygavagetogroupsof50maleand50femaleF344/
N rats and B6C3F1 mice, 5 days perweek for 103weeks.
The doses used were: male rats-0, 15, or 30 mg/kg;
female rats-0, 30, or 60 mg/kg; male mice-0, 25, or 50
mg/kg; female mice-0, 100, or200 mg/kg. The selection
ofthese doses was based largely on data from 14-day or
16-day studies and 13-week studies in which reduced
body weight gain and reduced survival occurred at
higher doses. Doses used in the 2-week studies ranged
from40to640mg/kginratsand25to800mg/kginmice;
in the 13-week studies, doses ranged from 3.75 to 60mg/
kg in rats and 12.5 to 200 mg/kg in mice. The recom-
mendedhumanadultdailyoral dose ofchlorpheniramine
maleate is up to 0.32 mg/kg.
Doses originally selected for male mice in the 2-year
studywere0,100, or200mg/kg;however,because ofpoor
survival, that study was stopped and a new study was
started atdoses of0,25, or50mg/kg. Atthe termination
ofthe study(week104), survival ofhigh dosefemale rats
(6/50) and high dose male mice (15/50) was lower than
that of the vehicle controls (29/50 and 39/50, respec-
tively). Survival of all other dosed groups was compar-
able to that of respective vehicle control groups. Mean
bodyweights ofdosedratswereabout10%-15% (male) or
about 10%-25% (female) lower than those of vehicle
controls; mean bodyweights offemale mice were gener-
ally 20%-35% lower than those ofvehicle controls.
No compound-related gross or microscopic pathologic
effectswereobservedineitherspeciesinthe16-dayor13-
week studies. Hyperactivity and hyperexcitability asso-
ciated with dosingwere frequently noted in the 13-week
and 2-year studies. There were no significant positive
trends or increases in the incidences of neoplasms in
either male or female rats dosed with chlorpheniramine
maleate for 103 weeks. Marginal increases in the inci-
dences ofadrenal gland capsule adenomas in male mice
(vehicle control, 2/50; low dose, 7/49; high dose, 4/49)
were not considered to be compound related, since there
was not a corresponding increase in the incidence of
adrenalglandcapsulehyperplasia(46/50;33/49;22/49).A
positive trend was seen for subcutaneous tissue tumors
in male mice (4/50; 5/49; 8/50); this marginal effect was
not considered to be compound related.
The incidences of thyroid gland follicular cell cysts
(2/48; 10/49; 13/47), thyroid gland follicular cell hyper-
plasia(3/48;29/49;36/47),andthyroidglandfollicularcell
adenomas (0/48; 4/49; 2/47)were greaterin dosedfemale
mice than in vehicle controls. This finding is tox-
icologicallyimportant, sincethyroidglandneoplasms are
uncommoninmiceandareoftenprecededbyhyperplasia
ofthe follicular epithelium.
Themajorrouteofexcretionofchlorpheniramine orits
metabolites is in the urine. In male F344 rats orally
administered 14C-chlorpheniraminemaleateatdosesof2
or 20 mg/kg, there was essentially no difference in the
percentage ofurinary or fecal excretion ofradioactivity
between these dose levels.
Chlorpheniramine maleate was not mutagenic to Sal-
monella strains TA98, TA100, TA1535, or T1537 in the
presence or absence of S9 metabolic activation systems
prepared from the liver of Aroclor 1254-treated male
Sprague-Dawley rats or male Syrian hamsters. Chlor-
pheniraminemaleatedidnotinduceforwardmutationsat
the TK locus of L5178Y mouse lymphoma cells with or
without metabolic activation. In Chinese hamster ovary
cells in culture, chlorpheniramine maleate induced a
weak but reproducible increase in sister-chromatid
exchanges in the absence ofexogenous metabolic activa-
tion. Chromosomal aberrationswereinduced atthehigh-
est dose tested but only in the presence of S9 from
Aroclor 1254-induced Sprague-Dawley male rat liver.
An audit of the experimental data was conducted for
these2-yearcarcinogenesis studies onchlorpheniramine
maleate. No data discrepancies were found that influ-
enced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was no evidence ofcarcinogenicity for F344/N
rats or B6C3F1 mice of either sex administered chlor-
pheniramine maleate in deionizedwater, 5 days perweek
for 2 years. Due to high mortality in high dose female
rats and high dose male mice, the sensitivity of these
groups to detect a carcinogenic response was reduced.
Chlorpheniramine maleate had a proliferative effect in
the thyroid gland of female mice, as shown by the
increased incidences of follicular cell cysts and hyper-
plasia in both low dose and high dose groups.
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Synonyms: 2-p-chloro-a-(2-dimethylaminoethyl) ben-
zyl]pyridine maleate; 2-Pyridinepropanamine; y-[4-
chlorophenyl]-N,N-dimethyl-[z]-2-butenedioate
Trade Names: Allerclor; Allergisan; Antagonate; Chlor-
mene; Chlorprophenpyridamine maleate; Chlor-
Trimeton; Chlor-Tripolon; Chloropiril; C-Meton; His-
tadur; Histaspan; Lorphen; M.P. ChlorcapsT.D.;Piriton;
Pyridamal-100; Teldrin
Report Date: September 1986
TR-318 Toxicology and Carcinogenesis
Studies ofAmpicillin lfihydrate (CAS No.
7177-48-2) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
Ampicillin trihydrate is a broad-spectrum semi-
synthetic penicillin that is effective in the treatment of
gram-positive and gram-negative bacterial infections
produced by Streptococcus, Bacillus anthracis,
Haemophilus influenzae, Neisseria gcnorrhoeae, and
Escherichia coli. Thisantibioticisusedinthetreatment
ofupperrespiratorytractinfections, genital andurinary
tract infections, and otitis media in children.
Toxicology and carcinogenesis studies of ampicillin
trihydrate (97%-99% pure) were conducted by admin-
isteringthechemicalincornoilbygavagetogroupsof50
F344/N rats and 50 B6C3F1 mice ofeach sex, 5 days per
week for103weeks. Male and female rats received doses
of 0, 750, or 1,500 mg/kg, and male and female mice
received doses of0, 1,500, or3,000mg/kg. Doses selected
for the 2-year studies were based on the lack of body
weight effects and histopathologic effects at2,400mg/kg
in the 14-day studies and 3,000 mg/kg in the 13-week
studies. Clinical signs in the 13-week studies included
diarrheaat3,000mg/kginmaleandfemaleratsandmale
mice. Corn oil suspensions containingmore than 300 mg
ampicillin trihydrate/ml were too viscous to be admin-
istered by gavage; therefore, a high dose of1,500 mg/kg
was selected forrats and ahigh dose of3,000 mg/kgwas
selected formice.
Duringthe2-yearstudies, meanbodyweights ofmale
andfemaleratswere similarto orslightlyincreased over
those ofthe correspondingvehicle control groups. Mean
bodyweights oflow dose and high dose male mice were
similar to those ofthe corresponding vehicle group dur-
ing year 1 of the study but were slightly below those of
thevehiclecontrolgroupduringthelasthalfofthestudy.
Mean body weights of low dose and high dose female
mice were greater than those of the vehicle controls
throughout most ofthe study. No significant differences
in survival were observed in groups of rats or mice of
either sex. Clinical signs observed in dosed rats included
diarrhea, excessive urination, and chromodacryorrhea
and in dosed mice included increased salivation and
decreased activity.
In male rats, administration of ampicillin trihydrate
was associated with an increased incidence of mono-
nuclear cell leukemia (vehicle control, 5/50; low dose,
14/50; high dose, 13/50). Malignant lymphomas were
observed in one additional vehicle control male rat and
two low dose male rats. Lymphocytic leukemiawas seen
in one high dose rat. High dose male rats showed
increasedincidences ofpheochromocytomas ofthe adre-
nal gland medulla (13/50; 12/50; 23/49). Malignant phe-
ochromocytomas were observed in 1150 vehicle control,
5/50lowdose,and1/49highdosemalerats.Theincidence
of adrenal gland medullary hyperplasia was not
increased in male rats (14/50; 10/50; 8/49). There were
increased incidences ofC-cell hyperplasia ofthe thyroid
gland in low dose male and high dose female rats. High
dose male rats showed increased incidences of hyper-
keratosis and acanthosis ofthe forestomach.
In male and female mice, ampicillin trihydrate admin-
istration was associated with increased incidences of
forestomach lesions, including ulcers, inflammation,
hyperkeratosis, acanthosis, and evidence offungal infec-
tion.
Ampicillin trihydrate was not mutagenic in Salmo-
nella typhimurium strains TA98, TA100, TA1535, or
TA1537 in the presence or absence of Aroclor 1254-
induced male Syrian hamster or male Sprague-Dawley
rat liver S9 when tested according to preincubation
protocol. Ampicillin trihydrate was not mutagenic in
L5178Ymouselymphoma cellswith orwithoutmetabolic
activation. Ampicillintrihydrate did notcausechromoso-
mal aberrations or sister-chromatid exchanges in Chi-
nese hamster ovary cells with or without metabolic
activation.
An audit was conducted for these 2-year studies.
Animal/carcass identification discrepancies were
observed in rats and mice. The most common findings
were the failure to clip some toes in rats and opened ear
holes in mice. Areview ofthe inlife data (including body
weights, clinical observations, and dosing records) indi-
cated that animals had not been interchanged among
groups. The dataare considered adequate to supportthe
conclusions.
Under the conditions of these 2-year gavage studies,
there was equivocal evidence of carcinogenicity of
ampicillin trihydrate for male F344/N rats as shown by
increased incidences ofpheochromocytomas ofthe adre-
nal medulla and by marginally increased incidences of
mononuclear cell leukemia. There was no evidence of
carcinogenicity forfemale F344/Nratsreceiving750 or
1,500 mg/kg orformale and female B6C3F1 mice receiv-
ing1,500or3,000mg/kgperday. Nonneoplasticlesionsof
the forestomach were seen in male rats and male and
female mice.
Synonyms and trade names: Acillin; Amcap; Amcill;
Aminobenzylpencillin trihydrate; (x-Aminobenzylpencil-
lin trihydrate; Amperil; Ampichel; Ampikel; Ampinova;
Amplin; Cymbi; Divercillin; Liffampil; Morepen; Pen A;
Pensyn; Polycillin; Princillin; Principen; Ro-ampen;
Irafarbiot
Report Date: April 1987
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TR-319 Toxicology and Carcinogenesis
Studies of1,4-Dichlorobenzene (CAS No.
106-46-7) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
1,4-Dichlorobenzene is commonly used as a space
deodorant in toilets and for moth control. Because ofits
extensive production and use and the absence of car-
cinogenicitydata, carcinogenesis studieswereconducted
by administering 1,4-dichlorobenzene (greater than 99%
pure) in corn oil by gavage (5 days per week) to male
F344/Nratsatdosesof0,150,or300mg/kgandtofemale
F344/N rats and male and female B6C3F1 mice at doses
of0,300, or600mg/kgperdayfor2years(50animalsper
group). Fourteen-day and 13-week studies were per-
formed to characterize the toxicity, identify affected
sites, and setdoses forthe 2-yearstudies. Clinical chem-
istryandhematologic studieswereperformedduringthe
13-week studies to assess the effects of 1,4-
dichlorobenzene on the liver, kidney, and hematopoietic
system and to assess whether the compound produced
hepatic porphyria.
Two 13-week studies were performed in rats. In the
first study, rats were dosed with 300-1,500 mg/kg 1,4-
dichlorobenzene. Because histologic changes were
observed in the kidney ofmale rats at all doses, a second
13-week studywas performed at doses of38-600 mg/kg.
Inthe13-week studies, survivalwas decreased in groups
ofmaleratsgiven 1,200 or1,500mg/kgandinfemalerats
given 1,500 mg/kg. Weight gain was decreased in male
rats receiving doses of300 mg/kg or more and in female
ratsgivendoses of1,200or1,500mg/kg. Doses of1,200or
1,500 mg/kg produced degeneration and necrosis of
hepatocytes, hypoplasia of the bone marrow, lymphoid
depletion ofthe spleen and thymus, and epithelial necro-
sis ofthe nasalturbinates inmale andfemale rats. Renal
tubular cell degeneration was observed in male rats
receiving 300 mg/kg or more in the first study, but only
slight changes were seen at 300 mg/kg in the second
study. Liverweighttobrainweightratioswereincreased
at 900 mg/kg or more forboth male and female rats. The
kidney weight to brain weight ratio was increased in
male rats receiving doses of600 mg/kg or more.
Administration of 1,4-dichlorobenzene to rats for 13
weeks produced slight but statistically significant
decreases in the hematocrit, red blood cell count, and
hemoglobinlevelin allmales receivingdoses of300-1,200
mg/kg. No clear hematologic changes were observed in
female rats. 1,4-Dichlorobenzene produced minimal
changes in clinical chemistry parameters in the 13-week
studies. Serumcholesterollevelswereincreasedbydoses
of600mg/kgormoreinmalerats and900mg/kgormore
in female rats. Serum triglycerides were reduced by
doses of300 mg/kg or more in male rats. The blood urea
nitrogen level was increased slightly in male rats dosed
with 900 mg/kg or more. Urinary porphyrins were
increased slightly in male rats administered 1,200 or
1,500 mg/kg and female rats receiving 1,200 mg/kg.
However, theseincreasesweremodestandindicative ofa
mild porphyrinuria rather than hepatic porphyria. Liver
porphyrins were not increased at any dose.
Two 13-week studies were performed in mice. The
doses selected for the first study were 600-1,800 mg/kg.
Survival was decreased in male and female mice receiv-
ing doses of1,500 mg/kg or more, and bodyweight gain
was decreased at all doses. Hepatocellular degeneration
was observed in both sexes at all doses, and the liver
weight to brain weight ratio was increased at doses of
900 mg/kg or more. Serum cholesterol levels were
increased in male mice at doses of 900 mg/kg or more,
whereas serumprotein andtriglycerides were increased
at doses of1,500 mg/kg ormore. These relativelymodest
clinical chemistry changes probably reflect the hepatic
effects ofthis compound. The white blood cell count was
reduced significantly in male mice receiving doses of600
mg/kg ormore andfemalemice receiving1,000mg/kg or
more,butthiseffectwasnotdramatic. Hepaticporphyria
was not found in mice at any dose in the 13-week study.
Because hepatic effects were seen in all dose groups in
the firststudy, a second 13-weekstudywasperformed at
doses of 85-900 mg/kg. In this study, hepatocellular
cytomegaly was observed im male and female mice at
doses of675 mg/kg or more but not at 338 mg/kg. Renal
damagewasnotobservedinmiceineither13-weekstudy.
Based on the histopathologic findings in the kidney of
maleratsandintheliverofboth sexes ofratsandmicein
the 13-week studies, the doses selected for the 2-year
studieswere150and300mg/kgformaleratsand300and
600 mg/kg for female rats and male and female mice. In
the 2-year studies, survival of female rats and of both
sexes of mice was comparable to that of the vehicle
controls; survivalofhighdosemaleratswassignificantly
lower than that of the vehicle controls (vehicle control,
32/50; low dose, 31/50; high dose, 20/50). Mean body
weights ofhigh dose male rats were 5%-8% lower than
those ofvehicle controls afterweek38, and those ofhigh
dose female ratswere 5%-7% lowerthan those ofvehicle
controlsafterweek55. Meanbodyweights ofmicedosed
with 1,4-dichlorobenzene were comparable to those of
vehicle controls throughout the studies.
Administration of 1,4-dichlorobenzene to male rats
increasedthe averageseveityofnephropathyandcaused
epithelial hyperplasia of the renal pelvis (1/50; 30/50;
31/50),mineralizationofthecollectingtubulesintherenal
medulla (4/50; 46/50; 47/50), and focal hyperplasia of
renal tubular epithelium (0/50; 1/50; 9/50). There were
increasedincidencesofnephropathyinbothlowandhigh
dose female rats compared with vehicle controls (21/49;
32/50; 41/49). 1,4-Dichlorobenzene produced a dose-
relatedincrease in theincidence oftubularcell adenocar-
cinomas ofthe kidney in male rats (1/50; 3/50; 7/50); one
tubular cell adenoma was observed in a high dose male
rat. These malignant tumors are uncommon in male
F344/N rats. They have been diagnosed in only 4/1,098
(0.4%) corn oil gavage controls in previous NTP studies.
There were no tubular cell tumors in dosed or vehicle
controlfemalerats.Therewas amarginalincreaseinthe
incidenceofmononuclearcellleukemiaindosedmalerats
comparedwith that in vehicle controls (5/50; 7/50; 11/50).
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1,4-Dichlorobenzene increased the incidences of non-
neoplasticliverlesions inmaleandfemalemice,including
alteration in cell size (cytomegaly and karyomegaly),
hepatocellular degeneration, and individual cell necrosis.
1,4-Dichlorobenzene also increased the incidences of
nephropathyinmalemiceandrenaltubularregeneration
in female mice. 1,4-Dichlorobenzene increased the inci-
dences of hepatocellular carcinomas in high dose male
(14/50; 11149; 32/50) and female (5/50; 5/48; 19/50) mice
and hepatocellular adenomas in dosed male (5/50; 13/49;
16/50) and high dose female (10/50; 6/48; 21150) mice.
Hepatoblastomas were observed in four high dose male
mice but not in vehicle controls. This rare tumor has not
occurred in 1,091 male vehicle control mice in NTP stud-
ies. An increase in thyroid gland follicular cell hyper-
plasia was observedindosedmalemice (1147;4/48;10/47),
and there was a marginal positive trend in the incidence
offollicular cell adenomas ofthe thyroid gland in female
mice (0/48; 0/45; 3/46). Pheochromocytomas (benign or
malignant, combined) oftheadrenal gland occurredwith
a positive trend in dosed male mice, and the incidence in
the high dose group was significantly greater than in
vehicle controls (0/47; 2/48; 4/49). The incidence ofadre-
nal gland medullary hyperplasia in male mice was 2/47;
4/48; and 4/49. Focal hyperplasia of the adrenal gland
capsule was also observed in dosed male mice (11147;
21148; 28/49).
1,4-Dichlorobenzene was notmutagenic inSalmonella
typhimurium strains TA98, TA100, TA1535, or TA1537
with or without activation by Aroclor 1254-induced male
Sprague-Dawley rat or male Syrian hamster liver S9
when tested according to a preincubational protocol at
concentrations up to 100 jig/plate. 1,4-Dichlorobenzene
did notinduceforwardmutationsinthe mouselymphoma
L5178Y/TK+/- assay in the absence of exogenous meta-
bolic activation; however, the results were equivocal in
this system in the presence of metabolic activation. 1,4-
Dichlorobenzene did not produce an increase in sister-
chromatidexchanges orchromosomalaberrationsinChi-
nese hamster ovary cells in culture with or without
exogenous metabolic activation. No increase in micro-
nucleated cells was seen inerythrocytes ofmicefromthe
first 13-week studies.
An audit of the experimental data was conducted for
the2-yearstudies of1,4-dichlorobenzene. Nodatadiscre-
pancies were found that influenced the final interpreta-
tions.
Under the conditions of these 2-year gavage studies,
1,4-dichlorobenzene produced clear evidence of car-
cinogenicity for male F344/N rats, as shown by an
increased incidence of renal tubular cell adenocar-
cinomas. There was no evidence ofcarcinogenicity for
female F344/N rats receiving doses of300 or 600 mg/kg.
There was clear evidence ofcarcinogenicity for both
male and female B6C3F1 mice, as shown by increased
incidences ofhepatocellular carcinomas and hepatocellu-
lar adenomas. Marginal increases were observed in the
incidences ofpheochromocytomas oftheadrenalglandin
male mice. Nonneoplastic effects in the kidney of male
and female rats, in theliver ofmale and femalemice, and
in thethyroidgland and adrenalgland ofmalemicewere
also associated with the administration of 1,4-
dichlorobenzene.
Synonyms: p-dichlorobenzene; para-dichlorobenzene;
para-chlorophenyl chloride
Report Date: January 1987
TR-320 Toxicology and Carcinogenesis
Studies ofRotenone (CAS No. 83-79-4) in
F344/N Rats and B6C3F1 Mice (Feed
Studies)
Toxicology and carcinogenesis studies of rotenone
(more than 98% pure), a pesticide, were conducted in
B6C3F1 mice and F344/N rats for14 days, 13weeks, and
2 years.
Results of the Fourteen-Day Studies: In the 14-day
studies (dietaryrotenone concentrations of0-600 ppm in
thefirst14-daystudies and 0-4,800ppminthe second 14-
daystudies), roughhaircoatsanddose-relateddecreases
inmeanbodyweightgainwereobservedinrats. Ratsfed
diets containing rotenone at concentrations of1,200 ppm
or higher lostweight. No compound-related toxic effects
were observed in mice.
Results ofthe Thirteen-Week Studies: In the 13-week
studies (concentrations of 0-1,200 ppm rotenone in feed
for rats and 0-50,000 ppm for mice), compound-related
effectsincludedlowerbodyweightgaininratsat150ppm
ormore; andbonemarrowatrophyandinflammation and
hyperplasiaoftheforestomachinmalerats at300ppmor
more and in female rats at 150 ppm or more. These
findings were used to establish the dietary concentra-
tions ofrotenone for the 2-year studies.
Experimental Design for the Two-Year Studies: Two-
year studies ofrotenone were conducted by administer-
ingdietscontaining0,38,or75ppmrotenonetogroupsof
50 F344/N rats ofeach sex for 103 weeks. Groups of 50
B6C3F1 mice of each sex were administered diets con-
taining 0, 600, or 1,200 ppm rotenone on the same sched-
ule. The estimated average amount of rotenone
consumed per day was 1.7 mg/kg or 3.5 mg/kg for low
doseorhighdoseratsand115mg/kgor250mg/kgforlow
dose and high dose mice.
Survival and Mean Body Weight in the Two-Year
Studies: Survival of control and dosed rats was similar
(male: control, 22/50; low dose. 31150; high dose, 30/50;
female: control, 27/50; low dose, 32/50; high dose, 31V50).
Mean bodyweights ofdosed and control male rats were
comparable. Meanbodyweights ofhigh dosefemale rats
were 5%-9% lower than those of the controls between
weeks 58 and 88. Survival of high dose male mice was
significantly greater than that of the controls (male:
29/50; 36/50; 47/50; female: 37/50; 42/50; 45/50). Final
mean bodyweights ofdosed mice were lowerthan those
of the controls by 8%-13% for males and 17%-24% for
females.
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Neoplastic Effects intheTwo-Year Studies: Parathyroid
gland adenomas were observed in 1/41 control, 0/44 low
dose, and4/44high dosemalerats. Thehistoricalincidence
ofthis uncommon tumor in untreated control male rats in
NTP studies is 4/1,314 (0.3%). Because these tumors are
rare and because the highest incidence ever seen in a
controlgroupis1/50,theincreaseinthesetumorsmayhave
been related to rotenone administration.
The incidence of subcutaneous tissue fibromas, fibro-
sarcomas, sarcomas, myxosarcomas, or neurofibrosar-
comas (combined) in low dose female rats was greater
(P<0.05)thanthatinthecontrols (0/50;5/50;3/50).These
tumorswere combined because oftheirpossible common
histiogenic origin from fibroblasts or undifferentiated
mesenchymal cells. The incidence ofthose tumors in the
low dose females was greater than the historical rats at
this laboratory (9/337, 3% + 1%) and throughout the
Program (50/2,021, 2% + 2%). Because of the lack of a
significant dose-related trend and because statistical
significance was attained only by combining tumors of
differing morphology, the subcutaneous tissue tumors in
female ratswere notconsidered tobe chemically related.
The incidences ofthese tumors in dosed male rats were
not significantly different from that in the controls.
Hepatocellular adenomas or carcinomas (combined)
occurred in male mice with a negative (P<0.02) trend,
and the incidence in the high dose group was lower than
that in the controls (12/47; 12/49; 1/50). Because this low
rate of combined liver tumors is unusual, this decrease
may have been related to rotenone administration.
Subcutaneous tissue fibromas, sarcomas, fibrosar-
comas, or neurofibrosarcomas (combined) in male mice
occurredwithasignificant(P<0.05)negativetrend(8/49;
4/50; 2/50). The incidence in the high dose group was
significantly lower than that in the controls by the life
table test (P =0.01).
Genotoxicity: Rotenone was not mutagenic when
tested according to a preincubational protocol with Sal-
mcnmella typhimurium strains TA100, TA1535, TA1537,
and TA98 with or without metabolic activation by rat or
hamsterliverS9. Rotenoneinducedforwardmutationsin
the mouse L5178Y/TK+/- lymphoma assay without
activation; itwasnottestedinthepresence ofS9. Results
of tests with rotenone in Chinese hamster ovary cells
were negative for induction of sister chromatid
exchanges (SCEs) inthe absence ofexogenous metabolic
activation (at concentrations at which the chemical was
verytoxic),equivocalforSCEsinthepresence ofratliver
S9 (due to a nonrepeatable positive response when tests
were conducted up to toxic concentrations), and negative
for chromosomal aberrations in both the presence and
absence ofmetabolic activation.
Data Audit: An audit of the experimental data was
conducted for the 2-year studies of rotenone. No data
discrepancies were found that influenced the final inter-
pretations.
Conclusions: Underthe conditions ofthese2-yearfeed
studies, there was equivocal evidence ofcarcinogenic
activity of rotenone for male F344/N rats, as indicated
byanincreasedincidenceofparathyroidglandadenomas
(uncommon tumors). There was no evidence of car-
cinogenic activity in female F344/N rats fed diets con-
taining38 or 75ppmrotenone. Therewasno evidence of
carcinogenic activity for male or female B6C3F1 mice
fed diets containing 600 or 1,200 ppm rotenone for 2
years.Thedecreasedincidenceofliverneoplasmsinmale
mice may have been related to the administration of
rotenone.
Synonym: 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-1-
methylethenyl)-[l]benzopyrano[3,4-b]furo[2,3-h][1]
benzopyran-6(6H)-one
Trade Names of Formulations: Derrin; Derris;
Thbatoxin; Nicouline; Prentox; Noxflsh; Rotocide; Bar-
basco; Cube Root; Haiari; Dactinol
Report Date: January 1988
TR-321 Toxicology and Carcinogenesis
Studies of Bromodichloromethane (CAS
No. 75-27-4) in F344/N Rats and B6C3F
Mice (Gavage Studies)
Bromodichloromethane (99% pure), one of several tri-
halomethanes commonly formed after chlorination of
water, was selected for studybecause no carcinogenicity
data were available for this compound and because chlo-
roform, a related trihalomethane, had been found to
causetumorsinrodents.Thegeneralpopulationmightbe
exposedtobromodichloromethane indrinkingwatersup-
plies, in swimming pools, and in a variety of food sub-
stances.
Single-administration, 14-day, 13-week, and 2-year
studies were conducted in F344/N rats and B6C3F1
mice. The chemical was administered by gavage in corn
oil because human exposure is primarily oral. Additional
studies were performed to evaluate the potential for
genetic damage in bacteria and mammalian cells.
Results of the Short-Term Studies: In the single-
administration studies, the chemicalwas administered at
doses of 150-2,500 mg/kg per day. All rats and female
mice at 1,250 and 2,500 mg/kg and all male mice at 600,
1,250,and2,500mg/kgdied;2/5malerats,1/5femalerats,
and 2/5 female mice at 600 mg/kg died; all animals at
lower dose levels survived.
Inthe14-daystudies,ratsreceiveddosesof38-600mg/
kg, andmicereceived doses of19-300mg/kgperday. One
female rat at 38 mg/kg and one female rat at 600 mg/kg
died. Weight loss or decreased weight gain was seen at
300 and 600mg/kginmale andfemale rats.Allmalemice
at 150 and 300 mg/kg died, and one female mouse at 300
mg/kgdied; noweighteffectswereobservedinsurviving
mice. Dose-related necropsy findings included reddened
renal medullae in male rats at 600 mg/kg and in male
mice at 150 and 300 mg/kg. Clinical signs seen in high
dose groups after dosing were hyperactivity in rats and
lethargy in mice.
In the 13-week studies, male and female rats received
doses of19-300 mg/kgper day, male mice received doses
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of 6.25-100 mg/kg per day, and female mice received
doses of25-400 mg/kg per day. Five of10 male rats and
2/10femalerats at300mg/kgdied. Noneofthemicedied.
Finalbodyweightsofmaleandfemaleratsat150and300
mg/kg were lower than those of vehicle controls
(45%-88% ofvehicle controlweights); finalbodyweights
ofmale mice at 100 mg/kg and female mice at400 mg/kg
were 92% and 94% of those of the vehicle controls.
Centrilobular degeneration in theliver and degeneration
and necrosis ofthe kidney were seen in male rats at 300
mg/kg; centrilobular degeneration was seen in female
rats at 300 mg/kg; degeneration and necrosis of the
kidney were seen in male mice at 100 mg/kg, and cen-
trilobular degeneration of the liver was seen in female
mice at 200 and 400 mg/kg.
Experimental Design of the Two-Year Studies: The
2-year toxicology and carcinogenesis studies of bro-
modichloromethane were conducted by administering
thechemicalincornoilbygavage,5daysperweekfor102
weeks, togroups of50male andfemalerats atdoses of0,
50, or 100 mg/kg per day; to groups of 50 male mice at
doses of0, 25, or 50 mg/kg per day; and to groups of50
female mice at doses of0, 75, or 150 mg/kg per day. The
studyin male rats was restarted because at 10.5 months
into the original study, a temperature elevation killed
45/50 vehicle control male rats.
Survival and Body Weight in the Two-Year Studies:
Final survival of dosed rats was comparable to that of
vehicle controls (male: vehicle control, 28/50; low dose,
36/50;highdose,28/50; female: 34/50;27/50;41150).Mean
body weights of high dose male and female rats were
decreased during the last 1.5 years of the study; final
mean body weights of high dose male and female rats
were 88% and 79% ofthe vehicle control mean weights.
Final mean body weights of low dose male and female
rats were comparable to those ofthe vehicle controls.
Final survival of dosed male mice was comparable to
that ofthevehicle controls (34/50; 32/50; 42/50). Atweek
84, survival offemale mice was greater than 50% in all
dose groups.Afterweek84, survival ofdosed andvehicle
control female mice was reduced (final survival: 26/50;
13/50; 15/50), and this decreased survival was associated
with ovarian abscesses (8/50; 19/47; 18/49). The final
mean bodyweight ofhigh dose male mice was 95% that
ofthevehicle controls; thefinalmeanbodyweight oflow
dose male mice was comparable to that of the vehicle
controls. Meanbodyweightsofthehighdosefemalemice
weredecreased duringthelast1.5years ofthestudy; the
final mean body weight was 75% that of the vehicle
controls. The final mean body weight of the low dose
female mice was 91% that ofthe vehicle controls.
Nonneoplastic Effects in the Two-Year Studies:
Compound-related nonneoplastic lesions included
cytomegaly and tubular cell hyperplasia of the kidney
andnecrosis andfattymetamorphosis oftheliverinmale
rats; eosinophilic cytoplasmic change, clear cell change,
focal cellular change, and fatty metamorphosis of the
liver and tubular cell hyperplasia ofthe kidneyin female
rats; fattymetamorphosis ofthe liver, renal cytomegaly,
andfollicularcellhyperplasiaofthethyroidglandinmale
mice; and follicular cell hyperplasia ofthe thyroid gland
in female mice.
Neoplastic Effects in the Two-Year Studies: Bro-
modichloromethane caused compound-related increases
in the incidences ofneoplasms ofthe large intestine and
kidneyin male and female rats, the kidneyin male mice,
and the liver in female mice, as shown in the table (see
page 5 of the Technical Report). The neoplasms of the
large intestine and kidney are uncommon tumors in
F344/N rats and B6C3F1 mice.
Administration of bromodichloromethane was also
associated with a decrease in the tumors ofthe adrenal
glands in male rats, the pituitary and mammary glands
in female rats, and the pituitary gland in female mice.
Genetic Toxicology: Bromodichloromethane was not
mutagenic in Salmonnella typhimurium strains TA98,
TA100, TA1535, orTA1537whentestedbythepreincuba-
tional protocol at concentrations up to 1,000 ,ug/plate
with orwithout metabolic activation. The compound was
not mutagenic in the mouse lymphoma L5178Y/TK+/-
assay in the presence of S9 but did induce forward
mutations in the system in the presence of metabolic
activation from rat liver S9. Cytogenetic tests with Chi-
nese hamster ovary cells demonstrated no induction of
chromosomal aberrations or sister chromatid exchanges
following treatment with bromodichloromethane in
either the presence or absence ofmetabolic activation.
Data Audit: An audit of the experimental data was
conducted for the 2-year toxicology and carcinogenesis
studiesofbromodichloromethane. Nodiscrepancieswere
found that influenced the final interpretations of the
results ofthese studies.
Conclusions: Under the conditions of these 2-year
gavage studies, there was clear evidence of car-
cinogenicactivity formale andfemale F344/Nratsand
B6C3F1 mice as shown byincreased incidences oftubu-
larcelladenomasandadenocarcinomas inthekidneyand
adenocarcinomas and adenomatous polyps in the large
intestine in male andfemale rats,increasedincidences of
tubular cell adenomas and adenocarcinomas in the
kidney of male mice, and increased incidences of
hepatocellular adenomas and carcinomasinfemalenmice.
Synonym: dichlorobromoethane
Report Date: October 1987
TR-322 Toxicology and Carcinogenesis
Studies ofPhenylephrine Hydrochloride
(CAS No. 61-76-7) in F344/N Rats and
B6C3F1 Mice (Feed Studies)
Phenylephrine hydrochloride is a sympathomimetic
aminerecommended foruse as anasaldecongestantand
as a mydriatic in ophthalmic applications. In 1977, total
U.S. human exposure was estimated at 1.9 x 107 g per
year. Phenylephrine hydrochloride was nominated for
toxicologyandcarcinogenesisstudiesbecauseofalackof
previous long-term studies and because two other sym-
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pathomimetic agents (soterenol hydrochloride and mes-
uprine hydrochloride) produced mesovarial leiomyomas
in Sprague-Dawleyrats.
Toxicology and carcinogenesis studies of USP-grade
phenylephrine hydrochloride were conducted by admin-
istering diets containing the chemical (99% pure) to
F344/N rats andB6C3F1 miceofeachsexinstudiesof14
days,12weeks, and2years. Inthe14-daystudies, notoxic
effectswereseeninratsormicefeddietscontainingupto
2,000 ppm phenylephrine hydrochloride. Doses were
increased in the 12-week studies, and deaths ofmale rats
andmalemicewereobservedingroupsfeddietscontain-
ing10,000 or20,000 ppm; V10male rats in the 5,000-ppm
group died. Otherthaninflammatory eyelesions (consid-
eredsecondarytothepharmacologic dryingactionofthe
chemical), no specific organ toxicity was noted. Body
weights decreased as concentrations of phenylephrine
hydrochloride in the diet were increased, and feed con-
sumption was lower in dosed rats. Doses of 0, 620, and
1,250 ppm for rats and 0, 1,250, and 2,500 ppm for mice
were selected for the 2-year studies because of the
decreased body weight gains in animals given higher
doses in the 12-week studies. In the 2-year studies, the
approximate amount of phenylephrine hydrochloride
consumedperdaywas24mg/kgforlowdoserats, 50mg/
kg for high dose rats, 133 mg/kg for low dose mice, and
270 mg/kg for high dose mice.
Body weight differences in rats appeared to be dose
related, and dosed animals were 3%-15% lighter than
controls. Body weights of dosed mice averaged 3%-14%
lower than those ofcontrols throughoutthe 2-year stud-
ies. Survival ofhighdosemaleratswasgreaterthanthat
ofthe controls (control,30/50; lowdose,33/50; high dose,
42/50); differences in survival were not significant for
female rats (42/50; 34/50; 36/50), male mice (35/50; 38/50;
43/50), orfemale mice (37/50; 34/50; 34/50).
Few nonneoplastic lesions were related to phe-
nylephrine hydrochloride dosingin rats ormice. Chronic
focalinflammation oftheliverwas observed atincreased
incidences in dosed rats (male: 2/50; 13/50; 17/50; female:
17/50; 28/50; 35/50). Inflammation of the prostate was
seen more frequently in dosed than in control males
(10/50; 24/50; 24/50). The incidence of focal cellular
change in the liver was increased slightly in high dose
male mice (0/50; 2/50; 7/50).
In male rats, mononuclear cell leukemia (24/50; 9/50;
5/50) and pheochromocytomas of the adrenal gland
(14/49; 11/50;2/50)occurredwithnegativetrends, andthe
incidences in the high dose groupwere lower than those
in the controls. No increases in neoplasia were seen in
dosed male or female rats or mice.
Phenylephrine hydrochloride was not mutagenic in
four strains of Salmonella typhimurium (TA100,
TA1535,TA1537, andTA98)with orwithoutAroclor1254-
induced liver S9frommale Sprague-Dawley rats ormale
Syrian hamsters. The results ofmutagenicity studies of
phenylephrine hydrochloride were equivocal in the
mouse lymphoma L5178Y/TK+/- assay in the absence of
S9;itwasnottestedinthepresenceofS9.Phenylephrine
hydrochloride induced sister-chromatid exchanges
(SCEs) but not chromosomal aberrations in Chinese
hamster ovarycells. Theincrease in SCEswas seen only
in the absence ofmetabolic activation with S9.
An audit of the experimental data was conducted for
the 2-year studies of phenylephrine hydrochloride. No
data discrepancies were found that influenced the final
interpretations.
Undertheconditionsofthese2-yearstudies,therewas
no evidenceofcarcinogenicity ofphenylephrine hydro-
chloride for male B6C3F1 mice given 1,250 or 2,500 ppm
infeed. Survival ofhigh dosemale ratswas greaterthan
that of controls, and the incidences of mononuclear cell
leukemia and pheochromocytomas were lower in dosed
than in control male rats. Inflammation was observed
more frequently in the liver and prostate gland ofdosed
male rats than in controls.
Synonyms: benzene methanol,3-hydroxy-cx[(methyla-
mino)methyl]hydrochloride ®-; (-)-meta-hydroxy-ac-
[(methylamino)methyl]benzyl alcohol hydrochloride;
meta-Synephrine hydrochloride; Neo-synephrine®
Report Date: January 1987
TR-323 Toxicology and Carcinogenesis
Studies ofDimethyl Methylphosphonate
(CAS No. 756-79-6) in F344/N Rats and
B6C3F1 Mice (Gavage Studies)
Dimethylmethylphosphonate (98%pure)is oneoffour
chemicalsnominatedbythe U.S.Armyfortoxicologyand
carcinogenesis studies because it was being considered
for use to simulate the physical and spectroscopic (but
not the biologic) properties ofanticholinesterase (nerve)
agents. Dimethyl methylphosphonate is also used as a
flame retardant, a preignition additive for gasoline, an
antifoam agent, a plasticizer and stabilizer, a textile
conditioner and antistatic agent, and an additive for
solvents and low-temperature hydraulic fluids. The
United States produces 0.2-2 million pounds
(91,000-910,000 kg) ofperyear. Gavagewaschosenasthe
route ofadministrationforallfourcandidate"simulants"
to mimic potential exposure.
Experimental Design: Dimethyl methylphosphonate
was administered in corn oil by gavage to male and
female F344/N rats and B6C3F1 mice in single-
administration, 15-day, and 13-week studies to obtain
toxicity data, to establish dose levels for the 2-year
studies, and toidentifytargettissues. Additional studies
were also performed to determine toxicity to the
reproductive system of male F344/N rats and B6C3F1
mice and to study the potential for genetic damage in
bacteria, mammalian cells, and Drosophila.
Single-Administration Studies: In the single-
administration studies, dimethyl methylphosphonate
was given to rats and mice at doses up to 6,810 mg/kg
body weight. No compound-related deaths were seen in
male or female rats or male mice; two high dose female
mice died. Rats exhibited inactivity, unsteady gait, and
prostration afterdosing;micewereinactiveafterdosing.
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Fifteen-Day Studies: Rats and mice received doses of
0, 1,250, 2,500, 5,000, 10,000, or 15,000 mg/kg dimethyl
methylphosphonate per day. Compound-related deaths
occurred inthethreehighestdosegroupsofratsandthe
two highest dose groups ofmice. Rats receivingdoses of
2,500mg/kgorhigherwereinactiveandat5,000or10,000
mg/kghad anunsteadygaitafter dosing; miceexhibited
inactivity, shallow breathing, and prostration at doses of
10,000mg/kgorhigher. Nolesionswerereported inrats.
Nonneoplastic lesions ofthe stomach were seen in some
malemiceatdosesof1,250mg/kgandhigherandinsome
female mice at doses of5,000 mg/kg and higher.
Thirteen-Week Studies: Dimethyl methylphosphonate
wasgivenatdosesupto8,000mg/kgperday.Compound-
related deaths occurred at2,000, 4,000, and 8,000 mg/kg
in rats and at4,000 and 8,000mg/kgin mice. Mean body
weights ofrats at 1,000 mg/kg and mice at 2,000 mg/kg
were similar to those ofthe vehicle controls; decreased
weight gain was seen at higher doses. No compound-
related clinical signs were reported. Minimal to mild
renal andtesticularlesionswere seen atall dosesinmale
rats, but the severity of these lesions did not increase
withincreasingdose ofthe chemical. No apparenttarget
tissues were identified in female rats ormale and female
mice.
Doses selected for the 2-year studies were based on
body weight effects and mortality seen in the 13-week
studies; the lesions seenin the kidney ofmale rats atthe
end of the 13-week studies were judged not to be life
threatening. In the 2-year studies, dimethyl meth-
ylphosphonatewas administered in corn oilbygavage at
doses of 0, 500, or 1,000 mg/kg per day to groups of 50
F344/N rats ofeach sex and at 0, 1,000, or 2,000 mg/kg
per day to groups of 50 B6C3F1 mice of each sex. All
animals were dosed 5 days per week for 103 weeks.
Body Weight and Survival in the Two-Year Studies:
Mean bodyweights ofhigh dose male ratswere 5%-10%
lowerthanthoseofthevehiclecontrolsbetweenweeks28
and 76 and were 10%-24% lower between weeks 80 and
104. Mean body weights of high dose female rats were
8%-12% lower than those of the vehicle controls after
week 80. Survival ofmale rats was greater than 50% in
all groups until week 80, and after this time, survival
decreased inboth groups, with the survival atthe end of
the studybeing27/50invehicle control,17/50 inlowdose,
and4/50inhigh dose groups. Survival oflowdosefemale
rats was comparable to that of the vehicle controls, but
the final survival ofhigh dosefemale ratswas decreased
(vehicle control, 30/50; lowdose,33/50; high dose, 23/50).
No othercompound-related clinical signswere observed.
Mean body weights of high dose male mice were
7%-16% lower than those of the vehicle control males
between weeks 36 and 76, and those ofhigh dose female
mice were 6%-12% lower between weeks 88 and 103.
Decreased survival between weeks 23 and 45 in high
dose male mice was associated with fighting. Seventeen
high dosemale and 22high dosefemalemice died during
week 45; these deaths were associated with the acciden-
tal administration of a dose mixture that had a con-
centration 34% greater than the targeted amount.
Eleven low dose male mice died on the same day during
week 77. By the end of the study, 29/50 vehicle control,
12/50 low dose, and 0/50 high dose male micewere alive;
41/50, 30/50, and 2/50 female mice survived to the end of
the study.
RenalEffectsintheTwo-YearStudies:Administration
of dimethyl methylphosphonate to male rats increased
the averageseverityofnephropathyandcausedmineral-
ization(calcification) ofthecollectingtubulesintherenal
papilla (12/50; 41/50; 36/49), hyperplasia of the transi-
tionalepitheliumliningtherenalpelvisandoverlyingthe
renalpapilla (0/50; 23/50; 21/49), andfocal hyperplasia of
the renal tubular epithelium (0/50; 8/50; 9/49). Admin-
istration of dimethyl methylphosphonate to male rats
was also associated with the occurrence of rare renal
tubular cell adenocarcinomas (0/50; 2/50; 3/49) and
papillomas of the transitional epithelium lining of the
renal pelvis (0/50; 2/50; 3/49); a transitional cell car-
cinoma occurred in a low dose male rat. There were no
tubularcellortransitionalcellneoplasmsofthekidneyin
female rats.
Hematopoietic System Effects in the Two-Year Stud-
ies: The incidence of mononuclear cell leukemia was
increased in high dose male rats (10/50; 11/50; 17/50).
Genetic Toxicity: Dimethyl methylphosphonate was
not mutagenic when tested in the Salmonella
typhimurium/microsome assay by the preincubational
protocol with strains TA98, TA100, TA1535, or TA1537
with or without metabolic activation. The chemical did
induce forward mutations in the mouse lymphoma
L5178Y/TK+/- assay system in the absence ofmetabolic
activation. ITeatmentofcultured Chinesehamsterovary
cells with dimethyl methylphosphonate did not induce
chromosomal aberrations; however, sister chromatid
exchanges were induced after exposure to this chemical
in both thepresence and absence ofmetabolic activation.
When fed to Drosophila, dimethyl methylphosphonate
induced a significant increase in the frequency of sex-
linked recessive lethal mutations but did not induce
reciprocal translocations. Dimethyl methylphosphonate
caused a dominant lethal effect in male rats and mice.
Studies of Reproductive Effects: Dimethyl meth-
ylphosphonate caused a dose-related increase in the
number offetal resorptions in undosed female rats and
mice mated with males that received the chemical by
gavageinwater5 days perweekfor13 weeks at doses of
0-2,000mg/kg per day. Afterthe 13-week dosingperiod,
histopathologic changes were seen in the kidney and
testis ofmale rats but not in male mice; dosed male rats
siredfewerlittersandfewerpupsperlitter. Dose-related
decreasesinspermcountand spermmotilityoccurredin
male rats but not in male mice. Toxic effects to the
reproductive system ofmale rats and mice were revers-
ible after a 13- to 14-week recoveryperiod.
Data Audit: An audit of the experimental data was
conducted for the 2-year studies on dimethyl meth-
ylphosphonate. No data discrepancies were found that
influenced the final interpretations.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
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cinogenic activity of dimethyl methylphosphonate for
male F344/N rats as shown by increased incidences of
tubular cell hyperplasia, tubular cell adenocarcinomas,
hyperplasia ofthe transitional cell epithelium, and tran-
sitional cell papillomas of the kidney. There was an
increased incidence ofmononuclear cell leukemiainmale
rats at 1,000 mg/kg. Renal toxicity and decreased sur-
vivaloccurredindosedmalerats.Therewasnoevidence
of carcinogenic activity of dimethyl methylphospho-
nate for female F344/N rats given doses of 500 or 1,000
mg/kg. The study in male B6C3F1 mice was an inade-
quate study of carcinogenic activity because of
decreased survival in both dosed groups. There was no
evidence of carcinogenic activity for female B6C3F1
mice receiving dimethyl methylphosphonate at1,000mg/
kg; decreased survival of female mice at 2,000 mg/kg
made this group inadequate for determination of car-
cinogenic activity.
Synonyms: fyrol DMMP; methyl phosphonic acid,
dimethyl ester; DMMP; methanephosphonic acid
dimethyl ester; dimethyl methanephosphonate
Report Date: November 1987
TR-324 Toxicology and Carcinogenesis
Studies ofBoric Acid (CAS No. 10043-35-3)
in B6C3F1 Mice (Feed Studies)
Boric acid is a component of cosmetics and phar-
maceuticals and is also used in numerous industrial
processes. Earlierlong-termstudiesdidnotdemonstrate
acarcinogenic effectin Sprague-Dawley rats. Because of
potentialwidespreadhumanexposure, corroborativeevi-
dence was sought in a second species. Toxicology and
carcinogenesis studies were conducted by feeding
technical-grade boricacid (99.7%pure) togroups ofmale
and female B6C3F1 mice for 14 days, 13 weeks, and 2
years.
In the 14-day studies (five mice per group), mortality
occurred in mice fed 25,000 ppm, 50,000 ppm, or 100,000
ppm boric acid; hyperplasia and/or dysplasia ofthe fore-
stomach was also seen in these dose groups. No
compound-related gross pathologic or histopathologic
effects were seen in male or female mice exposed at
concentrations up to 12,500 ppm in feed. In the 13-week
studies, groups of 10 male and 10 female mice were fed
boric acid at concentrations up to 20,000 ppm; 8 male
miceand1femalemousereceiving20,000ppmand1male
receiving10,000ppmboric acid diedbefore theendofthe
studies. Maleandfemalemicereceiving20,000ppmboric
acidweighed23%and18%less,respectively, thandidthe
controls at the end ofthe studies. Testicular atrophy in
8/10 male mice, hyperkeratosis and acanthosis of the
stomach in 8/10 male and female mice, and extramedull-
ary hematopoiesis of the spleen in all male and female
mice receiving 20,000 ppm boric acid indicated that the
testis, stomach, and spleen were potential target organs
in the 2-year studies. Based on these results, 2-year
toxicologyandcarcinogenesis studieswereconductedby
feedingdiets containingboric acid atconcentrations of0,
2,500, or 5,000 ppm to groups of 50 male and 50 female
mice.
Survival ofhigh dose male mice after week 63 and of
low dose mice after week 84 was lower than that ofthe
controls (final survival: control, 41; low dose, 30; high
dose, 22), which may have reduced the sensitivity ofthe
carcinogenicity study; the numbers of female mice (33;
33; 37) that survived to the end of the studies were
considered adequate for toxicologic evaluation. Body
weightgainwasreducedineach sexafterweek30; mean
finalbodyweightswere 7%and 13%belowcontrolvalues
for exposed male mice and 7% and 20% below those of
controls for exposed female mice. No chemically related
clinical signs were reported.
At the top dose, boric acid caused an increased inci-
dence oftesticular atrophy (control, 3/49; lowdose, 6/50;
high dose, 27/47) and interstitial cell hyperplasia (0/49;
0/50; 7/47) in male mice. The testicular atrophy was
characterized by variable loss of spermatogonia, pri-
mary and secondary spermatocytes, spermatids, and
spermatozoa from the seminiferous tubules. The semi-
niferous tubules contained primarily Sertoli cells and
variable numbers ofspermatogonia. In somemice, there
were accumulations ofinterstitial cells, indicatinghyper-
plasia.
Inlowdosemalemice,therewereincreasedincidences
of hepatocellular carcinomas (5/50; 12/50; 8/49) and
hepatocellular adenomas or carcinomas (combined)
(14/50; 19/50; 15/49) and an increased incidence of sub-
cutaneous tissue fibromas, sarcomas, fibrosarcoinas, or
neurofibrosarcomas (combined) (2/50; 10/50; 2/50). No
increased incidence of subcutaneous tissue neoplasms
was seen in male mice receiving 5,000 ppm. Because the
incidence of subcutaneous tissue tumors is variable in
historical controls, because there was no corresponding
increase in the high dose male mice, and because the
incidence ofhepatocellulartumorswas notsignificantby
the incidental tumor test and was within the historical
control range, neither ofthese tumors was considered to
be related to the administration ofboric acid.
Boric acid was not mutagenic in the Salmonella/
microsome assay with Salmonella typhimurium
strains TA98, TA100, TA1535, or TA1537. Boric acid was
negative in the mouse lymphoma L5178Y/TK+/- assay
and did not induce sister-chromatid exchanges or chro-
mosomal aberrations in Chinese hamster ovarycells. All
assays were preformed with and without metabolic
activation.
The data, documents, and pathology materials from
the 2-year studies ofboric acid were audited at the NTP
Archives. Theauditfindings showthattheconductofthe
studies is documented adequately and support the data
and results given in this Technical Report.
Under the conditions of these 2-year feed studies,
there was no evidence ofcarcinogenicity ofboric acid
atdosesof2,500 or5,000ppmformale orfemaleB6C3F1
mice. Testicular atrophy and interstitial cell hyperplasia
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were observed in high dose male mice. The decrease in
survival of dosed male mice may have reduced the sen-
sitivity ofthis study.
Synonyms: orthoboric acid; boracic acid
Report Date: October 1987
TR-325 Toxicology and Carcinogenesis
Studies ofPentachloronitrobenzene (CAS
No. 82-68-8) in B6C3F1 Mice (Feed Studies)
Toxicology and carcinogenesis studies of pen-
tachloronitrobenzene (99% pure) a fungicide, were con-
ducted by administering diets containing 0, 2,500, or
5,000 ppm pentachloronitrobenzene to groups of 50
B6C3F1 miceofeachsexfor103weeks.Thesedoseswere
selected because, in 13-week studies in which the chemi-
calwas administeredinfeedatdosesupto20,000ppmin
male mice and up to 40,000 ppm in female mice, body
weight gain depression was observed at 10,000 ppm and
above inmales and female and deaths occurred at40,000
ppm in females.
The National Cancer Institute had conducted 2-year
(diet) studies in B6C3F1 mice and Osborne-Mendel rats
(See TR-61 reported in 1978). Survival amongmale mice
was low, not all livers were examined from dosed female
mice, and the size ofthe control group was considered to
be small. Forthese reasons, the NCI decided to conduct
additional 13-week and 2-year studies in B6C3F1 mice.
Under the conditions of the NCI studies, pen-
tachloronitrobenzene was not carcinogenic in either
Osborne-Mendel rats or B6C3F1 mice.
In the studies reported in this Technical Report, the
survival ofmalemicewas comparable amongcontrol and
dosed groups (control, 35/50; low dose, 31150; high dose,
32/50). Final mean body weights of low dose and high
dose male mice were 96%,md 90% that ofthe controls.
All groups of female mice showed evidence of bacterial
infection. At week 84, survival in dosed and control
female mice was 38/50; 34/50; 30/50; after week 84,
survival in dosed groups decreased, with the final sur-
vival being 30/50; 20/50; 15/50. The mean bodyweight of
highdosefemalemicewasmorethan10%lowerthanthat
of the control group after week 20 and was 21% lower
than controls atweek 104. The mean bodyweight oflow
dose female mice was within 10% that of the control
group until week 88 and was 18% lower than controls at
week 104.
No compound-related neoplastic lesions were seen in
either male or female mice. The nonneoplastic lesions
observedinfemalemicewereconsidered tobesecondary
to bacterial infection (primarily Klebsiella) and included
hematopoiesis ofthe liver (9/50; 21150; 23/50) and spleen
(14/50; 23/48; 27/50), plasmacellhyperplasia ofthemedi-
astinal lymph nodes (1/44; 4/47; 9/45), and ovarian
abscesses (12/49; 22/50; 29/50).
Pentachloronitrobenzene wasnotmutagenicinSalmo-
nella typhimurium strains TA98, TA100, TA1535, or
TA1537 in the presence or absence of Aroclor 1254-
induced male Syrian hamster or male Sprague-Dawley
ratliverS9whentested accordingtothepreincubational
protocol. Pentachloronitrobenzene was not mutagenic at
the TK+/- locus ofL5178Y mouse lymphoma cells in the
presence or absence ofAroclor 1254-induced F344/N rat
liver S9. In cultured Chinese hamster ovary cells, pen-
tachloronitrobenzene did not induce sister-chromatid
exchanges but did induce chromosomal aberrations both
with and without Aroclor 1254-induced male Sprague-
Dawley rat liver S9.
An audit of the experimental data was conducted for
the 2-year studies ofpentachloronitrobenzene. No data
discrepancies were found that influenced the final inter-
pretations.
Under the conditions of these 2-year feed studies,
there was no evidence of carcinogenicity for either
male or female B6C3F1 mice receiving 2,500 or 5,000
ppm ofpentachloronitrobenzene. Infection is considered
to have decreased survival ofthe female mice and thus
reduced the sensitivity for determining the presence or
absence of a carcinogenic response.
Synonyms orTrade Names:Avicol®; PCNB; quintozene;
Botrilexg; Brassicol®;folosang; PKhNB; Tilcarex®; Ter-
raclor®; Tritosan®
Report Date: January 1987
TR-326 lTxicology and Carcinogenesis
Studies ofEthylene Oxide (CAS No.
75-21-8) in B6C3F1 Mice (Inhalation
Studies)
Ethylene oxide is a major industrial chemical used
primarilyas anintermediate inthemanufacture ofother
chemicals; e.g., ethylene glycol, a major component of
automotive and other antifreeze products. Exposure to
ethylene oxide is greatest in the health care industry,
where an estimated 75,000 workers are potentially
exposed. Ethylene oxide was nominated for toxicology
andcarcinogenesis studiesinB6C3F1micebecauseofits
extensive production; the potential for human exposure
intheworkplace, frommedical devices, orfromfood; the
positive results of genetic toxicology assays; and the
previous use of only F344/N rats in inhalation car-
cinogenicity studies.
Twoinhalation studiesreportedin1984bySnellings et
al. and by Lynch et al. demonstrated carcinogenic
responses in F344/N rats. Results were similar in both
studies and consisted of increased incidences of mono-
nuclearcellleukemia,peritonealmesotheliomas, andpri-
mary brain tumors.
Experimental Design: Tbxicology and carcinogenesis
studies of ethylene oxide (greater than 99% pure) were
conductedbyexposinggroupsof50B6C3F1 miceofeach
sex to air containing 0, 50, or 100 ppm ethylene oxide, 6
hoursperday,5daysperweekfor102weeks.Thesedoses
were selected because, in 14-week studies, all mice
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exposed at 600 ppm died within 1 week, and all mice
exposed at 400 ppm died by week 4. Rhinitis was
observed inboth sexes exposed at200, 400, and 600 ppm
as was renal tubular degeneration in both sexes at 100,
200, and400ppm. The lattereffects observed at100ppm
were slight and deemed not to be life threatening in
2-year studies.
Two-Year Studies: Survival of exposed and control
micewascomparableinthe2-yearstudies (male: control,
28/50; low dose, 31150; high dose, 34/50; female: 25/50;
24/50; 31V50). Final mean body weights in exposed mice
were 95%-102% ofthose ofthe controls. No compound-
related clinical signs were observed.
Those neoplastic lesions that occurred at elevated inci-
dencesinmiceexposedtoethyleneoxidearereportedinthe
followingtable(seepage6oftheTechnicalReport). Inmale
mice, alveolar/bronchiolar carcinomas, alveolar/bronchiolar
adenomas, and papillary cystadenomas of the harderian
gland occurred with positive trends. In female mice,
alveolar/bronchiolar adenomas, alveolar/bronchiolar car-
cinomas, papillary cystadenomas of the harderian gland,
malignant lymphomas, and uterine adenocarcinomas
occurred with positive trends. Mammary gland tumors
also were increased in exposed female mice.
Data Audit: An audit of the experimental data was
conducted for the 2-year studies of ethylene oxide. No
data discrepancies were found that influenced the final
interpretations.
Conclusions: Under the conditions of these 2-year
inhalation studies, there was clear evidence of car-
cinogenic activity for B6C3F1 mice as indicated by
dose-relatedincreased incidences ofbenign ormalignant
neoplasms of the lung and benign neoplasms of the
harderian gland in both male and female B6C3F1 mice
followingexposure toethylene oxidevapors at50 and100
ppm. In female mice, ethylene oxide caused additional
malignantneoplasmsoftheuterus,mammarygland,and
hematopoietic system (lymphoma).
Synonyms: oxirane; EO; ETO; dihydrooxirene;
dimethylene oxide; 1,2-epoxyethane; oxane; a,,B-
oxidoethane
Report Date: November 1987
TR-327 Tbxicology and Carcinogenesis
Studies ofXylenes (Mixed) (60% m-Xylene,
14%p-Xylene, 9% o-Xylene, and 17%
Ethylbenzene) (CAS No. 1330-20-7) in F344/
N Rats and B6C3F1 Mice (Gavage Studies)
The technical grade of xylenes (mixed) (hereafter
termed xylenes) contains the three isomeric forms and
ethylbenzene (percentage composition shown above).
The annual production for 1985 was approximately 7.4 x
108 gallons. Xylenes is used as a solvent and a cleaning
agent and as adegreaser and is a constituent ofaviation
and automobile fuels. Xylenes is also used in theproduc-
tion ofbenzoic acid, phthalate anhydride, andisophthalic
and terephthalic acids as well as their dimethyl esters.
Toxicologyand carcinogenesis studies ofxyleneswere
conducted in laboratory animals because alarge number
ofworkersareexposedandbecausethelong-termeffects
ofexposuretoxyleneswerenotknown. Exposure forthe
present studies was by gavage in corn oil. In single-
administration studies, groups of five F344/N rats and
B6C3F1 miceofeachsexreceived500,1,000,2,000,4,000,
or6,000mg/kg.Administration ofxylenes caused deaths
at 6,000mg/kgin rats and mice ofeach sex and at 4,000
mg/kginmalerats. Inrats,clinicalsignsobservedwithin
24 hours ofdosing at 4,000mg/kg included prostration,
muscularincoordination,andlossofhindlimbmovement;
these effects continued through the second week of
observation. Tremors, prone position, and slowed
breathing were recorded for mice on day 3, but all mice
appeared normal by the end of the 2-week observation
period. In 14-day studies, groups offive rats ofeach sex
wereadministered 0,125,250, 500, 1,000, or2,000mg/kg,
and groups offive mice ofeach sex received 0, 250, 500,
1,000, 2,000, or 4,000mg/kg. Chemical-related mortality
occurred only at 2,000 mg/kg in rats and at 4,000 mg/kg
in mice. Rats and mice exhibited shallow breathing and
prostrationwithin48hoursfollowingdosingat2,000mg/
kg. These signs persisted until day 12 for rats, but no
clinical signs were noted during the second week for
mice. In 13-week studies, groups of 10 rats of each sex
received0,62.5,125,250, 500, or1,000mg/kg, and groups
of10 mice ofeach sex received 0, 125, 250, 500, 1,000, or
2,000 mg/kg. No deaths or clinical signs oftoxicitywere
recorded in rats. However, high dose male rats gained
15% lessweightand females 8% lessweightthan did the
vehicle controls. Twofemalemicedied atthe2,000mg/kg
dose. Lethargy, short and shallow breathing, unsteadi-
ness, tremors, and paresis were observed for both sexes
in the 2,000 mg/kg group within 5-10 minutes after
dosing and lasted for 15-60 minutes.
Two-year toxicology and carcinogenesis studies were
conducted by administering 0, 250, or 500 mg/kg
xylenes in corn oil by gavage to groups of 50 F344/N
rats ofeach sex, 5 days per week for 103 weeks. Groups
of50 B6C3F1 mice ofeach sexwere administered 0,500,
or 1,000 mg/kg xylenes on the same schedule. Although
the mortality was dose related in male rats (final sur-
vival: vehicle control, 36/50; low dose, 26/50; high dose,
20/50), manyofthe earlydeathsin the dosed maleswere
gavage related. Bodyweights ofthe high dose male rats
were5%-8%lowerthanthoseofthevehiclecontrolsafter
week 59. The meanbodyweights oflowdose andvehicle
control male rats and those ofdosed and vehicle control
female rats were comparable. Survival rates of female
rats and both sexes ofdosed mice were not significantly
different from those of the vehicle controls. The mean
weights ofdosedmale and femalemicewere comparable
to those of the vehicle controls. Hyperactivity lasting
5-30 minutes was observed in high dose mice after
dosing, beginning after week 4 and continuing through
week 103.
At no site was the incidence of nonneoplastic or
neoplastic lesions in dosed rats or mice of either sex
considered to be related to the administration of
xylenes.
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Neither xylenes nor any ofits components (o-xylene,
m-xylene, p-xylene, or ethylbenzene) were mutagenic
when tested with orwithout metabolic activation in Sal-
manella typhimurium strains TA100, TA1535, TA97, or
TA98 with the preincubation protocol. In addition, eth-
ylbenzene was tested in cytogenetic assays using
cultured Chinese hamster ovary cells both with and
without metabolic activation; neither sister-chromatid
exchangesnorchromosomalaberrationswereinducedby
ethylbenzene.
An audit of the experimental data was conducted for
the2-yearstudiesofxylenes. Nodatadiscrepancieswere
found that influenced the final interpretations.
Under the conditions of these 2-year gavage studies,
there was no evidence of carcinogenicity of xylenes
(mixed) formale orfemale F344/N rats given 250 or 500
mg/kg or for male or female B6C3F1 mice given 500 or
1,000 mg/kg.
Report Date: December 1986
TR-328 lTxicology and Carcinogenesis
Studies ofMethyl Carbamate (CAS No.
598-55-0) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
Methyl carbamate is used as a chemical intermediate
bythetextileindustryforthemanufacture ofdimethylol
methyl carbamate-based resins that are applied on
polyester/cotton blend fabrics as durable-press finishes.
Experimental Design: Toxicology and carcinogenesis
studies ofmethyl carbamate (98% pure) were conducted
byexposing groups ofF344/N rats and B6C3F1 mice by
gavage inwater in a single dose and byrepeated admin-
istration for 16 days, 13 weeks, 6 months, 12 months, 18
months, and 2 years. In addition, short-term muta-
genicity studies in bacteria, mammalian cells, and Dros-
ophilaandofunscheduled DNAsynthesisinratlivercells
were conducted.
Single-Administration Studies: In the single-
administration studies, 5/5 male and 5/5 female rats that
received8,000mg/kgmethylcarbamate and2/5maleand
5/5 female thatreceived 4,000mg/kg died before the end
ofthe 15-day observational period. Five offive male and
5/5femalemicethatreceived8,000mg/kgand1/5females
that received 4,000 mg/kg died before the end ofthe 15-
day observational period. No compound-related mor-
phologic effects were observed in rats or mice that
received 2,000 mg/kg.
Sixteen-Day Studies: In the 16-day studies, all rats
dosed at2,000 or4,000mg/kgdied, and3/5maleratsthat
received 1,000mg/kgdied. Malemice thatreceived 2,000
or 4,000 mg/kg, female mice that received 4,000 mg/kg,
and 1/5 female mice that received 2,000 mg/kg died. No
compound-related gross pathologic or histopathologic
effects were seen in male or female rats (groups offive
each) that received 500 mg/kg or in mice that received
1,000 mg/kg.
Thirteen-Week Studies: In the 13-week studies,
groupsof10maleand10femaleratsandmicereceivedup
to800mg/kg(malerats), 1,000mg/kg(femalerats), 1,500
mg/kg(malemice), or2,000mg/kg(female mice). Fourof
10maleratsthatreceived800mg/kgand1/10femalerats
that received 1,000 mg/kg died of compound-related
causes before the end of the studies. Toxic hepatitis,
splenic pigmentation, bone marrow atrophy, and testicu-
laratrophywereobservedinthetwohighestdosegroups
ofrats. One ofthefemalemicethatreceived2,000mg/kg
died. The dosed female mice had significantly greater
liverweights than did the vehicle controls.
Experimental Design of Six-, Twelve-, and Eighteen-
Month and Two-Year Studies: Based on the findings in
the short- term studies, 2-year studies ofmethyl carba-
matewere conductedbyadministering 0,100, or200mg/
kgmethyl carbamatein distilledwaterbygavage, 5 days
per week for 103 weeks, to groups of 50 F344/N rats of
eachsexfor103weeks.Groupsof50B6C3F1 miceofeach
sex were administered 0, 500, or 1,000 mg/kg methyl
carbamate onthe same schedule.Additional groups of30
ratsofeachsexwereadministered0or400mg/kgmethyl
carbamate, and additional groups of30 mice ofeach sex
were administered 0 or1,000mg/kgmethyl carbamatein
distilled water by gavage, 5 days per week. Ten animals
fromeach groupwere killed at 6, 12, or 18months so that
the progression oflesions could be followed.
Results ofthe Six-, Twelve-, and Eighteen-Month and
Two-Year Studies: In the 6-month studies, all vehicle
control and dosed (400 mg/kg) rats survived. Cytologic
alterations and atypical proliferative changes were
observed in the liver of all dosed male and female rats,
and neoplastic nodules ofthe liverwere observed in 6/10
dosed male and 5/10 dosed female rats. In the 12-month
studies, all vehicle control male and female rats and
dosed female rats survived. One of 10 dosed male rats
died.Neoplasticnodulesoftheliverwereobservedin7/10
dosed male and 9/10 dosed female rats, and hepatocellu-
larcarcinomaswereobservedin8/10dosedmaleand6/10
dosed female rats. In the 18-month studies, V10 dosed
male and 8/10 dosed female and all vehicle control rats
survived. Hepatocellular carcinomas were observed in
9/10 dosed male and 8/10 dosed female rats. Compound-
related neoplastic changes were not observed in mice in
the 6-,12-, or 18-month studies.
In the 2-year studies, meanbodyweights ofhigh dose
(200 mg/kg) male rats were generally5%-9% lowerthan
those of the vehicle controls after week 20. Mean body
weights ofhigh dosefemale ratswere 5%-8% lowerthan
those of the vehicle controls after week 56. Survival of
dosed and vehicle control rats was similar (male: vehicle
control, 19/50; low dose, 26/50; high dose, 29/50; female:
29/50; 36/50; 35/50). The meanbodyweights ofhigh dose
(1,000 mg/kg) male mice were about 8%-18% lower than
those of the vehicle controls after week 24. The mean
body weights of high dose (1,000 mg/kg) female mice
were about 16% lower than those ofthe vehicle controls
after week 16 and 30% lower after week 64. Survival of
dosed and vehicle control mice was similar (male: 28/50;
35/50; 28/50; female: 38/50; 36/50; 32/50).
194ABSTRACTSFROMLONG-TERM CANCER STUDIES, 1976-1992
Chronic focal inflammation and cytologic alteration of
the liver were observed at increased incidences in high
dose rats of each sex. Hyperplasia of hepatocytes was
observed atincreased incidences in dosed male and high
dose female rats. Neoplastic nodules or hepatocellular
carcinomas (combined) in female rats occurred with a
significant positive trend (0/50; 0/50; 6/49; P<0.01); the
incidence of neoplastic nodules or hepatocellular car-
cinomas (combined) inhigh dosefemale ratswasgreater
(P<0.03) than that in the vehicle controls. Incidences of
liver neoplasms in dosedmale ratswere notsignificantly
increased (4/50; 0/50; 7/49). Inflammation of the hard-
erian gland was observed at increased incidences in
dosed rats (male: 4/50; 11150; 16/50; female: 7/50; 16/50;
30/50). The lesions were considered to be chemically
related. In the 2-year studies in rats, significant
decreases in tumor incidences included the following:
leukemia (both sexes), pituitary gland (male), adrenal
gland (male), and mammary gland (female).
In the 2-year mouse studies, multinucleate giant cells
in the liver were observed at increased incidences in
dosed male mice (14/50; 31150; 31149). Adenomatous
hyperplasia and histiocytosis ofthe lung were observed
at increased incidences in high dose mice (adenomatous
hyperplasia-male: 13/50; 19/50; 24/49; female: 7/49;
10/50; 18/50; histiocytosis-male: 11150; 7/50; 21149;
female: 9/49; 10/50; 21150).
Genetic Toxicology: Methyl carbamate was not muta-
genic inSalmanella typhimurium strains TA97, TA98,
TA100, or TA1535when testedwith orwithout metabolic
activation in a preincubation protocol at doses up to 10
mg/plate. Methyl carbamate did not induce forward
mutations in the mouse L5178Y/TK+/- lymphoma assay
with orwithout metabolic activation at doses up to 5mg/
ml. Unscheduled DNA synthesis was not detected in rat
hepatocytes after in vitro treatment with methyl carba-
mate at concentrations of 1.0-1,000 ,ug/ml. When tested
in Drosophila at doses of 25,000-50,000 ppm, methyl
carbamate did not induce sex-linked recessive lethal
mutations. Results oftests forinduction ofchromosomal
aberrations and sister chromatid exchanges by methyl
carbamate in cultured Chinese hamster ovarycellswere
also negative at doses up to 5 mg/ml.
Data Audit: An audit of the experimental data was
conductedforthe6-,12-, and18-monthand2-yearstudies
ofmethyl carbamate. No data discrepancies were found
that influenced the final interpretation.
Conclusions: Underthe conditions ofthese 6-, 12-, and
18-month and 2-year gavage studies, there was clear
evidence ofcarcinogenic activity for male and female
F344/N rats given methyl carbamate as indicated by
increasedincidences ofhepatocellularneoplastic nodules
andhepatocellularcarcinomas.Therewasnoevidenceof
carcinogenic activity formaleandfemaleB6C3F1 mice
given methyl carbamate at doses of500 or 1,000 mg/kg.
Methyl carbamate also induced inflammation of the
harderian gland in male and female rats and ade-
nomatous hyperplasia and histiocytosis of the lung in
male andfemale mice.
Synonyms: carbamic acid, methyl ester; methylurethan;
methylurethane; urethylane
Report Date: November 1897
TR-329 Toxicology and Carcinogenesis
Studies of1,2-Epoxybutane (CAS No.
106-88-7) in F344/N Rats and B6C3F1 Mice
(InhalationStudies)
1,2-Epoxybutane was selected forstudybecause itis a
short-chainepoxidethathadbeenshowntobemutagenic
and because no carcinogenicity data were available.
Approximately 8 million pounds of 1,2-epoxybutane are
produced annually in the United States. The chemical is
usedprimarilyas astabilizerinchlorinatedhydrocarbon
solvents.
Single-Exposure, Fourteen-Day, and Thirteen-Week
Studies: Single-exposure, 14-day, 13-week, and 2-year
studies were conducted in F344/N rats and B6C3F1
mice. The chemical was greater than 99% pure and was
administered as avaporbythe inhalation route to mimic
worker exposure; room air was used as the control
exposure during these studies. Exposures were 6 hours
per day (5 days perweek), except in the single-exposure
studies (4 hours). Additional studies were performed to
evaluate thepotentialforgeneticdamageinbacteriaand
in mammalian cells. In the single-exposure studies, the
chemicalwasadministered atexposureconcentrations of
400-6,550 ppm in rats and 400-2,050 ppm in mice. In the
14-day studies, rats and mice were exposed at 400-6,400
ppm, and in the 13-week studies, rats and mice were
exposed at 50-800 ppm.
All rats in the single-exposure studies at 6,550 ppm
died; compound-related deaths were not seen in other
dosed groups. Allmice at2,050 ppm and4/5mice ofeach
sex at 1,420 ppm died; compound-related mortality was
not seen in other dosed groups.
In the 14-day studies, all rats at 3,200 and 6,400 ppm
and 2/5 female rats at 1,600 ppm died; all mice at 1,600,
3,200, and 6,400 and115malemice at800ppmdied. Final
mean body weights of surviving rats exposed at 800 or
1,600 ppm were 12%-33% lower than those of the con-
trols; final mean body weights of surviving mice at 800
ppm were 10%-12% lower than those of the controls.
Compound-related lesions included pulmonary hemor-
rhage and rhinitis in rats at 1,600 ppm and nephrosis in
mice at 800 and 1,600 ppm.
Inthe13-weekstudies, no compound-relatedmortality
was observed in rats; all mice exposed at 800 ppm died.
Nocompound-relatedclinicalsignswereseeninratsorin
surviving mice. The final mean body weight of rats
exposed at 800 ppm was 23% lower than that ofcontrols
formales and 16% lowerforfemales. Finalbodyweights
ofsurviving mice were unaffected by exposure. Inflam-
mation of the nasal turbinates was seen in rats at 800
ppm but not at lower exposure concentrations. Renal
tubular necrosis was seen in mice at 800 ppm but not at
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lower concentrations. Inflammation of the nasal turbi-
nates was observed in female mice at 100, 200, 400, and
800 ppm and in male mice at 200, 400, and 800 ppm. The
highest exposure concentration selected for the 2-year
studies in rats was 400 ppm because of body weight
effects and nasal lesions observed at 800 ppm. The
highest concentration selected for the 2-year studies in
mice was 100 ppm because the nasal lesions seen at 200
and400ppmwereconsideredtobepotentiallylifethreat-
ening.
Two-Year Studies: The 2-year toxicology and car-
cinogenesis studies of 1,2-epoxybutane were conducted
by exposing groups of50 animals per species and sex to
the chemical by inhalation, 6 hours per day 5 days per
week. Rats were exposed at concentrations of0, 200, or
400 ppm for 103 weeks and mice at 0, 50, or 100 ppm for
102weeks.
Body Weight and Survival in the Two-Year Studies:
The survival ofall groups ofdosed ratswas atleast 50%
untilweek98,butfinal survivalwasreducedinthe dosed
groups (final survival-male: control, 30/50; low dose,
18/50;highdose,23/50; female: 32/50;21/50;22/50). Mean
body weights of control and exposed male rats were
similar until week 86; thereafter, mean body weights of
high dose male rats were 4%-8% lower than those of
controls. Mean body weights of high dose female rats
were 5%-10% lowerthanthose ofcontrols afterweek 22.
Survival in male mice was comparable among groups
(final survival: 41/50; 45/50; 33/50). Survival in female
mice was greater than 50% in all groups atweek 86 and
thenwas reduced inhigh dosefemales towardthe end of
the study (final survival: 29/50; 25/50; 9/50). This
decreased survival was associated with suppurative
inflammationoftheovaryanduterus.Klebsiellaoxytoca
was isolated from these ovarian/uterine lesions. Mean
bodyweightsofhighdosemalemicewere10%-14%lower
than those of the controls after week 69; mean body
weights of low dose male mice were 4%-8% lower than
thoseofthecontrolsafterweek86.Meanbodyweightsof
highdosefemalemicewere13%-23% lowerthanthose of
thecontrolsafterweek60, andmeanbodyweights oflow
dose female mice were 12%-16% lower than those ofthe
controls afterweek 73.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Dosed rats had nonneoplastic lesions of the
nasal cavity including inflammation, epithelial hyper-
plasia, squamous metaplasia, hyperostosis of the nasal
turbinate bone, and atrophy ofthe olfactory epithelium.
Seven papillary adenomas ofthe nasal cavity were seen
in high dose male rats and two in high dose female rats.
The historical incidences of nasal cavity adenomas in
untreated male and untreated female F344/N rats are
less than 0.1%. The incidences of alveolar/bronchiolar
carcinomas (0/50; 1/50; 4/49) and adenomas or car-
cinomas (combined) (0/50; 2/50; 5/49) were increased in
high dose male rats; no increased incidences of these
tumors were observed in dosed female rats.
Dosed mice had increased incidences ofnonneoplastic
lesions ofthe nasal cavity but no significant increase in
theincidenceofneoplasticlesionsofthenasalcavity. The
nonneoplastic lesions included suppurative inflammation
(empyema), epithelial hyperplasia, erosion, regeneration,
and squamous metaplasia in the nasal cavity; atrophy of
the olfactory sensory epithelium ; hyperplasia of the
nasal gland (Bowman's glands); and inflammation and
hyperplasia ofthe nasolacrimal duct. Asingle squamous
cell papilloma was seen in the incisive duct of one high
dose male mouse.
GeneticToxicology: 1,2-Epoxybutanewasmutagenicin
Salmonella typhimurium strains TA100 and TA1535
when tested with a preincubational protocol with or
without rat liver S9, indicating that it is a direct-acting
mutagen capable of inducing base-pair substitutions in
prokaryotes; it did not cause gene reversion in strains
TA1537 or TA98. 1,2-Epoxybutane induced forward
mutations at the TK locus of cultured mouse L5178Y
lymphoma cells with and without metabolic activation.
Both chromosomal aberrations and sister chromatid
exchanges were induced in cultured Chinese hamster
ovary cells after exposure to 1,2-epoxybutane in the
presence and absence of metabolic activation. 1,2-
Epoxybutane, when fed to male Drosophila, caused sig-
nificant increases in the number of sex-linked recessive
lethal mutations and reciprocal translocations in the
germ cells.
Data Audit: An audit of the experimental data was
conducted for the 2-year studies of1,2-epoxybutane. No
data discrepancies were found that influenced the flnal
interpretations.
Conclusions: Under the conditions of these 2-year
inhalation studies, there was clear evidence of car-
cinogenic activity of1,2-epoxybutane for male F344/N
rats, as shown by an increased incidence of papillary
adenomas of the nasal cavity, alveolar/bronchiolar car-
cinomas, and alveolar/bronchiolar adenomas and car-
cinomas (combined). There was equivocal evidence of
carcinogenic activity forfemale F344/N rats, as shown
bythepresenceofpapillaryadenomasofthenasalcavity.
Therewasnoevidenceofcarcinogenic activityformale
or female B6C3F1 mice exposed at 50 or 100 ppm. 1,2-
Epoxybutane exposure was associated with ade-
nomatous hyperplasia and inflammatory lesions of the
nasal cavityinrats andinflammatorylesions ofthenasal
cavity in mice.
Synonyms: 1-butene oxide; 1,2-butene oxide; butylene
oxide; 1,2-butylene oxide; ethyl ethylene oxide; ethyl
oxirane
Report Date: March 1988
TR-330 Toxicology and Carcinogenesis
Studies of4-Hexylresorcinol (CAS No.
136-77-6) in F344/N Rats and B6C3F1 Mice
(GavageStudies)
4-Hexylresorcinol, which is used as an anthelmintic
and antiseptic, was nominated by the National Cancer
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Institute for study. Toxicology and carcinogenesis stud-
ies were conducted by administering 4-hexylresorcinol
(greaterthan99%pure)incornoilbygavagetogroupsof
F344/N rats and B6C3F1 mice ofeach sexfor16 days, 13
weeks, or 2 years.
Sixteen-Day and Thirteen-Week Studies: In the 16-
day studies, groups offive rats and five mice ofeach sex
were administered 0, 31.3, 62.5, 125, 250, or 500 mg/kg
4-hexylresorcinol. Survival was not affected. Decreased
bodyweights were seen inmale rats thatreceived 250 or
500 mg/kg 4-hexylresorcinol. No other effects were
observed. Inthe13-week studies, groups of10 ratsand10
mice ofeach sexwere administered 0, 62.5, 125, 250, 500,
or 1,000 mg/kg ofthe chemical, 5 days perweek. All rats
and male mice and 9/10 female mice that received 1,000
mg/kg died before the end of the studies. Final mean
bodyweights ofmale rats thatreceived 250 or500mg/kg
were 22% or 38% lower than that ofthevehicle controls;
final mean bodyweights offemale rats that received 250
or 500 mg/kg were 16% or 9% lower. No compound-
related gross or microscopic pathologic effects were
observed in rats. No body weight effects were observed
formice. Mild tomoderatenephropathywas doserelated
in male and female mice.
Based on these results, 2-year toxicology and car-
cinogenesis studies of4-hexylresorcinol were conducted
by administering 0, 62.5, or 125 mg/kg to groups of 50
F344/N rats and 50 B6C3F1 mice ofeach sex, 5 days per
week.
Body Weight and Survival in the Two-Year Studies:
Mean bodyweights ofhigh dose male rats were 7%-11%
lower than those of the vehicle controls throughout the
study. Mean body weights of low dose male and dosed
female rats were similar to those ofthe vehicle controls.
The body weights of dosed male and dosed female mice
were comparable to those of vehicle controls except
during the last 16 weeks of the studies, when body
weights were 6%-16% lower in the dosed groups. No
significant differences in survival were observed
between any groups of rats or mice of either sex (male
rats: vehicle control, 30/50; low dose, 29/50; high dose,
33/50; female rats: 28/50; 32/50; 30/50; male mice: 36/50;
26/50; 30/50; female mice: 35/50; 32/50; 35/50).
Nonneoplastic and Neoplastic Lesions intheTwo-Year
Studies: Two astrocytomas and an oligodendroglioma
were observed in high dose male rats, a glioma was
observed in one low dose male rat, and an oligo-
dendroglioma was observed in one vehicle control male
rat. Theseneoplasmswerenotconsidered toberelated to
4-hexylresorcinol administration.
Focal medullary hyperplasia ofthe adrenal gland was
observed at increased incidences in dosed male mice
(5/50; 16/50; 10/49). Pheochromocytomas in male mice
occurredwith amarginalupward trend(1150; 2/50; 5/49).
Historically, theseneoplasms areobservedinabout1%of
corn oil vehicle control B6C3F1 male mice. The inci-
dences ofneoplasms ofthe harderian gland in male mice
were slightly increased overthose in the vehicle controls
(adenomas or carcinomas, combined: 0/50; 4/50; 3/50).
Decreases were observed in the incidences of mono-
nuclearcellleukemiain dosedmale (12/49; 7/50; 1150) and
female (16/50; 3/50; 2/50) rats, hepatocellular adenomas
or carcinomas (combined) in dosed male mice (21V50;
9/50; 9/50), and circulatory system tumors inmale (10/50;
4/50; 2/50) and female (6/50; 2/49; 0/50) mice. These
decreased incidences of tumors in rats and mice are
considered to be possibly related to 4-hexylresorcinol
administration.
The incidences and severity of nephropathy (male:
39/50; 43/50; 47/50; female: 7/50; 40/49; 47/50) and inci-
dences ofosteosclerosis (male: 5/50; 5/50; 15/50; female:
21150; 25/49; 40/50) were increased in both dosed male
and female mice and are considered to be related to
chemical exposure.
Genetic Toxicology: 4-Hexylresorcinol was not muta-
genic for Salmonella typhimurium strains TA98,
TA100, TA1535, or TA1537 with or without S9 metabolic
activation. 4-Hexylresorcinol induced forward mutations
at the TK locus in mouse L5178Y cells in the presence of
S9; noresponsewas observedintheabsence ofmetabolic
activation. In cytogenetic assays with cultured Chinese
hamster ovary (CHO) cells, 4-hexylresorcinol caused an
increase in the frequency ofsister chromatid exchanges
(SCEs) in the absence ofmetabolic activation; no induc-
tion of SCEs was observed in the presence of S9. Chro-
mosomal aberrations were notinduced in CHO cellswith
or without metabolic activation.
DataAudit:The data, documents, andpathologymate-
rials from the 2-year studies of 4-hexylresorcinol were
audited at the NTP Archives. The audit findings show
that the conduct ofthe studies is documented appropri-
ately and support the data and results given in this
Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was no evidence ofcarcinogenic
activity of4-hexylresorcinol for male or female F344/N
rats given doses of62.5 or 125mg/kg. Therewas equivo-
cal evidence ofcarcinogenic activity of 4-hexylresor-
cinol for male B6C3F1 mice, as shown by marginally
increased incidences ofpheochromocytomas (and hyper-
plasia) of the adrenal medulla and of harderian gland
neoplasms. There was no evidence of carcinogenic
activity for female B6C3F1 mice given doses of 62.5 or
125 mg/kg 4-hexylresorcinol. Decreased incidences of
three tumors types were considered related to 4-hexy-
lresorcinol administration: mononuclear cell leukemia in
male and female rats, hepatocellular neoplasms in male
mice, and circulatory system tumors in male and female
mice.
Synonyms: 4-hexyl-1,3-benzenediol; 4-hexyl-1,3-
dihydroxybenzene
Report Date: May 1988
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TR-331 Toxicology and Carcinogenesis
Studies ofMalonaldehyde, Sodium Salt (3-
Hydroxy-2-propenal, Sodium Salt) (CAS
No. 24382-04-5) in F344/N Rats and B6C3F
Mice (Gavage Studies)
Malonaldehyde occurs as a natural metabolic
byproduct ofprostaglandin biosynthesis and as an end
productofpolyunsaturatedlipidperoxidation. Toxicology
and carcinogenesis studies ofmalonaldehyde were con-
ductedbyadministeringthechemical asmalonaldehyde,
sodium salt, a stabilized form ofmalonaldehyde, in dis-
tilled water by gavage to groups of F344/N rats and
B6C3F1 mice ofeach sex for 14 days, 13 weeks, and two
years. The studymaterialwas 63%-79% malonaldehyde,
sodium salt, 22%-38% water, and 1% or less other
impurities. The water content was taken into account
when the dose mixtures were prepared.
Fourteen-Day and Thirteen-Week Studies: In the 14-
day studies, groups offive rats and five mice ofeach sex
were dosed with 250, 500, 750, 1,000, or 1,500 mg/kg
malonaldehyde, sodium salt. Controls were untreated.
Rats andmicethatreceived 1,500mg/kgmalonaldehyde,
sodium salt, did not survive to the end of the 14-day
studies. No compound-related gross lesions were seen in
the dosed animals.
In the 13-week studies, groups of 10 males and 10
females ofeach species were administered 0, 30, 60,125,
250, or500mg/kgmalonaldehyde, sodiumsalt. Nineof10
male rats, 10/10 female rats, 3/10 male mice, and V10
female mice that received 500 mg/kg malonaldehyde,
sodium salt, died before the end of the studies. Body
weightswerereducedbymorethan15%inratsreceiving
250 or 500 mg/kg and in mice receiving 500 mg/kg.
Compound-related nonneoplastic lesions were present
in the stomach, testis, and kidney of rats and in the
pancreas, stomach, and testis ofmice. Focal and multifo-
calerosivelesionswereobservedinthegastricmucosaof
the glandular stomach in the 500 mg/kg groups ofmale
and female rats. Dilatation of the gastric glands of the
stomach mucosa occurred in the 500 mg/kg male mice.
Lesions ofthe kidney included membranous glomerular
nephropathyin the 250 and 500mg/kgmale rats and the
125,250, and500mg/kgfemaleratsandmineralizationin
the250and500mg/kgmaleratsandthe60,125,250, and
500 mg/kg female rats. Degeneration of the testicular
germinal epithelium was observed inmale rats andmale
mice receiving 250 and 500 mg/kg. Atrophy of the
exocrine pancreas was seen in the 125, 250, and 500 mg/
kg male and the 250 and 500 mg/kg female mice.
Based on these results, 2-year studies of mal-
onaldehyde, sodium salt, were conducted by exposing
groups of50 F344/N rats ofeach sex at doses of0, 50, or
100 mg/kg, administered 5 days perweek for 103 weeks.
Doses of 0, 60, or 120 mg/kg were administered in the
same schedule to groups of 50 male and 50 female
B6C3F1 mice.
Body Weight and Survival in the Two-Year Studies:
Final mean body weights at the end of the study were
reduced by 26% and 36% for high dose male and female
rats compared with those for the vehicle controls. The
final mean bodyweight ofhigh dose male micewas 92%
that ofthevehicle controls. The final meanbodyweights
of low dose male mice, low dose rats, and all groups of
female mice were comparable to those of the vehicle
controls.
The survival of high dose male and female rats was
significantlylowerthan that ofthevehicle controls, with
survival declining rapidly after week 76 for high dose
males and after week 59 for high dose females
(survival-male: vehicle control, 37/50; low dose, 33/50;
high dose, 15/50; female: 37/50; 37/50; 14/50). Survival of
allgroups ofmalemicewaslow(male:24/50;20/50;14/50;
female: 41/50; 38/50; 30/50). Survival of the high dose
groups ofmale mice was significantlylower than that of
the vehicle controls; no other significant differences in
survival were observed between any groups ofmice.
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: The incidences of a variety of nonneoplastic
lesions were increased in dosed rats of each sex, pri-
marily in the high dose male and female rat groups.
These lesions were ulceration and inflammation of the
glandular stomach; epithelial hyperplasia of the fore-
stomach;inflammation ofthecornea,retinalatrophy, and
cataracts ofthecrystallinelens;focallipoiddegeneration
of the adrenal cortex; and diffuse pancreatic atrophy.
Cytoplasmicvacuolization and cystic degeneration in the
liveroccurredatincreasedincidencesinthehighdoserat
groups; in addition, the incidences of bile duct hyper-
plasia and bile duct fibrosis were increased in the high
dose female and male rat groups, respectively. Bone
marrowhematopoietic hyperplasia, hematopoiesis ofthe
spleen, and ultimobranchial cysts of thyroid gland
occurred with increased incidences in high dose female
rats.
The incidences of thyroid gland follicular cell ade-
nomas or carcinomas (combined) were significantly
increased in high dose male (vehicle control, 4/50; low
dose, 8/49; high dose, 13/50) and female (2/50; 1/50; 7/50)
rats. Follicular cell hyperplasia ofthe thyroid gland also
occurred at an increased incidence in high dose female
rats (10/50; 10/50; 26/50) but not in male rats (9/50; 7/49;
7/50). Theincidence ofpancreaticisletcell adenomaswas
increased in low dose male rats (0/49; 9/50; 1/49). Ade-
nomas and adenomas or carcinomas (combined) of the
anterior pituitary gland occurred at significantly lower
incidences inhighdoseratsthanthoseinvehiclecontrols
(combined incidence-male: 20/47; 14/49; 8/49; female:
18/49; 10/49; 2/48).
Nonneoplastic lesions that occurred at increased inci-
dences in dosed mice included atrophy ofthe pancreatic
acinus and dilatation of the uterus. Depigmentation of
hair shafts and change ofcoat color from agouti to gray
were observed in high dose mice. No compound-related
neoplasms were observed in dosed mice.
Genetic Toxicology: Malonaldehyde, sodium salt, was
not mutagenic in the Salmonella typhimurium/
microsome assaywhentested atdosesofupto10,000 ,ug/
plate in a preincubational protocol using the excision-
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repairdeficientstrainsTA98,TA100,TA1535, andTA1537
with or without S9 metabolic activation. The chemical
induced forward mutations in mouse L5178Y lymphoma
cells in the absence of S9; it was not tested with S9.
Malonaldehyde, sodium salt was not mutagenic in the
Drosophila melanogaster sex-linked recessive lethal
mutagenicitytestinwhich adult male flieswere exposed
eitherbyfeeding orbyabdominal injection. In cytogene-
tic assays with cultured Chinese hamster ovary (CHO)
cells, malonaldehyde, sodium salt, produced a dose-
related increase in the frequency of sister-chromatid
exchanges both in the presence and absence ofrat liver
S9; no increase in the number of chromosomal aberra-
tions was observed in CHO cells in the absence or
presence ofS9.
Audit: The data, documents, and pathology materials
from the 2-year studies of malonaldehyde, sodium salt,
have been audited. The audit found no special circum-
stances orsignificant deficienciesinthe conduct ordocu-
mentation of the studies which needed to be taken into
consideration for reporting purposes.
Conclusions: Under the conditions of these 2-year
gavage studies, there was clear evidence of car-
cinogenic activity for male and female F344/N rats
administered malonaldehyde, sodium salt, as shown by
the increased incidences of follicular cell adenomas or
carcinomas (combined) ofthe thyroid gland. Pancreatic
islet cell adenomas were also observed at an increased
incidenceinlowdosemalerats.Therewasnoevidenceof
carcinogenic activity forB6C3F1 miceadministered 60
or 120 mg/kg malonaldehyde, sodium salt, in distilled
water by gavage 5 days perweek for 2 years.
Chemically related increased incidences of non-
neoplasticlesionsincludedulcersandinflammationofthe
glandular stomach and epithelial hyperplasiaofthe fore-
stomach;cornealinflammation, retinalatrophy,andcata-
racts of the crystalline lens; and cystic degeneration of
the liver, bile duct fibrosis, and bile duct hyperplasia in
rats. Most of these nonneoplastic lesions as well as the
thyroid gland follicular cell neoplasms occurred pri-
marilyin thehigh dose ratgroups, inwhich survival and
final body weights were reduced in high dose male and
female rats. Increased incidences ofatrophy ofthe pan-
creatic acinus and pigmentation loss in hair shafts were
seen in high dose mice.
Synonyms: malonaldehyde, enol, sodium salt; pro-
panedial, sodium; 3-hydroxy-2-propenal, sodium salt;
sodium ,B-oxyacrolein
Report Date: November 1988
TR-332 Toxicology and Carcinogenesis
Studies of2-Mercaptobenzothiazole (CAS
No. 149-30-4) in F344/N Rats and B6C3F
Mice (GavageStudies)
Toxicology and carcinogenesis studies of technical-
grade 2- mercaptobenzothiazole (96%-97% pure), a rub-
ber accelerant and preservative, were conducted by
administeringthechemicalbygavageinacornoilvehicle
to groups of F344/N rats and B6C3F1 mice ofeach sex
for 16 days, 13 weeks, or 2 years. 2-Mercaptobenzo-
thiazole was nominated for study by the National
Institute of Environmental Health Sciences and the
National Institute for Occupational Safety and Health.
Sixteen-Day and Thirteen-Week Studies: In 16-day
studies, mean body weight gains of rats receiving 2,500
mg/kgwere6-7glowerthanthose ofvehiclecontrols;4/5
maleand 5/5femalemice dosedwith 3,000mg/kgand4/5
female mice dosed with 1,500 mg/kg died; lethargy and
prostration occurred in most of these animals after
gavage. Based on these results, doses were selected for
both speciesinthe13-weekstudieswere 0,94(miceonly),
188, 375, 750, and 1,500 mg/kg.
In the 13-week studies, no chemical-related deaths
occurred in rats, but body weight gains in males dosed
with 1,500 mg/kg and in females dosed with 750 or 1,500
mg/kg were lower than those in the vehicle control
groups. Hepatomegalyoccurred atthetwohighestdoses
in males and at all doses in females; however, no micro-
scopicpathologic changeswerenoted in anytissue. More
than half the mice dosed with 1,500 mg/kg died, but no
compound-related body weight changes occurred. Clini-
cal signsinmicewere dose related andincluded lethargy
in animals dosed with 375 mg/kg and lacrimation, sali-
vation, and clonic seizurein somedosedwith 750 or1,500
mg/kg. No association between these clinical signs of
toxicity and gross ormicroscopic pathologic effects were
observed. Doses selected for the 2-year studies were 0,
375, and 750mg/kgformalerats andformiceofeach sex
and 0, 188, or 375 mg/kg for female rats.
Body weight and Survival in the Two-Year Studies:
Fifty animals ofeach species and sexwere administered
2-mercaptobenzothiazole in corn oilbygavage5daysper
week for 103 weeks. Administration of 2-mercap-
tobenzothiazole resulted in decreased survival in dosed
male rats (vehicle control, 42/50; low dose, 22/50; high
dose, 20/50) and in the high dose group of female mice
(37/50; 39/50; 22/50) but not in female rats (28/50; 31150;
25/50) or in male mice (38/50; 33/50; 30/50). No effect on
body weight gain in dosed rats was observed; in dosed
mice,minorreductionsoccurredbetweenweeks3and64,
with recoverythereafter. Postgavage lethargyand pros-
tration occurred frequently in dosed rats and mice.
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: The severity of nephropathy was increased in
dosed male rats. Ulcers and inflammation of the fore-
stomachwere prevalent in dosed rats, as were increased
incidencesofepithelialhyperplasiaandhyperkeratosisin
male rats, but no neoplasms of the forestomach were
observed. There were no increases of nonneoplastic
lesions in mice which were considered to be compound
related.
Theincidences ofavarietyoftumorswereincreasedin
rats dosed with 2-mercaptobenzothiazole; some of the
increased incidences were not dose related. In low dose
male rats, increased incidences (P<0.01) were observed
for mononuclear cell leukemia (7/50; 16/50; 3/50) and
199NTP/NIEHS
pancreatic acinar cell adenomas (2/50; 13/50; 6/49).
Increased tumor incidences with dose-related trends
(P<0.05) included pituitary gland adenomas in females
(15/49; 24/50; 25/50), preputial gland adenomas or car-
cinomas (combined) in males (1150; 6/50; 5/50), adrenal
gland pheochromocytomas or malignant phe-
ochromocytomas (combined) in males (18/50; 27/50;
24/49), and pheochromocytomas in females (1V50; 5/50;
6/50). These tumors were observed at significantly
greaterincidences (P.0.05)inthehighdosegroupsthan
in the vehicle controls.
An increased incidence (P=0.028) of hepatocellular
adenomas or carcinomas (combined) was observed only
in low dose female mice (4/50; 12/49; 4/50). No significant
increases in tumor incidences were seen in male mice.
Genetic Toxicology: 2-Mercaptobenzothiazole was not
mutagenic in Salmonella typhimurium strains TA98,
TA100, TA1535, or TA1537 with or without metabolic
activation. In the presence of rat liver S9, 2-mercap-
tobenzothiazole increasedthefrequency ofchromosomal
aberrations and sister chromatid exchanges (SCEs) in
Chinese hamster ovary(CHO) cells, aswell asmutations
at the TK locus ofmouse L5178Y lymphoma cells.
Audit: The data, documents, and pathology materials
fromthe2-yearstudies of2-mercaptobenzothiazolewere
audited at the NTP Archives. The audit findings show
thattheconduct ofthe studies is documented adequately
and support the data and results given in this Technical
Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity of2-mercaptobenzothiazole for male
F344/N rats, indicated byincreased incidences ofmono-
nuclear cell leukemia, pancreatic acinar cell adenomas,
adrenal gland pheochromocytomas, and preputial gland
adenomas or carcinomas (combined). There was some
evidence of carcinogenic activity for female F344/N
rats, indicated by increased incidences of adrenal gland
pheochromocytomas and pituitary gland adenomas.
There was no evidence of carcinogenic activity of
2-mercaptobenzothiazole for male B6C3F1 mice dosed
with375 or750mg/kg. Therewasequivocal evidenceof
carcinogenic activity for female B6C3F1 mice, indi-
cated by increased incidences of hepatocellular ade-
nomas or carcinomas (combined).
Synonyms and Trade Names: Captax; Dermacid; Mer-
tax; Thiotax; 2(3H)-benzothiazolethione; 2-ben-
zothiazolyl mercaptan
Report Date: May 1988
TR-333 Toxicology and Carcinogenesis
Studies ofN-Phenyl-2-naphthylamine
(CAS No. 135-88-6) in F344/N Rats and
B6C3F1 Mice (FeedStudies)
N-Phenyl-2-naphthylamine, formerlyused as aantiox-
idant in the rubber industry, was selected for toxicology
and carcinogenesis studies because at the time ofnomi-
nation (1976) it had a large annual production and wide-
spread human exposure.Additionalreasonsforselection
includeditstructural similarityandpossiblemetabolism
to the known human urinary bladder carcinogen,
2-naphthylamine. Toxicology and carcinogenesis studies
were conducted by feeding diets containingN-phenyl-2-
naphthylamine (approximately 98% pure and containing
less than 1 ppm 2-naphthylamine) at various concentra-
tions to groups ofF344/N rats and B6C3F1 mice ofeach
sex for 14 days, 13 weeks, or 2 years.
Fourteen-Day and Thirteen-Week Studies: In 14-day
studies, 3/5male and4/5female rats thatreceived 50,000
ppm N-phenyl-2-naphthylamine died before the end of
the studies. Final mean body weights of rats that
received 12,500 ppm or more were considerably lower
(18%-57%) than those of the controls. Arched backs,
rough coats, and diarrhea were observed for males that
received 12,500 ppm or more and for females that
received 25,000 or 50,000 ppm. All mice were alive at the
endofthestudies,andnocompound-related clinicalsigns
oftoxicitywereobservedinmicegivenfeedcontainingup
to 20,000 ppm.
In 13-week studies, deaths occurred in 4/10 male and
9/10 female rats that received the highest dose (40,000
ppm) of N-phenyl-2-naphthylamine. Final mean body
weights of rats that received 5,000-40,000 ppm were
9%-60% lower than those of the controls. The liver
weight to body weight ratios increased with increasing
dose, with the ratios for male rats at10,000 ppm or more
and forfemale rats at 5,000 ppm being greater (P<0.05)
than those ofcontrols. Acompound-related nephropathy
occurred in rats and was characterized by renal tubular
epithelial degeneration and hyperplasia. Othereffects in
rats included hematopoietic hypoplasia or atrophy ofthe
femoral bone marrow, testicular hypospermatogenesis,
lymphoid degeneration of the thymus, and lymphoid
depletion ofthe spleen.
In mice, 2/10 males and 7/10 females that received
40,000 ppm died before the end of the 13-week studies.
Thefinalmeanbodyweights ofmicethatreceived10,000,
20,000, or 40,000 ppm were 9%-32% lower than those of
the controls. The liver weight to body weight ratios for
miceincreasedwithincreasingdose.Thoseformalemice
at10,000 ppm ormore and forfemale mice at20,000 ppm
or more were greater (P<0.05) than those for the con-
trols. Nephropathywas observed atincreased incidences
and severity in dosed mice.
Because of kidney lesions, liver enlargement, lower
weightgain, andincreasedmortalityinthe shorterterm
studies, dietary concentrations of N-phenyl-2-
naphthylamine selectedforthe2-yearstudies in rats and
mice were 0, 2,5000, and 5,000 ppm.
Body Weight and Survival in the Two-Year Studies:
The mean body weights of dosed rats were lower than
those of the controls throughout the studies (12% and
16% lower for dosed males and 15% and 31% lower for
dosed females at the end of the studies). The average
dailyfeed consumption forratswas 94%-87% thatofthe
controls fordosed males and 88% thatofthe controls for
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dosed females. The estimated average amount of
N-phenyl-2-naphthylamine consumed per day was 100
mg/kg and 225 mg/kg for male rats and 120 mg/kg and
260 mg/kg for female rats. The survival ofthe high dose
group ofmale ratswas greater (P<0.05) thanthatofthe
controls after week 101 (male: control, 24/50; low dose,
28/50; high dose, 34/50; female: 26/50; 44/50; 38/50).
Finalmeanbodyweights ofhighdosemaleandfemale
mice were lower (male, 9%; female, 23%) than those of
the controls. The estimated average dailyfeed consump-
tion by dosed mice was within 10% that ofthe controls.
The average amount ofN-phenyl-2-naphthylamine con-
sumedperdaywas approximately500 or1,000mg/kgfor
male mice and 450 or 900 mg/kg for female mice. No
significant differences in survival were observed
between any groups ofmice ofeither sex (male: control,
33/50; low dose, 36/50; high dose, 28/50; female: 36/50;
30/50; 35/50).
Nonneoplastic and Neoplastic Effects in theTwo-Year
Studies: As in the 13-week studies, the kidney was the
principal target for toxic effects of N-phenyl-2-
naphthylamine. Mineralization ofthe kidney, necrosis of
therenalpapilla, andepithelialhyperplasia andcalculiof
the kidney pelvis were observed at increased incidences
in high dose female rats. Hydronephrosis, atrophy,
fibrosis, and chronic focal inflammation of the kidney
were observed at increased incidences in high dose
femalerats. Cystsand acutesuppurativeinflammationof
the kidney were observed at increased incidences in
dosed male and high dose female rats. No compound-
related renal neoplasms were observed in rats.
Nuclear enlargement of renal tubular epithelial cells
and nephropathy were observed at increased incidences
in high dose female mice. Atypical tubular cell hyper-
plasia occurred in two high dose female mice. A tubular
cell adenoma was found in one high dose female mouse,
and a tubular cell adenocarcinoma was found in another
high dose female mouse. No renal neoplasms were
observed in dosed male mice.
Neoplasms of several organs occurred in rats with
negative trends and/or at significantly lower incidences
in high dose groups. These included thyroid gland C-cell
neoplasms in males and females and mammary gland
fibroadenomas, pituitary gland adenomas, and mono-
nuclear cell leukemia in females. The lack of car-
cinogenicity in rats may be related to an inability to
metabolize this compound to the known animal and
human carcinogen 2-napththylamine.
Genetic Toxicity: N-Phenyl-2-naphthylamine was not
mutagenic in the Salmmnella typhimurium/microsome
assaywith strains TA97,TA98, TA100, orTA1535with or
withoutinducedhamsterorratliverS9.Thechemicaldid
notinduce chromosomal aberrations in cultured Chinese
hamster ovary (CHO) cells with or without metabolic
activation. No increase in sister chromatid exchanges
(SCEs) was observed in the absence ofmetabolic activa-
tion; inthepresence ofratliverS9,theSCE resultswere
judged to be equivocal.
DataAudit: Thedata,documents, andpathologymate-
rials from the 2-year studies of N-phenyl-2-naph-
thylamine were audited at the NTP Archives. The audit
findings show that the conduct of the studies is docu-
mented adequately and support the data and results
given in this Technical Report.
Conclusions: Undertheconditions ofthese2-yearfeed
studies, therewasno evidence ofcarcinogenic activity
formale orfemaleF344/Nratsfeddietscontaining2,500
or5,000ppmN-phenyl-2-naphthylamine. Decreasedinci-
dencesofseveralneoplasmswereobservedindosedrats:
thyroidgland C-cellneoplasmsinmales andfemales and
mononuclear cell leukemia, pituitary gland adenomas,
and mammary gland fibroadenomas in females. There
was no evidence of carcinogenic activity for male
B6C3F1 mice fed diets containing 2,500 or 5,000 ppm
N-phenyl-2-naphthylamine. There was equivocal evi-
dence of carcinogenic activity of N-phenyl-2-
naphthylamine for female B6C3F1 mice as indicated by
the occurrence oftwo rare kidneyneoplasms. Chemical-
related nonneoplastic lesions (nephropathy,
karyomegaly, and hyperplasia) occurred in the kidneyof
rats and mice.
Synonyms: N-(2-naphthyl)aniline; 2-naphthylpheny-
lamine; ,B-naphthylphenylamine; 2-phenylaminonaph-
thalene; phenyl-,B-naphthylamine; N-phenyl-I-
naphthylamine
Trade Names: Aceto PBN; Agerite Powder: Antioxidant
116; Neosone D; Neozon D; Nilox PBNA; Nonox D;
PBNA; Stabilizator AR
Report Date: January 1988
TR-334 Toxicology and Carcinogenesis
Studies of2-Amino-5-Nitrophenol (CAS
No. 121-88-0) in F344/N Rats and B6C3F
Mice (GavageStudies)
2-Amino-5-nitrophenol is used as a colorant in semi-
permanent hair dyes and in the manufacture of C.I.
Solvent Red 8, an azo dye for synthetic resins, lacquers,
and wood stains. 2-Amino-5-nitrophenol was nominated
fortoxicologyandcarcinogenesis studiesbythe National
Cancer Institutebecauseofwidespreadhumanexposure
associated with its use in hair dyes.
Toxicologyand carcinogenesis studieswere conducted
by administering 2-amino-5-nitrophenol (98% pure) by
gavage in corn oil 5 days per week to groups ofF344/N
ratsandB6C3F1 miceofeach sexin16-day, 13-week, and
2-year studies. In the 2-year studies, male and female
rats were given doses of 0, 100, or 200 mg/kg and male
andfemalemiceweregivendosesof0,400, or800mg/kg.
Sixteen-Day and Thirteen-Week Studies: During the
16-day studies, F344/N rats ofeach sex received 0, 156,
313, 625, 1,250, or 2,500 mg/kg2-amino-5-nitrophenol by
gavage in corn oil vehicle. One of the five males that
received2,500mg/kg,1/5femalesthatreceived 1,250mg/
kg, and 2/5 females that received 313 mg/kg died before
the end ofthe studies. Final mean bodyweights ofrats
that received 1,250 or 2,500 mg/kg were 11% and 30%
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lower than that ofvehicle controls formales and 9% and
13% lowerforfemales. B6C3F1 mice ofeach sexreceived
doses of 0, 313, 625, 1,250, 2,500, or 5,000 mg/kg
2-amino-5-nitrophenol. Two offivemales and 5/5females
thatreceived 5,000mg/kg,3/5males and3/5females that
received 2,500mg/kg, 3/5females thatreceived1,250mg/
kg, 1/5 females that received 625 mg/kg, and 2/5 male
vehicle controls died before the end ofthe studies. Final
mean bodyweights ofchemically exposed micewere not
different from those of the vehicle controls. Rats that
received 625, 1,250, or 2,500 mg/kg and male mice that
received 5,000 mg/kg had loose stools.
In 13-week studies, F344/N rats and B6C3F1 mice of
both sexes received 0, 100, 200, 400, 800, or 1,600 mg/kg
2-amino-5-nitrophenol by gavage in corn oil. Five of 10
male and 2/10 female rats that received 1,600 mg/kg, V10
male and 3/10 female rats that received 800 mg/kg, and
1/10 male rats that received 400 mg/kg died before the
endofthestudies. Finalmeanbodyweights ofmalesthat
received 400, 800, or 1,600 mg/kg were 10%, 25%, and
43% lower than that ofvehicle controls. The final mean
body weight of females that received 1,600 mg/kg was
16 9 lower that ofvehicle controls.
Four of 10 male and 3/10 female mice that received
1,600 mg/kg died before the end ofthe 13-week studies.
The final mean body weight ofmale mice that received
1,600 mg/kgwas 11% lower than that ofvehicle controls;
maleandfemalemicethatreceived1,600mg/kgappeared
lethargic.
During the 13-week studies, acute/chronic per-
ivasculitis ofvessels ofthececumandcolonwasobserved
in rats thatreceived 400, 800, or1,600 mg/kgand in mice
that received 1,600 mg/kg.
Body Weight and Survival in the Two-Year Studies:
Mean body weights of rats receiving 200 mg/kg were
5%-10% lower than those ofvehicle controls after week
33 for males and 4%-5% lower than those of vehicle
controls afterweek 93 for females. Survival ofmale rats
was significantlylowerthanthatofvehicle controls after
week 99 for the 100 mg/kg dose group and afterweek 75
for the 200 mg/kg dose group (final survival: vehicle
control, 33/50; 100 mg/kg group, 16/50; 200 mg/kg group,
4/50). Survival offemale rats was comparable to that of
vehicle controls (30/50; 32/50; 29/50). Loose or poorly
formed stools were observed formale rats and occasion-
ally for females that received 200 mg/kg.
Mean body weights of mice that received 800 mg/kg
were 8%-11% lower than those of vehicle controls
between weeks 29 and 74 for males and 8%-13% lower
than those ofvehicle controls afterweek 69 for females;
meanbodyweights ofmicethatreceived 400mg/kgwere
greater than those ofvehicle controls after week 69 for
males and 5%-9% lower than those of vehicle controls
afterweek 69 forfemales. Survival ofmice thatreceived
800 mg/kgwas significantlyreduced compared withthat
ofvehicle controls after week 20 for males and week 22
for females and was not considered adequate to evaluate
a carcinogenic response (final survival-male: vehicle
control, 31/50; 400mg/kg group, 36/50; 800mg/kg group,
12/50; female: 37/50; 36/50; 10/50).
Nonneoplastic and Neoplastic Effects in the Two-Year
Studies: Pigmentation was present at increased inci-
dences in all groups of chemically exposed animals and
was characterized by varying amounts of an orange,
granularpigmentpresentinthefibrousconnectivetissue
of the lamina propria, in the submucosa, and around
vesselsinthesubmucosaofthececumandcolon.Pigmen-
tation of the rectum was observed at increased inci-
dences in male rats that received 100 mg/kg, male and
female rats that received 200 mg/kg, and both groups of
chemicallyexposedmice.
No pigmentation was found in the intestines ofvehicle
control rats or mice. Associated with pigmentation was
an increased incidence of acute/chronic inflammation in
thececumandcolonofallgroupschemicallyexposedrats
andmice; thisinflammation was similarto thatobserved
inthe13-week studiesbutwas ofgreaterseverity.Acute/
chronic inflammation was also present in the rectum of
male rats that received 100 mg/kg, male and female rats
thatreceived200mg/kg, andmalemicethatreceived800
mg/kg.
The incidence ofpancreatic acinar cell adenomas was
significantly increased (P< 0.002) in male rats that
received 100 mg/kg 2-amino-5-nitrophenol (vehicle con-
trol,1/50;100mg/kg,10/50;200mg/kg,3/49);theincrease
was considered to be associated with chemical exposure.
The reduced survival ofmale rats that received 200 mg/
kg markedly reduced the sensitivity of this group for
detecting the presence of neoplasms. The incidences of
adenomas or carcinomas (combined) of the preputial or
clitoral glands were marginally increased in male or
female rats that received 200 mg/kg 2-amino-5-
nitrophenol (preputial gland: 3/50; 2/50; 5/50; clitoral
gland: 3/50; 3/50; 7/50). Neoplasmsfoundintheintestinal
tract of 3/50 male rats that received 100 mg/kg (one
leiomyoma ofthe small intestine, one adenocarcinoma of
thejejunum, oneleiomyoma ofthe cecum), 2/50malerats
that received 200 mg/kg (one lipoma and one osteosar-
comaofthececum), and1/50femaleratsthatreceived200
mg/kg(oneleiomyomaofthececum)werenotconsidered
to be the result of chemical exposure. No compound-
related neoplasms were found in mice exposed to
2-amino-5-nitrophenol in the 2-year studies.
Genetic Toxicology: 2-Amino-5-nitrophenol was muta-
genicinSalmonellatyphimurium strainsTA98,TA100,
and TA1537when tested in apreincubation protocolwith
andwithoutexogenousmetabolic activation, anditexhib-
ited equivocal mutagenic activityin strain TA1535 in the
presence of induced liver S9. 2-Amino-5-nitrophenol
induced forward mutations in mouse L5178Y lymphoma
cells in the absence of metabolic activation; it was not
tested with S9. An increase in chromosomal aberrations
andsisterchromatidexchangeswasobservedincultured
Chinese hamster ovary (CHO) cells followingincubation
with 2-amino-5-nitrophenol both in the presence and
absence ofexogenous metabolic activation.
DataAudit: Thedata,documents, andpathologymate-
rials from the 2-year studies of 2-amino-5-nitrophenol
were audited at the NTP Archives. The audit findings
show that the conduct of the studies is documented
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adequately and supportthe dataandresults giveninthis
Technical Report.
Conclusions: Under the conditions of these 2-year
gavage studies, there was some evidence of car-
cinogenic activity for male F344/N rats that received
100 mg/kg 2-amino-5-nitrophenol, as shown by the
increased incidence of acinar cell adenomas ofthe pan-
creas. Reduced survival of male F344/N rats that
received 200 mg/kg decreased the sensitivity of this
group for detecting a carcinogenic response. There was
no evidence of carcinogenic activity for female rats
that received 100 or 200 mg/kg per day. Marginally
increased incidences of preputial or clitoral gland ade-
nomas or carcinomas (combined) occurred in male and
female F344/N rats administered 200 mg/kg 2-amino-5-
nitrophenol. There was no evidence of carcinogenic
activity for B6C3F1 mice that received 400 mg/kg
2-amino-5-nitrophenol; reduced survivalofB6C3F1 mice
that received 800 mg/kg caused this group to be consid-
ered inadequate for detecting a carcinogenic response.
Report Date: February 1988
TR-335 lTxicology and Carcinogenesis
Studies ofC.I. Acid Orange 3 (CAS No.
6373-74-6) in F344/N Rats and B6C3F
Mice (Gavage Studies)
C.I. Acid Orange 3 is a dinitrodiphenylamine deriva-
tive used exclusively as adye (up to 0.2%) in semiperma-
nent hair coloring products. This study was one of a
series on semipermanent hair dyes, which included HC
Blue No.1 (NTP TR 271), HC Blue No. 2 (NTP TR 293),
HC Red No. 3 (NTP TR 281), and C.I. Disperse Blue 1
(NTP TR 299). Toxicology and carcinogenesis studies of
C.I. Acid Orange 3 (90% pure, containing 10% water for
short-term studies and containing 6%-8% water and
2%-4% acetone for 2-year studies) were conducted by
administering the dye in corn oil by gavage to F344/N
ratsandB6C3F1 miceofeachsexfor14days,13weeks, or
2 years.
Fourteen-Day and Thirteen-Week Studies: In the 14-
daystudies (at94-1,500mg/kginratsand62-1,000mg/kg
in mice), no compound-related deaths or body weight
changes were observed and no adverse effects were
observed at necropsy.
In the 13-week studies (at 94-1,500 mg/kg in rats and
31-2,000mg/kginmice), compound-relatedkidneylesions
were observedinrats andmice ofeach sex.Theselesions
includedvariabledegreesofdegenerationandnecrosisof
epithelial cells in the proximal convoluted tubules,
regeneration oftubularepithelium, andgranularcastsin
the tubules. In a few female rats of the highest dose
group, necrosis of the renal papillae and suppurative
inflammation were also observed. Mean body weights
were generally comparable among groups of rats and
mice. Mice receiving 2,000 mg/kg had body weights
11%-12% lower than those ofvehicle controls. Five of10
female ratsthatreceivedthehighestdoseof1,500mg/kg
diedbeforetheendofthe study,butnocompound-related
deaths occurred in male rats or mice ofeither sex.
Based on these results, 2-year studies of C.I. Acid
Orange 3 were conducted by administering the dye by
gavage in corn oil at 0, 375, or 750mg/kgto groups of50
F344/N rats ofeach sex, 5 days perweek for 103 weeks.
Groups of 50 male B6C3F1 mice were administered 0,
125, or 250 mg/kg C.I. Acid Orange 3 on the same
schedule, and groups of 50 female B6C3F1 mice were
administered 0, 250, or 500 mg/kg. These doses were
selected on the basis of the nature and severity of the
renal lesions in both species.
Body Weights and Survival in the Two-Year Studies:
Mean body weights of high dose rats were generally
more than 10% lowerthan those ofvehicle controls after
week 52 for males and week 70 for females. Mean body
weights forlowdose groupswere comparable to those of
vehicle controls. The survival of high dose male (after
week 33) and female (after week 14) rats was lower
(P<0.05)thanthatofvehicle controls andwasattributed
to nephrotoxicity (final survival-male: vehicle control,
36/50; low dose, 30/50; high dose, 0/50; female: 43/50;
34/50; 7/50). Mean body weights of dosed male and
female mice were lower than those of vehicle controls
(high dose, 5%-11% after week 74; low dose, 7%-17%
afterweek 48). Survival ofboth the lowdose (afterweek
102) and high dose (afterweek 100) groups ofmale mice
waslowerthanthatofthevehiclecontrols (finalsurvival:
38/50; 25/50; 26/50). Although survival was lower than
usual, no notable differences in survival were observed
between groups of female mice (final survival: 23/50;
23/50; 24/50).
Nonneoplastic and Neoplastic LesionsintheTwo-Year
Studies: For both species, the kidney was the major
target organ for C.I. Acid Orange 3. These findings are
summarized in the accompanying table. The incidences
of renal pelvic epithelial hyperplasia were increased in
dosed rats of each sex. No renal neoplasms were
observed in dosed male rats, but atubular cell adenocar-
cinoma was observed in a vehicle control male rat. Six
transitioilal cell carcinomas ofthe kidneywere observed
in high dose female rats; kidney transitional cell neo-
plasms have not been observed in 1,697 corn oil vehicle
control female F344/N rats.
Nonneoplastic lesions characteristic of secondary
renal hyperparathyroidism or secondary to uremia also
occurred in dosed rats. The lesions included parathyroid
hyperplasia, fibrous dysplasiaofbone, erosion andulcers
oftheglandularstomach, andmineralization ofthe aorta
and glandular stomach.
Epithelial hyperplasia of the urinary bladder was
observed in one low dose and three high dose female
mice.Asquamous cell carcinomawas seenintheurinary
bladder of one low dose female mouse. Even though no
squamous cell urinary bladder neoplasms have been
observed in 1,665 corn oilvehicle control female B6C3F1
mice, this single neoplasm in a low dose animal was not
considered toberelated totheadministration ofC.I.Acid
Orange 3.